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Abstract 
 
Glycosylation is an abundant post translational modification of proteins, which occurs in 
the endoplasmic reticulum and Golgi. Nearly every secreted and plasma membrane 
localised protein is glycosylated. Mesenchymal stromal/stem cells (MSCs) are adult stem 
cells that can self-renew and differentiate into multiple cell types including: osteoblasts, 
adipocytes and chondrocytes. Due to their tri-lineage capacity and their 
immunoregulatory functions, MSCs are attractive tools for the treatment of multiple 
diseases and conditions. Key to their use in regenerative medicine is knowledge about 
what influences a MSC to differentiate into a particular cell type. Despite previous studies 
describing distinct glycan profiles of cells at different stages of development, whether 
glycans play a functional role in directing MSC differentiation is currently unknown. 
Here, utilizing an immortalized primary human MSC line (hTERT-MSCs), the N-glycans 
from MSCs and osteoblasts were harvested using the Filter aided N-glycan Separation 
(FANGS) method. Following permethylation, N-glycans were analysed by mass 
spectrometry (MALDI-TOF/TOF). This method allowed the reliable, quantitative, relative 
abundance of different glycan structures to be compared between the two cell types for 
the first time. Complex N-glycans were significantly more abundant in osteoblasts 
compared to MSCs. The N-glycan profiles of different hTERT-MSC lines were not 
significantly different, despite variations in differentiation potential. The glycosylation 
pathway was genetically disrupted by targeting a subunit of the Conserved Oligomeric 
Complex (COG) with a shRNA. As predicted, since COG is responsible for the tethering of 
vesicles carrying Golgi resident enzymes, Cog4 knock-down hTERT-MSCs had disrupted N- 
and O-glycan synthesis. Interestingly, Cog4 knock-down hTERT-MSCs showed reduced 
osteogenic capacity with reduced levels of mineralised extracellular matrix (ECM). 
Surprisingly, the chemical inhibition of complex N-glycan synthesis increased ECM 
mineralisation, whilst inhibition of O-glycan synthesis or proteoglycan sulfation mimicked 
the Cog4 knock-down cells with reduced mineralisation. These results showed a novel 
role of both N-and O-glycans in osteogenesis.  
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Chapter 1 : Introduction  
1.1 The Golgi 
In 1898 Camillo Golgi described an ‘internal reticular apparatus’ in the cytoplasm of nerve 
cells [1]. Following observations of the same structure in many different cell types, and 
the identification of the structure by electron microscopy 50 years later [2], the existence 
of the organelle was finally accepted and became widely known as the Golgi.  
The Golgi is formed of stacks of individual membrane ribbons or cisternae that are 
spatially and functionally divided into different regions. The cis Golgi network is 
comprised of cisternae adjacent to the endoplasmic reticulum (ER) and receives vesicles 
containing newly translated proteins.  As proteins move from the cis to the trans Golgi 
network they undergo post translational modifications such as glycosylation. Proteins are 
finally transported from the trans Golgi network, at the plasma membrane end of the 
stack, to their cellular destination such as the plasma membrane or lysosome (Figure 1.1).  
 
Figure 1.1 The Golgi 
 
Diagram depicts location of the Golgi inside a cell, near the endoplasmic reticulum (ER). 
Cisternae of the Golgi are spatially and functionally separated, with the cis Golgi adjacent 
to the ER and the trans Golgi at the plasma membrane end of the stack. The content of 
cisternae changes or matures via retrograde transport vesicles that deliver Golgi enzymes 
back to newly formed cis cisterna. After post-translational modifications in the Golgi 
proteins are transported to their cellular location. 
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1.1.1 Models of protein traffic through the Golgi 
In order for correct post translational modifications of proteins to occur, a distinct 
distribution of Golgi resident enzymes in the different cisternae must be maintained. 
Simultaneously, proteins are transported in an anterograde (forward) direction through 
the Golgi. Several models have been proposed for how this might be achieved. The vesicle 
transport model proposes that the cisternae are in fixed positions with anterograde 
vesicles transporting proteins from the cis to the trans Golgi network. Any mislocalized 
Golgi enzymes are retrieved to the correct cisternae by retrograde (backward) transport 
vesicles. Alternatively, the cisternal maturation model suggests that cisternae form by the 
fusion of vesicles containing proteins from the ER, which then moves itself in an 
anterograde direction (as depicted in Figure 1.1). The content of the cisternae changes or 
matures via retrograde transport vesicles that deliver Golgi enzymes back to newly 
formed cis cisterna. A third model described by Patterson et al (2008) [3], suggests that 
proteins are rapidly partitioned into either processing or export domains of individual 
cisternae. Although the exact process of protein traffic through the Golgi is still under 
debate, several studies have shown evidence for cisternal maturation using fluorescent 
microscopy techniques. For example, Rizzo et al (2013) modified a cis-Golgi resident 
enzyme so that it could be reversibly polymerized, and monitored its location within the 
Golgi using electron microscopy. When in monomer form, it was found in vesicles and 
localised between cis and trans Golgi markers. In agreement with the cisternal maturation 
model, after polymerization, which would prevent entry into vesicles, the enzyme then 
co-localised with trans Golgi markers [4]. Importantly, in all models the retrograde traffic 
of vesicles is required for the maintenance of correct enzyme distribution throughout the 
Golgi.  
 
1.1.2 Retrograde vesicle traffic  
The mechanism by which retrograde vesicles form, tether, bind, and then fuse to target 
cisternae involves a myriad of proteins. The exact mechanism of retrograde vesicle 
transport in the Golgi, especially how cargo is targeted to its specific destination, is still 
under investigation. The process is similar to other cellular vesicle trafficking events but 
uses Golgi specific coat proteins, Rabs, tethers and SNAREs. To begin with during vesicle 
budding, Arf1, a small GTPase, is recruited to the Golgi membrane. GTPases are a group 
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of GTP binding proteins found throughout the cell. They act as molecular switches, 
interchanging between inactive (GDP-bound) and active (GTP-bound) forms. At the Golgi, 
Arf1 recruits cargo from inside the Golgi and a vesicle coat protein from outside [5]. 
Coatomer protein complex-I (COPI) is a known coat protein involved in Golgi vesicle 
transport, as it is present on Golgi vesicles and at the rims of Golgi cisternae [6]. COPI 
polymerizes in order to bend the membrane and form a vesicle. As in other vesicle 
transport pathways in the cell, vesicle-SNARES and target-SNARES form trans-SNARE 
complexes that direct the fusion of vesicles with target membranes. Two different SNARE 
complexes have been identified at the Golgi, Syntaxin5-Ykt6-GOS28-GS15 at the medial-
trans-Golgi, and Syntaxin5-membrin-Sec22-Bet1 at the cis-Golgi [7]. A gradiented 
distribution of the different v-SNARE and t-SNARE components of each complex 
influences the binding of vesicles to target membranes. Alongside SNARES several Ras-
family small GTPases called Rabs, organise vesicle trafficking and transport via their 
interactions with downstream effectors. One group of effectors at the Golgi are golgins, 
which are tethering proteins responsible for engaging the vesicle. For example, Rab1 
interacts with Golgin protein p115 to tether vesicles from the ER to the cis Golgi [8]. 
Different golgins interact with a different combination of Rab proteins that are expressed 
on vesicles carrying different cargo [9]. This selectivity also provides some specificity in 
intra-Golgi vesicle transport. 
1.1.3 Conserved Oligomeric Golgi complex 
The other major tethering factor in intra-Golgi retrograde transport is a multisubunit 
tethering complex called the Conserved Oligomeric Golgi (COG) Complex. The 
identification of COG began with the discovery of two mutant Chinese hamster ovary 
(CHO) cell lines that had poor low-density lipoprotein (LDL) uptake, named ldlB and ldlC 
[10]. The cause for poor LDL uptake was found to be low levels of LDL-receptor, due to 
rapid turnover at the plasma membrane. The rapid turnover of LDL-receptor was linked to 
poor Golgi associated glycosylation [11]. Simultaneous biochemical, yeast and CHO cell 
experiments, identified proteins which were later proved to be part of the same 8 subunit 
COG complex [12]. Further to this, electron microscopy of COG purified from bovine brain 
showed a bi-lobe structure. Together with studies on yeast homologue subunits, this 
identified the distribution of subunits, with lobe A containing subunits 1-4 and lobe B 
containing subunits 5-8 (Figure 1.2) [12, 13]. 
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Figure 1.2 Structure of the Conserved Oligomeric Golgi Complex (COG) 
Diagram depicting the distribution of subunits within COG. The bi-lobe structure was 
previously identified by electron microscopy. The distribution of subunits within the two 
lobes was previously determined in part through co-purification and in part, due to the 
similarity of the severity of mutations to subunits in the same lobe, in yeast.   
 
 
The distribution of subunits shown in (Figure 1.2) was supported by the difference in 
severity of phenotypes in yeast when units from different lobes were mutated. Mutations 
to subunits in lobe A in yeast were lethal, whilst, mutations to subunits in lobe B lead to 
more mild phenotypes [13]. The vesicle transport role of COG was first indicated by the 
glycosylation defects observed in the COG CHO cell mutants, which had reduced N- and 
O-glycan sialylation, which is a predicted consequence of mislocalized Golgi resident 
enzymes [11]. Furthermore, the intra-Golgi transport in a cell free assay model was 
inhibited when antibodies against a COG subunit were used [14]. Measurements of 
vesicle transport at the Golgi using another cell free assay were also reduced when 
cytosol from patients with mutations in COG were used in the assay [15]. These in vitro 
experiments supported the notion that COG is an essential factor in vesicle traffic at the 
Golgi. Experiments in which Cog3 was knocked down using siRNA in HeLa cells, 
demonstrated that COG is a tethering factor of retrograde vesicles at the Golgi. Cog3 
knock-down HeLa cells accumulated vesicles, which could be washed away from Golgi 
cisternae, showing that they were un-tethered. Furthermore, anterograde traffic of 
vesicular stomatitis virus G protein (VSVG) was not impaired; however, retrograde traffic 
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of Shiga toxin was impaired in the Cog3p knock-down cells [16].  Further evidence for 
COG’s role in retrograde vesicle traffic is the interaction of different COG subunits with 
various Rabs, golgins, SNAREs, the SM protein Sly1 as well as with the COPI coat [17]. 
Through these interactions and functional studies, COG has been proposed to initiate 
docking of vesicles, support SNARE complex formation and vesicle fusion. Specificity of 
retrograde vesicle transport may be derived from the combinations of Rabs, golgins, COG 
subunits, and SNARE interactions that occur at different vesicle-cisternae sites.  
1.1.3.1 Function of COG and COG subunits 
The complete content of the retrograde vesicles, which COG tethers is still under 
investigation. Both models of protein transport through the Golgi, suggest that retrograde 
vesicles contain Golgi resident enzymes that need to be recovered to an earlier cisternae 
in order to maintain their distinct distribution between cisternae. The purpose of these 
enzymes is to modify glycan structures, which are attached to nearly every cell surface or 
secreted protein. There are several different types of glycan structure, which are 
described in the section below. In brief, glycans can be attached to lipids or proteins, and 
consist of short branched chains of oligosaccharides, or be large extended structures as in 
proteoglycans, which considerably add to the total molecular weight of the protein. COG 
through its vesicle tethering, may maintain the synthesis of numerous different types of 
glycan structures, which if abnormal can have consequences for protein function and 
following this have physiological effects. 
Mutations to COG in cell lines such as CHOs mentioned earlier, had no effect on growth, 
but did perturb LDL uptake. In larger model organisms defects in COG have greater 
physiological effects, reflecting the difference in glycan sensitivity between simple cell 
lines and whole organisms. In C.elegans mutations to Cog1 resulted in reduced 
fucosylation of N-glycans, affecting the function of Mig17, a protein involved in 
gonadogenesis [18]. In D. melanogaster, deletion of the Cog5 homologue results in male 
fly sterility, with Cog5 indirectly affecting spermatogenesis, likely dependant on correct 
intracellular remodelling and key glycoproteins [19].  
The yeast studies involved in identifying COG’s bi-lobed structure, identified that 
mutations to subunits in lobe A were lethal, whilst mutations to lobe B subunits caused a 
milder phenotype with just reduce growth rates [13]. This lead to investigations in to 
whether the different individual subunits of COG, have different cellular functions. 
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Protein association studies of COG subunits with Golgi associated Rabs, SNAREs and 
golgins suggest different interaction hubs between different subunits, which could 
indicate separate functions of the lobes of COG. For example, Cog2 interacted with all 
golgins tested, but not with any Rabs or SNAREs indicating it could be a golgins hub, whilst 
through selective interactions with Rabs, Cog4 and Cog5 could be a Rab hub [17]. Cell 
lines and even patients with mutations in different COG subunits show different 
phenotypes and symptoms – although the variability among patients may be down to 
difference in the severity of the mutation. Cog5 loss in HeLa cells results in much more 
mild phenotype compared Cog1 or Cog2 mutations in CHO cells, with no effect on LDLR 
turnover in the Cog5 mutated HeLa cells [20]. Furthermore, studies monitoring the 
localization of specific N-glycan processing enzymes in cell lines with mutations to either 
lobe A or lobe B  COG subunits, have shown that lobe A units are essential for correct 
Golgi architecture overall as well as cis/medial Golgi enzyme maintenance, whilst lobe B 
subunits contribute to the maintenance of trans Golgi enzyme trafficking [21, 22]. 
Importantly, mutation of any COG subunit has been shown to alter protein glycosylation 
to some degree and so is a valid target to perturb cellular glycosylation.    
The main function of the Golgi is protein sorting and protein modification, such as 
glycosylation, prior to secretion. The next section will introduce types of glycosylation and 
explain how disruption of glycan synthesis, via COG mutations for example, can have 
physiological effects.  
1.2 Glycosylation 
Glycosylation involves the attachment of single sugars /monosaccharides or 
oligosaccharide chains to proteins or lipids and it is the most abundant post-translational 
modification. Nearly all cell surface proteins are glycosylated and it can double the 
predicted molecular weight of a protein. Therefore a cell’s surface can be described as a 
forest of glycans, which can have many effects on a cell’s behaviour and function. There 
are many different types of glycans that are processed in the ER and Golgi (Figure 1.3). 
The form of attachment can be broadly used to classify the different types of glycans, 
however, it is important to note that a single protein may have multiple types of glycan 
modifications and fluctuations in abundance of sugar donors or substrates may affect the 
synthesis of multiple glycan structures.  
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Figure 1.3 The diversity of glycans 
Examples of the common types of glycans found on mammalian cells (not to scale). The 
structures shown are examples from a wide variety of structures that can be produced. 
Other less common glycan linkages to proteins also exist, such as O-fucose. A glycolipid 
often refers to a GPI anchored protein or a glycosphingolipid. A proteoglycan refers to a 
protein with glycoaminoglycan (GAGs) chains attached. Whilst a glycoprotein is a term 
used for proteins with N-or/and O-glycans attached. In reality a protein may have a 
mixture of different types of glycans attached to it. The types of glycosylation described 
above occur in the ER and Golgi, which is typical of membrane bound or extracellular 
proteins. 
Adapted from: Varki A, Cummings RD, Esko JD, et al., editors. Essentials of Glycobiology. 
2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. 
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1.2.1 Glycolipids 
Glycolipids are glycan structures attached to lipid moieties. The most common type is 
glycosphingolipids (GSL), which contain a glycan structure linked to a ceramide backbone 
by a β-glycosidic bond. The synthesis of GSL starts at the ER with the formation of the 
ceramide, following this, the synthesis pathway then branches; either the ceramide is 
galactosylated in the ER to form GalCer; or it is trafficked to the Golgi where it is 
glucosylated to form GlcCer. These two precursor GSLs are then extended in the Golgi by 
the step-wise addition of other monosaccharides. GSL can contain small linear glycan 
structures, or larger branched, sialylated structures. Some of the precursor structures are 
substrates for multiple glycotransferases, resulting in competition between the different 
enzymes. A running theme for all glycans, is that contributing to the final glycan structure, 
is the presence and abundance of different Golgi resident glycotransferases and donor 
sugars throughout the different Golgi cisternae. Since the ceramide can vary in chain 
length and saturation, and there is a wealth of potential glycan structures that can be 
attached, there is a large heterogeneity of possible GSL structures. GSL are transported 
from the Golgi to the plasma membrane where they cluster in “lipid rafts”. Through this 
clustering GSL are thought to have a greater binding affinity for interacting proteins, 
which affects cell-cell interactions and the signalling of lipid-raft host proteins, such as the 
insulin receptor [23]. Inhibition of GSL synthesis at a cellular level in vitro has no effect on 
growth, however, the inhibition of GlcCer synthesis in vivo is embryonic lethal [24], 
showing a requirement of GSL in whole organism development. GalCer is the most 
abundant glycan in the brain and is produced by oligodendrocytes as a component of 
myelin sheaths. Through different knock-out mouse studies, phenotypes suggest that 
GSLs that are extended from GlcCer play roles in supporting neuronal development and 
function [25]. Although there aren’t well known diseases of GSL synthesis, there are 
several well studied diseases of GSL degradation. Tay-Sachs and Gaucher’s disease are 
both lysosomal storage disorders caused by errors in GSL catabolism, due to mutations in 
lysosomal enzymes that would normally degrade GSL into its subunits.  
Alternative types of glycans, introduced below, share the GSL synthesis pathway and 
some of its glycotransferases. It is therefore possible that diseases that are associated 
with alterations in other types of glycans, described in each glycan section, also affect GSL 
synthesis and vice versa.     
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1.2.2 Glycosylphosphatidylinositol (GPI) - anchored glycoproteins 
Another type of glycolipid are glycosylphosphatidylinositol(GPI)-anchored glycoproteins. 
Here a protein is attached to an ethanolamine phosphate that is linked to a glycan bridge. 
The glycan bridge contains 3 mannose (Man) and 1 glucosamine that is attached to a 
phosphatidylinositol(PI) group, which is anchored to the cell surface lipid bi-layer. This 
core structure (EtNP-6Manα1-2Manα1-6Manα1-4GlcNα1-6(PI)) is common to all GPI 
anchored proteins, however variation exists in terms of lipid substituents and the 
structure of additional glycan structures attached to the core structure [26]. The synthesis 
of the common core structure occurs at the ER, to start with on the cytoplasmic face and 
then onwards from the synthesis of the glycan bridge, in the lumen of the ER. The multi-
subunit complex GPI transamidase transfers the preassembled GPI precursor onto the 
protein in the ER. The attachment occurs at a carboxy terminal GPI addition signal 
peptide, which contains 3 amino acids, followed by a polar domain of 5 residues, followed 
by a hydrophobic domain of 15-20 hydrophobic amino acids. Following the transfer of the 
protein onto the GPI anchor, lipid remodelling and addition of glycan side-chains to the 
glycan bridge occurs in the ER and Golgi.  
One of the first GPI anchored glycoproteins identified was the variant surface 
glycoprotein (VSG) expressed by T. brucei, a parasite that causes sleeping sickness. Each 
trypanosome has 1x107 GPI linked VSG molecules on its surface, in order to protect 
against complement mediated lysis. Although not essential for mammalian cell culture, 
GPI anchor synthesis has been shown to be essential for embryonic development in mice 
[27]. Relevant to this research, the enzyme alkaline phosphatase (ALP), which is highly 
expressed in bone tissue, has a GPI-anchor [28]. One disease caused by mutations in 
genes responsible for GPI-anchor synthesis is Hyperphosphatasia with Mental Retardation 
Syndrome (HMRS). Symptoms include, elevated serum ALP levels, hypotonia, neurological 
features such as seizures and intellectual disability [29]. Another disease caused by 
mutations to GPI-anchor synthesis genes is Paroxysmal nocturnal hemoglobinuria (PNH). 
The main symptom of PNH is haemolytic anaemia that is caused by a sequence of events 
starting with the somatic mutation of PIGA, which is a X linked gene that produces an 
enzyme involved in the first steps of GPI-anchor synthesis. Hematopoietic stem cells 
(HSCs) that gain mutations in PIGA produce erythrocytes that lack several GPI-anchored 
proteins, including CD55 and CD59. The absence of these protein leads to complement 
activation lysis of erythrocytes [30]. The continued survival of the mutated HSCs is 
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thought to be due to increased mobility, due to decreased binding of other GPI-anchor 
proteins to adhesion molecules at the HSC niche [31]. As genome sequencing 
technologies become more widely available, patients with mutations to other GPI-anchor 
synthesis genes are likely to be identified, and knowledge of the molecular roles of GPI-
anchored glycoproteins will expand.    
1.2.3 Proteoglycans 
Proteoglycans are a diverse group of glycan modified proteins, which in general have 
chains of oligosaccharides attached to a glycan linker structure that is attached to a serine 
residue of a “core protein”. The chains of oligosaccharides called glycoaminoglycans 
(GAGs) are made of repeating disaccharide units containing an amino sugar and an uronic 
acid or galactose. Several common GAGs are described in the chart below. The cellular 
location of proteoglycans varies, some are secreted into the extracellular matrix (ECM), 
some stored in intracellular granules, and others are inserted into the plasma membrane. 
Hyaluronan is an unusual GAG because it is secreted into the ECM without being 
covalently bound to a protein. As with other glycan types, proteoglycans are 
heterogeneous, for example the GAGs attached can vary in their epimerisation and 
sulfation pattern. Furthermore, the number of GAGs attached to a proteoglycan can vary 
from 1-100, with each chain potentially containing 80 oligosaccharides [32].  
GAG Disaccharide composition Sulfation 
positions  
Protein 
linkage  
Chondroitin 
sulphate (CS) 
N-acetylgalactosamine (GalNAc) – 
Glucuronic acid (GlcA) 
4-O or 6-O 
sulfation of 
GalNAc 
GluA-Gal-
Gal-Xyl 
Dermatan sulphate 
(DS) 
N-acetylgalactosamine – 
Glucuronic/Iduronic acid (IdoA) 
4-O or 6-O 
sulfation of 
GalNAc and 
2-O sulfation 
of IdoA 
GluA-Gal-
Gal-Xyl 
Heparan sulphate 
(HS) 
N-acetylglucosamine (GlcNAc) – 
Glucuronic/Iduronic acid 
6-O or N-
position 
sulfation of 
GlcNAc and 
GluA-Gal-
Gal-Xyl 
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2-O sulfation 
of IdoA 
Keratan sulphate 
(KS) 
N-acetylglucosamine – Galactose 6-O sulfation 
of GlcNAc 
and 6-O 
sulfation of 
Galactose 
N- or O-
glycans 
Hyaluronan (HA) N-acetylglucosamine – Glucuronic 
acid 
None None 
 
The glycan linker structure that attaches the GAG to the core protein is the same for all 
protein bound GAGs, apart from keratin sulphate. The common glycan linker structure is 
a tetrasaccharide formed by the sequential addition of xylose, two galactose units and a 
glucosamine. Xylosylation has been shown to occur in the ER and Golgi and does so 
without an apparent consensus site, preventing the prediction of GAG attachment sites to 
proteins [33, 34]. In the Golgi the addition of either β1-4 N-acetylgalactosamine or α1- N-
acetylglucosamine initiates the formation of the repeating disaccharide chain that 
polymerizes into either chondroitin sulphate or dermatan sulphate, or, heparan sulphate 
GAGs respectively. As mentioned above keratin sulphate (KS) is a different type of GAG 
comprised of a sulphated poly-N-acetyllactosamine chain. Instead of a xylose linker 
structure, KS is found within N-or O-glycan structures (introduced later).              
1.2.3.1 Function of Proteoglycans 
Proteoglycans are found in nearly all tissues of the body and are the major component of 
ECM. The GAG sulphation makes the chains negatively charged that attracts Na+ ions, 
which in turn increases the hydrophilic properties of the GAGs. In connective tissues such 
as cartilage, the GAGs in the extracellular matrix form a porous gel that provides 
supportive structure to the cells imbedded in it, and is capable of withstanding 
compressive forces. Other than acting as a hydrated-spacing agent in between cells, GAGs 
and proteoglycans can interact with proteins to influence cell signalling. For example, 
fibroblast growth factors bind to proteoglycans, which results in downstream signalling 
events leading to cell growth and proliferation [35]. The density of GAGs in the ECM can 
influence the mobility of signalling proteins and nutrients, thereby affecting the resident 
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cells’ behaviour [36]. One of the earliest studied GAGs is heparin, which is a highly 
sulphated form of HS that is secreted in granules by mast cells. Due to its ability to bind to 
antithrombin, heparin is purified commercially and used as an anticoagulant. 
Proteoglycans are a major component of bone tissue and vary in their structure and 
function. Small leucine-rich repeat proteoglycans are abundant in bone matrix and 
influence mineralization through binding to collagen fibres, organising the ECM structure, 
and by interacting with growth factors regulating the activity and differentiation of 
osteoblasts [37]. Larger secreted proteoglycans such as aggrecan and membrane bound 
proteoglycans such as syndecan-3 are also present in bone tissue and affect bone 
development and structure. Due to the variety and abundance of proteoglycans in bone 
tissue, it is not surprising that mice in which different proteoglycans are knocked out 
show a variety of bone and cartilage symptoms, from dwarfism to osteoporosis [37].  
In humans, Hereditary Multiple Exostoses (HME) is an autosomal dominant disease 
associated with cartilage/bony outgrowths called exostoses that form adjacent to the 
growth plate of long bones, ribs and pelvis. The exostoses protrude into neighbouring 
tissues causing pain and hinder the mobility of the limb affected. Patients undergo 
surgery to remove the exostoses, which don’t reform after puberty, when the growth 
plate closes [38]. The genetic cause of HME in most cases is mutations in the genes EXT1 
or EXT2, which encode for the glycosyltransferases responsible for HS chain elongation. In 
vitro studies have shown that knock-down of EXT1 or EXT2 results in shorter HS chains, 
and a combination of overexpression studies lead to the speculation that EXT1 and EXT2 
form a complex, in which EXT1 is responsible for the enzymatic action, and EXT2 is a 
chaperone for EXT1 into the Golgi [39]. The mechanism by which shorter HS chain 
formation leads to exostoses formation is still under investigation, the basic reasoning is 
that shorter HS chains leads to impaired cell signalling, as growth factor gradients and 
signalling molecule interactions are no longer initiated by the shorter HS chains. Indian 
Hedgehog, Wnt and BMP signalling, which are all required for correct skeletogenesis, 
have been shown to be modulated by HS [40-42]. These interactions are likely reduced or 
absent in HME which leads to the altered growth plate development, showing that small 
changes to glycan formation can have developmental effects [40].   
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1.2.4 O-glycans 
Proteins that have glycans attached to serine or threonine residues via an O-glycosidic 
bond are called O-glycans. There are less common types of O-glycans such as O-fucose 
and O-mannose, but here, O-glycans shall refer to the most common type - O-GalNAc – 
which starts with the addition of an N-acetylgalactosamine (GalNAc) to a hydroxyl group 
of a serine or threonine residue. In the Golgi, chains or branches are then elongated by 
the sequential addition of monosaccharides. There are 8 different O-glycan core 
structures (Figure 1.4), which can contain antigenic groups and be elongated by several 
branches of polysaccharides. Proteins that have clusters of O-glycans are known as 
mucins and are commonly found in mucous secretions in the body. The clustering of O-
glycans occurs on mucins due to protein regions abundant in serine or threonine, called 
variable tandem repeat regions. In humans, the addition of the initial GalNAc is carried 
out by one of 24 different GalNAc-transferases, which are located throughout the Golgi 
[43]. Some GalNAc-transferases have carbohydrate-binding domains, and so the presence 
of nearby GalNAc units promotes the transfer of another, contributing towards the 
formation of densely O-glycosylated mucins. As with other types of glycans, O-
glycosylation is heterogeneous with a large number of possible glycan structures and 
variety in potential site occupation. Mucin proteins may have 100 O-glycans attached, but 
there are proteins that are modified by just 1 O-glycan structure.  
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Figure 1.4 O-glycan structures 
A) Diagram showing structure of Tn and T antigen, as well as an example of an extended 
core 1 type O-glycan. B) Structures of the 8 known O-glycan cores. 
 
1.2.4.1 Function of O-glycans 
As already mentioned O-glycosylated proteins are abundant in mucous secretions of the 
body. Similar to the GAG chains, the O-glycans are negatively charged and can attract 
water to form gels or mucous, which protects the tissues and traps pathogens. O-
glycosylated proteins can span the membrane and act in signal transduction. The 
expression of O-glycan structures changes during cancer affecting the ability of cells to 
bind to lectins expressed on epithelial cells [44]. Small changes to the O-glycosylation of 
MUC1, a mucin transmembrane protein overexpressed in breast cancer, causes altered 
EGF, MAPK and Wnt signalling that favours tumour growth [45]. Human diseases 
associated with O-glycan synthesis have mostly been overlooked or understudied as 
many of the patients suffer from N-glycosylation defects as well, due to shared synthesis 
localization and some common synthesis components. One disease that occurs due to 
mutations in an O-glycan exclusive protein is familial tumoral calcinosis (FTC). Here, 
mutations to GalNAc-transferase3, one of the enzymes responsible for initiating O-glycan 
synthesis, affects FGF23 activity, mutations of which can also cause the disease as it 
regulates phosphate levels in the blood [46]. Patients have calcium deposits in skin and 
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subcutaneous tissues. Deposits can be asymptomatic, being identified after unrelated 
scans, or can grow quite large and restrict movement of joints and cause pain. Altered O-
glycosylation has been identified in breast cancer samples. The symptoms of patients with 
defects in enzymes shared between O- and N-glycosylation pathways will be described 
after the introduction of N-glycosylation synthesis below.   
 
1.2.5 N-glycans 
Finally, N-glycans are also attached to protein residues but have different structures and 
are synthesized differently to O-glycans, as described in more detail below. A glycoprotein 
can refer to a protein with either N- or O-glycans, however, glycoproteins can have a 
mixture of the glycan modifications mentioned above. Importantly, most secreted and 
membrane proteins are N-glycosylated, explaining why it has been estimated that two 
thirds of all proteins (identified in the SWISS-PROT database) are N-glycosylated [47]. The 
abundance of this modification on secreted and plasma membrane proteins indicates 
how important N-glycosylation is to cellular processes.   
1.2.5.1 N-glycan synthesis 
N-glycosylation occurs in the ER and Golgi. During translation the protein is translocated 
into the lumen of the ER and the oligosaccharyl transferase (OST) complex recognises the 
N-glycosylation consensus site - Asn-X-Ser/Thr – (in which X cannot be Pro) and attaches a 
pre-formed  14 unit oligosaccharide, made up of a 2 N-acetylglucosamine (GlcNAc) unit 
base, a 9 mannose unit core, with 3 glucose units attached at the terminal end of one 
branch (Glu3Man9GlcNAc2) [48]. The glucose residues are removed in the ER prior to the 
glycoprotein being transported to the Golgi, with the Man9GlcNAc2 precursor glycan 
attached. Here the precursor glycan is modified by sequential removal and addition of 
sugars by a variety of glycosidases and glycosyltransferases that are present at varying 
levels in the cis, medial and trans Golgi cisternae (Figure 1.5a). Again, which enzymes the 
glycoprotein encounters and when during its transport through the Golgi network, 
influences the form of the final glycan structure. The structure of the protein itself will 
also influence enzyme binding and the final glycan structure, which enables a cell to 
produce different glycoproteins with different glycan structures, using the same Golgi 
network. There is a vast variety of different glycan structures that can be produced. 
Glycans can have various numbers of branches, with different degrees of fucosylation and 
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a variety of terminal monosaccharides at the end of branches. Broadly, N-glycan 
structures can be grouped into 3 different types; 1) oligomannose that have terminal 
mannose sugars; 2) complex that have branches starting with an GlcNAc attached to the 
mannose core, which can be followed by galactose and then terminal sialic acid residues; 
or 3) hybrid that are a combination of the other two (Figure 1.5b). As with other types of 
glycan modifications, the presence of an N-glycan consensus site doesn’t always result in 
the addition of a glycan. Some sites are always glycosylated whilst others are variably 
occupied. Added to this, the final glycan structure at the same site, on the same protein, 
can vary. For example a standard glycoprotein RnaseB has just one N-glycan site, yet 5 
different N-glycan structures can be isolated from a sample of RnaseB (Figure 1.5c). The 
key points of N-glycan synthesis, which are common to all types of glycan synthesis, are 
that the process is a step-wise, enzymatic reaction. Also, glycan structure is dependent on 
the glycoprotein itself, the presence of sugar donors, and the presence/competition of 
specific glycosyltransferases during transport through the Golgi. 
Despite most secreted and plasma membrane proteins being modified by N-glycans, the 
extent that N-glycans influence specific protein function remains unknown for most 
glycoproteins. The next sections will describe the known roles of N -glycans in regulating 
protein folding, cellular processes, and development.   
31 
 
 
Figure 1.5 N-glycan synthesis and heterogeneity 
A) Schematic of N-glycan synthesis in the ER and Golgi. For simplicity only one final N-
glycan structure is shown in the trans Golgi. Black arrows indicate action of glycosidases 
and glycotransferases. B) Examples of the three classes of N-glycan structures. C) Mass 
spectrometry spectrum of N-glycans isolated from RNaseB. Peaks are annotated with 
predicted glycan structures based on the calculated mass of monosaccharide units and 
knowledge of the synthesis pathway. Spectrum shown covers 1500m/z to 2500m/z. 
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1.3 Biological functions of glycans 
1.3.1 Protein folding  
N-glycans are known to impact glycoprotein folding prior to exit from the ER. This is 
accomplished by two protein chaperones that are lectins called, calnexin and calreticulin. 
In the ER the chaperones selectively bind to a partially trimmed monoglucosylated N-
glycan core structure on a glycoprotein. Following this, the two enzymes act in concert, 
one that trims the final glucose releasing the glycoprotein from the chaperones. The 
other enzyme binds only  to unfolded glycoproteins and then attaches a terminal glucose, 
resulting in re-binding with the chaperones or eventual degradation of any unfolded 
protein [49]. This mechanism regulates the passage of proteins from the ER to the Golgi, 
ensuring only folded proteins traffic to the Golgi.  
1.3.2 Protein and cellular function  
As well as a role in regulating protein folding in the ER, N-glycans have been shown to 
influence protein function, thereby affecting multiple cellular processes. Since most cell 
surface proteins are N-glycosylated the first point of contact for a cell is its coat of 
glycans. It follows then, that N-glycans and lectins are involved in processes in the 
immune system and in immune system evasion. For example, the binding of influenza 
virus to host cells is glycan dependant [50]. Many studies have shown cancer cells to have 
altered N-glycosylation. Linking altered N-glycosylation and the increased migratory 
behaviour of cancer cells, a study showed integrin-fibronectin binding was dependant on 
correct N-glycosylation [51]. As well as lectin-glycan interactions, N-glycans have been 
shown to affect the function of the glycoprotein itself. For example, the presence of a 
core fucosylated N-glycan on epidermal growth factor receptor (EGFR) is required for 
epidermal growth factor simulated phosphorylation of EGFR [52]. Interestingly, 
Rabinovich et al (2007) described how formation of galectin lattices can reduce receptor 
turnover, thereby potentially influencing multiple cell signalling pathways [53]. Although 
there are many examples of functional N-glycans there are also glycoproteins whose 
function appears un-altered in the absence or modification of glycans. The effect of many 
N-glycans on their glycoprotein function is currently unknown. Clearly there are N-glycans 
that play a role in cellular function and in the next sections the known roles of N-glycans 
in development and human disease will be introduced.  
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1.3.3 N-glycans in development 
Initial studies into the importance of N-glycans involved the mutation of different 
enzymes in the N-glycan synthesis pathway, using classic biological models such as mice 
and Arabidopsis. Metzler et al (1994), created mice which lacked UDP-N-
acetylglucosamine: alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I 
(GlcNAc-TI). This enzyme initiates complex glycan branching in the medial Golgi, by the 
addition of GlcNAc to the core Man5GlcNAc2 structure. Demonstrating the importance of 
complex N-glycans, the knock-out mice died during embryonic development by day 10.5. 
Already at day 9, embryos had severe symptoms including reduced vascularization, 
impaired neural tube formation and altered left-right body asymmetry [54]. Using 
Arabidopsis, Boisson et al (2001) found that glucosidase I knock-out caused seeds to fail 
to develop, showing that N-glycans are important in plant as well as mammalian 
development [55].      
The role of N-glycans in human development starts with fertilization. The sperm cell has a 
thick glycan coating called glycocalyx, which affects its ability to interact with epithelium 
during transport to the oocyte. The oocyte has its own specialized glycan-extracellular 
matrix coating called zona pellucida, which interacts with lectins on the sperm cell 
membrane, affects cell binding, and ultimately fertilization [56].  
Alongside in vivo mouse studies, the role of N-glycans in human development can in part 
be elucidated by observing patients that have mutations in genes encoding proteins 
involved in the N-glycan synthesis pathway.  
1.3.4 Congenital disorders of glycosylation  
Congenital disorders of glycosylation (CDGs) are a fast expanding group of autosomal 
recessive diseases. Genes that code for proteins involved in any of the different glycan 
synthesis or processing pathways are estimated to make up 2% of the human genome 
[57]. Since 2000 an increasing number of patients have been diagnosed with CDG due to 
mutations in genes responsible for different steps of glycan synthesis and processing [58]. 
The increase in diagnosis is in part due to new diagnostic tools as well as increased 
awareness of CDGs, which can be difficult to identify due to multiple body-systems being 
affected and the variability of symptoms between patients. For example, patients can 
suffer a wide variety of impaired developmental symptoms including mild motor defects, 
dysmorphic face, hypotonia, frequent infections, epilepsy, neurological defects, or multi-
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system failures resulting in death a few weeks after birth [59]. The standard diagnostic 
test for CDG is analysis of a serum glycoprotein called transferrin. Transferrin has two N-
glycosylation sites that are normally both occupied by complex, biantennary N-glycans. 
Transferrin from a patient that is not glycosylated at all, points to a mutation in a gene 
involved in N-glycan precursor synthesis or transfer of the N-glycan to the protein. 
Alternatively, transferrin from a patient that has structurally altered N-glycans, points 
towards genes involved in N-glycan processing. The ease of this diagnostic test, which 
identifies N-glycosylation pathway related mutations, probably contributes towards why 
more patients have been diagnosed with defects in N-glycan synthesis, compared to 
others such as O-glycan and proteoglycan synthesis. In 2003, Wopereis et al developed a 
molecular test for aberrant O-glycan synthesis [60]. It involved the isoelectric focusing of 
a serum protein called Apolipoprotein C III (ApoCIII), which is normally modified by one O-
glycan, and has 3 isoforms that correspond to varying O-glycan length and sialylation. 
Using this test Wopereis et al (2003) identified a CDG patient with a mutation in an 
unknown N-glycan processing gene that also had reduced O-glycan sialylation [60]. This 
test enables the identification of O-glycan mutations in other suspected CDG cases that 
show normal transferrin results, despite CDG symptoms.      
The most common CDG with over 500 patients world-wide is PMM2-CDG (previously 
known as CDG1a) [59]. Here, phosphomannomutase is deficient, which is an enzyme that 
generates mannose 1-P, a sugar unit used to make GDP-mannose, used for building the 
precursor oligosaccharide. Symptoms include inverted nipples, abnormal subcutaneous 
fat pads, hypotonia and a mortality rate of 20% in the first year. Despite a high carrier 
frequency of 1/70 in Europe for one mutation in PMM2, there are currently no incidences 
of homozygotes for that particular mutation, indicating that it is lethal in the homozygous 
state. Trials using mannose supplements as a treatment proved unsuccessful for PMM2-
CDG patients despite relieving symptoms in PMI-CDG patients, which have mutations in 
the gene upstream of PMM2 in the GDP-mannose biosynthesis pathway [59, 61]. Apart 
from mannose and fucose therapies for the PMI-CDG and GDP-fucose transporter 
deficiencies, all of the treatments for CDGs are aimed at managing the symptoms rather 
than treating the molecular cause of the disease.      
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1.3.4.1 COG related CDGs 
Since 2004, a small number of CDG patients have been found to have mutations in 
subunits of COG. The first to be identified were two  patients (siblings) who had 
mutations in Cog7 [62]. Since then patients with mutations in subunits 1, 2, 4, 5, 6, and 8 
have also been identified [63-68]. Patients have reduced N-and O-glycan sialylation, 
shown using transferrin and ApoCIII isoelectric-focussing, lectin staining, mass 
spectrometry, or a combination of these techniques. Patient symptoms are similar to 
other CDG patients and vary dramatically, from the mildest (CDG-Cog5) involving mild 
neurological impairments to the much more severe (CDG-Cog7), involving growth 
retardation, microcephaly, epilepsy, feeding problems, body dysmorphia, hypothermia 
and death before 3 months of age (Table 1).  
Since N-glycans are on nearly every cell surface it is unsurprising that CDG patients suffer 
a wide variety of symptoms, affecting nearly every system in the body. Although these 
diseases provide useful evidence that glycans are physiologically important, it is difficult 
to elucidate a molecular link between altered N-glycans and a specific developmental 
symptom. The differentiation of stem cells into mature cell types is a developmental 
process that can be easily studied in vitro. Research using this type of model enables a 
closer look at the role of N-glycans in a specific process of development, without the web 
of interconnected systems found in whole organisms. Before describing what is currently 
known about the role of N-glycans in this process, methods used to study glycans will be 
introduced. 
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Cog5 [69]    +  +       +               
Cog6 [66] +                ++    ++  +     
Cog7 [62, 
70] 
++ +   ++ + + + + + + +  + + + ++ +          
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  + ++ + +    +   +           ++ ++ + + 
Table 1. Symptoms of COG related CDGs.
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1.4  Methods used to study glycans 
1.4.1 An introduction to lectins 
Lectins are a widely used tool for studying glycans. Lectins are proteins that are capable of 
binding oligosaccharide structures. They were first discovered by Peter Hermann Stillmark 
in 1888, who isolated a compound capable of agglutinating erythrocytes, from the seeds 
of the castor tree (Ricinus communis) [71]. He named the hemagglutinin ricin, which rose 
to fame in 1978, after its toxic property was used in the “umbrella murder” of Georgi 
Markov. Following the work of Stillmark, Karl Landsteiner won the Nobel Prize for his 
discovery of the ABO blood groups, which had huge clinical impacts by improving the 
safety of blood transfusions. Blood sera from different individuals had different 
capabilities in agglutinating donor red blood cells, indicating specific antigens on red 
blood cells. Later experiments, using blood from different animals, showed varied ability 
of different bean extracts to agglutinate erythrocytes, suggesting specificity in binding 
(reviewed in [72]) . It wasn’t until 1936, after the purification of concanavalin A (ConA) 
isolated from jack bean, which experiments showing that sucrose could inhibit ConA 
induced hemagglutination, indicated for the first time that agglutinins were binding to 
oligosaccharide structures on the surface of red blood cells [73]. Indeed following this 
discovery, the ABO antigens were shown to be specific sugar structures. In 1954, plant 
agglutinins were re-named lectins from the latin legere, to pick out/or choose, due to 
different plant agglutinins being able to distinguish between erythrocytes of different 
blood groups [74]. Since their discovery, hundreds of lectins have been purified, isolated 
from mostly plants but also from animals e.g. eel, snail and horseshoe crab.  
1.4.2 Lectins as tools for glycobiology  
The labelling of lectins with biotin, horseradish peroxidase (HRP) or fluorescein 
isothiocyanate (FITC) enables lectins to be used in the same way that antibodies are used 
to analyse protein expression and localization.   
The relative ease of availability of lectins and their specificity to sugars independent on 
the underlying protein makes them variable over antibodies raised against 
oligosaccharide structures. However, different lectins have varied affinities for specific 
oligosaccharides.  The binding of lectins to different oligosaccharide structures is 
dependent on the branching of the glycan structure, as well as the the total glycan 
structure in which the target sugar resides. For example, ConA binds to mannose within 
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N-glycan structures. It binds tightly to both the mannose within branched oligomannose 
glycans and to mannose branches of hybrid glycans. It binds more weakly to the core 
Man3 structure within all N-glycan structures however, binding does not occur to 
complex glycans that are tri- or tetraantennary.    Due to this broad glycan specificity 
profile, the use of a panel of lectins is required to draw conclusions on the nature of 
glycan structure changes between samples. High-throughput lectin micro-arrays enable 
the comparison of binding to hundreds of lectins and can be used to elucidate specific 
differences between samples. A considerably cheaper, but also quantitative, alternative 
used in this study, is the use of multiple lectins and flow cytometry, to discern differences 
in glycan abundance on the cell surface of samples. Disadvantages to using lectins, 
includes the lack of information regarding the exact N-glycan structure to which the lectin 
is bound, i.e. ConA will bind the structures Man5HexNAc2 and Man9HexNAc2 equally. In 
the next section an alternative technique to lectin staining will be introduced, focussing 
on mass spectrometry which is relevant to this study.  
1.4.3 Mass spectrometry for analysis of glycans 
Similar to protein analysis, the use of analytical chemistry methods for analysis of glycans 
has several advantages over lectin/antibody based approaches. Importantly, detailed 
structural information of individual glycan species can be determined, as well as their 
relative abundance in a sample. If required tandem MS can be carried out to determine 
the exact linkage orientation in a single glycan species.  
The basic process of analysing glycans by mass spectrometry involves purification of 
glycans from glycoproteins, glycan derivatization, followed by separation and analysis by 
mass spectrometry or chromatography methods. Depending on the type of glycan to be 
analysed, specific techniques are preferred for each step, for example O-glycans require 
chemical release from glycoproteins, via β-elimination method, whilst glycolipids, 
proteoglycans and N-glycans can be released enzymatically. Glycan samples are then 
derivatized and/or labelled in order to improve detection sensitivity by mass 
spectrometry or chromatography respectively.  
Both matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and 
Electrospray ionization mass spectrometry (ESI-MS) are routinely used in glycan profiling. 
As with protein analysis by mass spectrometry, samples are ionized, and these ions are 
separated based on their mass-to-charge ratio, detected and represented as a spectrum. 
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In this study MALDI- time of flight (TOF) mass spectrometry was used, as it is regarded as 
one of the most sensitive methods for glycan profiling and produces spectrum in which 
glycan species are singly charged, so that the mass-to-charge ratio equals the predicted 
mass of the glycan structure, facilitating easier spectrum analysis (reviewed in [75]). 
Alternatively, ESI-MS is a ‘soft’ ionization technique and should therefore reduce the 
amount of in-source decay of samples. Unlike MALDI-MS as matrix is not used for 
ionization, spectra do not contain background matrix peaks. However, ESI-MS is 
considerably more labour intensive, as spectrum can contain a complex pattern of 
multiple charged states for each glycan species.     
Earlier sections have described multiple types of glycans and some of their current known 
cellular functions and roles in diseases. As stated before, the study of stem cell 
differentiation in vitro is an ideal model to investigate the role of glycans in a specific 
process of development, without the web of interconnected systems found in whole 
organisms. Before describing what is currently known about the role of glycans in this 
process, mesenchymal stem cells and their differentiation in vitro and in vivo will be 
introduced.          
 
1.5 Stem cells 
Human embryonic stem cells (hESCs) are isolated from the inner cell mass of a pre-
implantation embryo. These cells are capable of differentiating into every cell type in the 
body, apart from extra-embryonic supporting tissues such as the placenta, and are 
therefore called pluripotent. Later during development, and residing in tissues 
throughout life, there are cells capable of self-renewal and differentiation into several 
adult cell types.  These adult stem cells are called multipotent. When tissues need to be 
renewed due to damage caused by injury or age, the adult stem cells divide 
asymmetrically in order to self-renew and provide cells that can differentiate into the 
required mature, functional cells for that tissue.  
1.5.1 Mesenchymal stem cells   
Mesenchymal stem cells or multipotent stromal cells (MSCs) are adult stem cells that act 
in vivo to differentiate into bone, fat and cartilage tissue when it is damaged or aged 
(Figure 1.6). In a paper by Pittenger et al (1999), MSCs were isolated from iliac crest bone 
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marrow and characterized in vitro [76]. MSCs were capable of multiple rounds of 
proliferation whilst retaining the ability to differentiate into different lineages when 
specific stimuli were added to the culture media. Experiments with single cell derived 
colonies suggested that MSC cultures are a heterogeneous population of cells. Within the 
population, some MSCs had the ability to differentiate into any cell type – osteoblast, 
adipocyte or chondrocyte – whilst others were less potent and more limited in their 
differentiation potential [76]. 
 
Figure 1.6 Differentiation capacity of MSCs 
MSCs both in vivo and cultured with specific stimuli in vitro can differentiate into 
adipocytes, chondrocytes and osteoblasts. 
1.5.1.1 Function of MSCs 
MSCs are typically isolated from bone marrow but cells with MSC-like characteristics have 
been successfully isolated from nearly every tissue in the body including the brain [77]. 
Aside from differentiating into adipocytes, chondrocytes and osteoblasts, MSCs have 
been shown to have immuno-regulatory roles. Since MSCs reside in the bone marrow 
alongside HSCs, which differentiate into all types of blood cells, including immune cells, 
the ability of MSCs to regulate lymphocyte proliferation was tested. In vitro results 
showed that MSCs reduced lymphocyte proliferation, and tests using skin grafts 
suggested that MSCs had immune-regulatory properties in vivo [78].  
The ability of MSCs to differentiate into different cell types means they could be used for 
regenerative medicine, for example by generating patient derived (autologous) new 
tissue to replace damage or diseased tissue.  The application of MSCs in regenerative 
medicine began with the treatment of bone defects or diseases. Successful results in 
sheep, using scaffolds loaded with MSCs to repair critical-size tibia bone defects, were 
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recapitulated in clinical trials using patients with various bone defects [79, 80]. Following 
the discovery of the immune-regulatory capacity of MSCs, there has been some success in 
clinical trials for the treatment of graft versus host disease, using MSCs. The exact dose of 
MSCs and the risk of complications still requires further investigations [81]. The number 
of trials using MSCs to treat a variety of conditions and diseases, such as muscle repair 
after heart attacks, diabetes or stroke [82-84], is ever increasing. Their success is likely 
due to a combination of MSCs tri-lineage differentiation potential and their immuno-
regulatory capabilities. 
1.5.1.2 Defining an MSC    
As the number of studies using MSCs was increasing, and research groups were isolating 
their MSCs from different tissues, using different selection conditions, a set of criteria for 
defining MSCs was published by the International Society for Cellular Therapy. This was to 
enable better comparison of studies and to ensure that the MSCs being used were the 
same population of cells between research groups. The criteria was for MSCs to be plastic 
adherent; capable of tri-lineage differentiation; and to express cell surface markers 
CD105, CD73, CD90; as well as be negative for HSC surface markers CD45, CD43, Cd14 or 
CD11b, CD79a or CD19 and HLA-DR [85].  
1.5.1.3 Controlling differentiation of MSCs 
Detailed understanding of the regulatory mechanisms that determine MSC fate would 
improve the success of MSCs in regenerative medicine, and could identify novel targets to 
treat or prevent disease. Currently, genomic and proteomic approaches have identified 
changes in gene expression and transcription factors, as well as the myriad of signalling 
pathways that influence MSC differentiation [86]. A combination of unique and shared 
mechanisms regulates the differentiation of MSCs into specific, mature, functioning cell 
types. Outlined below are the main transcription factors and signalling pathways involved 
in osteogenesis; the differentiated lineage that will be the focus of this research.   
1.6 Osteogenesis  
The major pro-osteogenic transcription factor is Runx2, which is expressed throughout 
osteogenesis. Studies that identified Runx2, found it bound to the promoter region of the 
osteoblast specific gene osteocalcin, as well as other osteogenic genes: α 1 collagen, bone 
sialoprotein (BSP) and osteopontin [87]. Expression of Runx2 was observed throughout 
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skeletal development and limited to osteoblast cells. Confirming its role in osteogenesis, 
the loss of Runx2 expression in mice was lethal and their skeletons showed a complete 
lack of bone ossification, indicating that Runx2 is required for osteogenesis [88]. 
Furthermore, overexpression of Runx2 in mouse-derived MSCs enhanced the expression 
of bone-related genes in vitro, and showed increased mineralization capacity in vivo [89]. 
Osterix is another pro-osteogenic transcription factor that acts downstream of Runx2, and 
is essential for bone formation [90]. Other pro-osteogenic transcription factors are Dlx3, 
Dlx5 and Dlx6, with overexpression of either transcription factor in vitro enhancing 
osteogenic differentiation [91, 92]. Transcription factors that inhibit osteogenic 
differentiation include Twist1 and to a lesser extent Msx2. Msx2 has been shown to 
promote osteoblast proliferation, which is required during early differentiation and 
inhibits matrix mineralisation, which is associated with later stages of osteogenesis [93]. 
Twist1 is another transcription factor that has roles in the timing of osteogenic 
differentiation. Overexpression studies in vitro showed that Twist1 can inhibit Bone 
morphogenetic protein 2 (BMP2) induced osteogenesis [94]. Patients with Saethre-
Chotzen syndrome suffer from premature cranial ossification, which is caused by 
mutations in Twist1. Patient osteoblasts showed increased rates of growth and 
mineralization without increased osteocalcin expression [95]. These findings suggested 
that Twist1 is required for the correct temporal expression of pro-osteogenic factors. 
The expression of transcription factors is modulated by several signalling pathways, which 
are activated by growth factors and signalling molecules from the cellular environment. 
Of the many signalling pathways that converge to regulate osteogenesis, BMP signalling is 
central. BMPs are members of the TGFβ superfamily that are morphogens, which are 
secreted as dimeric ligands. BMPs act at different stages of development and BMP2 is 
implicated in directing osteogenesis. Addition of BMP2 to culture media can induce 
osteogeneic differentiation of MSCs in vitro. The downstream signalling pathway of BMPs 
and TGF-β involves the binding to distinct receptors, which results in the phosphorylation 
of receptor SMAD proteins that form complexes with other SMAD proteins and 
translocate to the nucleus, where they affect transcription factor activity. BMP2 and TGF-
β1 have been shown to activate Runx2 [96]. BMP2 also increases Osterix activity via Dlx5, 
independently of Runx2 [97]. Another major signalling pathway involved in osteogenesis 
is the canonical Wnt pathway. Through a signalling cascade active Wnt signalling prevents 
the phosphorylation and the following destruction of β catenin, this allows un-
43 
 
phosphorylated β catenin to translocate to the nucleus and modulate gene transcription 
via the LEF/TCF family of transcription factors. Studies into the role of Wnt signalling in 
osteogenesis have been somewhat contradictory. Mice studies using a Wnt pathway 
inhibitor that protects β catenin from phosphorylation, showed an increase in 
osteogenesis in vitro and in vivo [98]. Further studies suggested Wnt signalling to promote 
osteogenesis, by identifying a TCF binding site in the promoter region of Runx2 [99]. 
However, studies using human MSCs showed that canonical Wnt pathway stimulation 
using Wnt3a inhibited osteogenesis, whilst, non-canonical Wnt pathway stimulation using 
Wnt5a promoted osteogenesis [100]. Quarto et al (2010) analysed MSCs at different 
stages of osteogenic differentiation and found stage-specific responses to Wnt3a, 
showing that Wnt signalling promoted osteogenesis of mature osteoblasts, but inhibited 
osteogenesis of MSCs [101]. Another signalling pathway active during bone development 
is the Hedgehog (Hh) signalling pathway. Similar to the Wnt pathway, binding of an Hh 
factor to a receptor prevents the suppression of a protein downstream, called 
Smoothened, which leads to the Gli family transcription factors being active. In vitro 
studies in which mouse MSCs were treated with the Hh signaling factor – Indian 
Hedgehog (IHh) – showed positive induction of osteogenesis after just 2 days of 
treatment [102]. In further support of this, IHh null mice showed reduced chondrogenesis 
and osteoblast formation, resulting in reduced endochondral bone formation [103]. 
Interestingly, the pro-osteogenic action of IHh has been shown to require active Wnt 
signalling in vitro, showing cross-talk between the signalling pathways regulating 
osteogenesis [102]. 
Osteogenesis is a complex process, with layers of proteomic and genomic control. 
Overlapping pathways interplay to insure the correct temporal and spatial stages of 
osteogenesis occur. Studies have also described how the MSC environment or niche is 
critical to its function [104]. However, although cells are covered in glycans that can 
interact with other cells and the ECM; and many of the components of osteogenic 
signalling pathways are glycoproteins (Table 2); there has been little research into the 
role of glycans in MSC differentiation. The next sections will describe the current 
knowledge of glycans and stem cells, as well as outline evidence that suggests glycans 
may have a role in MSC differentiation.   
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Signalling pathway Lineage Glycoprotein Effect on function Ref 
Wnt Osteoblast, Adipocyte 
and Chondrocytes 
Wnt3a Wnt3a has 2 N-glycan sites. Glycosylation required for secretion. Some hint at 
reduced binding to z8-CRD (post PNGase F). 
[105, 
106] 
   Wnt1 Removal of 4 glycan sites shown not to affect ability of retroviral vector to transform 
a mouse epithelial line.   
[107] 
  Frizzled 1-10  Putative N-glycan sites identified only.  [108] 
  LRP6  Mest reduced LRP6 secretion accompanied by a reduction in LRP6 glycosylation, 
which promoted adipogenesis.  
[109] 
Non canonical Wnt  Wnt5a 4 N-glycan sites identified. Removal didn’t affect function, but secretion was lower. [106] 
Hedgehog 
pathway 
Pro- osteogenic 
Anti-adipogenic 
Patched  
 
Patched receptor has 2 putative glycan sites. Treatment with tunnicamycin reduced 
ability of Smoothened (co-receptor) to bind to Patched.  
[110] 
TGF-β Osteogenic, 
Chondrogenic and 
Anti-adipogenic 
Type II TGF-β 
receptor  
2 N-glycosylation sites, which affect localization to membrane thereby affecting TGF-
β sensitivity.  
[111, 
112]  
BMP Osteogenic BMP-6 Removal of glycosylation of BMP-6 blocks binding to receptor. [113] 
Insulin  Adipogenic Insulin growth 
factor receptor 
Alternative glycosylation induced by media glucose deprivation caused alternative 
proreceptor to be degraded which prevented  tyrosine kinase activity. 
[114] 
Table 2 . Glycosylation of receptors and ligands in several pathways key to differentiation of MSCs.  
Table includes some of the receptors and ligands identified as glycoproteins, which are involved in signalling pathways key to MSC differentiation. Many 
receptors and ligands have only putative glycosylation sites identified from sequence data, others have yet to be analysed for the presence of N-glycan 
consensus sites.   
1.7  Glycosylation changes during cellular development 
Studies have shown that the glycosylation profile of cells changes during development.  In 
fact, several markers of hESCs, such as stage-specific embryonic antigens (SSEAs), are 
glycoproteins and glycolipids [115]. Lectin binding arrays have revealed differences in cell 
surface glycans between undifferentiated hESCs and 12-day-old differentiated embryoid 
bodies, such as the loss of α 1, 2 linked fucose after differentiation [116]. Furthermore, 
again using lectin binding arrays, differences in glycosylation between MSCs, neural 
progenitors cells (NPCs), and hESCs have been identified [117]. This shows that 
glycosylation is different not only between cells at different stages of differentiation, but 
also between cell types at the same level of differentiation – i.e. between MSCs and NPCs.  
1.8  Glycan profile of MSCs and functional roles 
Mass spectrometry has been used to analyse the glycome of MSCs and osteoblasts 
derived from them [118]. MSCs were shown to have more oligomannose type glycans 
than osteoblasts, which had more complex glycans as well as more glycans with terminal 
galactose, than MSCs [118]. Moreover, a study investigating the function of glycans 
compared the ability of MSCs, osteoblasts, or adipocytes to support myelopoiesis. 
Adipocytes were found to be less supportive than osteoblasts, and had decreased glycan 
branching compared to both MSCs and osteoblasts. When MSCs were treated with a 
mannosidase I inhibitor (deoxymannojirimycin), this resulted in both reduced glycan 
branching and reduced myelopoistic support, suggesting that glycosylation plays a 
functional role in the ability of cells to support  myelopoiesis [119]. A study by Sackstein 
et al (2008), showed that MSC glycans have another cellular function. The glycosylation of 
CD44 on MSCs, was altered ex vivo in order to recognise the lectin found specifically in 
bone marrow vessels. This successfully improved bone infiltration rates of intravenously 
administered MSCs, without changing their ability to proliferate or differentiate, showing 
both the importance, and functional specificity of cellular glycans [120]. Together these 
studies have shown that glycans on MSCs can influence cellular function and that the 
glycan profile changes during differentiation. However, critically, none of the studies 
mentioned above have shown the role of glycans (if any) in the differentiation of MSCs.   
Evidence that supports a role of glycans in determining MSC fate, includes the skeletal 
related symptoms, such as short stature; absent humerus and tibial; and clinodactyly 
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(bent little fingers), that many CDG patients suffer from [121]. Furthermore, many of the 
receptors and ligands in the signalling pathways already identified as key to MSC 
differentiation are known to be glycosylated (Table 2). The degree of glycosylation is 
known for some, and for a few glycoproteins the effect of glycosylation on function has 
been studied, by either altering the consensus site so a glycan is no longer attached at all, 
or by using glycosidase inhibitors to prevent complex glycan formation in the Golgi. A 
major change to cellular glycosylation would alter the glycosylation of many signalling 
molecules, and if an effect on cellular function was bought about, it would be challenging 
to dissect out a single culprit glycoprotein that has bought about the change. However, 
due to the redundancy in many signalling pathways, it is possible that an alteration to a 
single glycoprotein would not result in an observable cellular change. 
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1.9  Project rationale and aims 
Glycosylation is an abundant post-translational modification, which can affect many 
cellular processes. Although most glycans are not required for in vitro cell culture, all 
types of glycan have been shown to be essential for embryonic development. Mouse 
studies and symptoms of CDG patients point towards a developmental role of glycans in 
many tissue types. The study of MSC differentiation provides an in vitro model of 
development, which can be easily manipulated and studied, without the web of 
interconnecting systems found in whole organisms. Research into what influences MSC 
differentiation is of importance to the regenerative medicine field, as it may improve 
differentiation techniques or identify novel targets that can be manipulated to influence 
stem cell behaviour in situ. 
There are multiple lines of evidence that signify a speculative role for glycans in MSC 
differentiation. These include: the abundance of glycosylated proteins on MSCs cell 
surface; known examples of glycans impacting protein function; the change in glycan 
profile between MSCs and differentiated cells; the skeletal symptoms of CDG patients; 
and the involvement of many glycoproteins in signalling pathways. To investigate if 
glycans can influence MSC osteogenesis, I propose to use mass spectrometry to profile 
the N-glycans of MSCs and osteoblasts derived from them. The glycan profile of 
subpopulations of MSCs, with varied differentiation capacity, will be compared. Further to 
this, the glycan synthesis pathway will be disrupted genetically and chemically, and the 
ability of MSCs to differentiate with modified glycan profiles will be assessed. As a result 
of these experiments, any changes in differentiation capacity will be compared back to 
alterations in glycan profile, providing a novel assessment of the role of glycans in 
osteogenesis.   
 
Chapter 2 Materials and methods 
2.1 Chemicals 
All chemicals were from Sigma unless otherwise stated. 
2.2 Cell culture 
2.2.1 Culture media 
All tissue culture components were from Invitrogen and the plasticware from Sigma-
aldrich unless otherwise stated. Cells were cultured in basal media composed of 
Dulbecco’s Modified Eagle Media (DMEM, high glucose, pyruvate, no glutamine) 
supplemented with 10% fetal bovine serum (FBS), 1% Penicillin/streptomycin (P/S) and 
1% Gluta-Max-I.  
2.2.2 hTERT-MSCs 
hTERT-MSCs were previously generated and characterized prior to this research [122]. 
These immortalized cell lines were created from primary human mesenchymal stromal 
cells that were isolated from a femoral head, and then transduced with lentivirus to drive 
the over expression of human telomerase. Single cell colonies derived from this 
transduction were isolated and expanded in culture. Lines used in this research were 
Y101, Y201 and Y202 hTERT-MSCs.  
2.2.3 hTERT-MSC culture  
Cells were grown in a humidified incubator at 37oC and 5% CO2. Cells were grown in tissue 
culture flasks or 10cm petri dishes, before cells reached full confluence cells were split 
1/6 or as required, by incubation with trypsin/EDTA for 5 minutes until detached.      
2.2.4 Mycoplasma 
Cells were tested for mycoplasma regularly throughout culture and whenever cells were 
bought up from liquid nitrogen storage. Briefly, cells were seeded into wells of a 24 well 
plate and serial diluted across several wells. After minimum of 2 days, culture media was 
removed and wells were washed with PBS twice followed by fixation with methanol for 5 
minutes. After removal of methanol, cells were incubated in a solution of 2µg/ml DAPI in 
PBS, for 5 minutes at room temperature in the dark. Post removal of DAPI and several 
washes with PBS, cells were visualised using a UV lamp, and another lab member 
requested to confirm absence of none nuclear staining.       
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2.2.5 Osteogenic media 
In order to induce osteogenesis cells were cultured in basal media described above that 
also contained 50μg/ml ascorbic acid, 5mM β-Glycerophosphate and 10nM 
dexamethasone. During differentiation (up to 28 days) media was changed every 3-4 
days.      
2.2.6 Adipogenic media 
In order to induce adipogenesis cells were cultured in basal media described above that 
also contained 1μM dexamethasone, 500μM 3-isobutyl-1-methylxanthine (IBMX), 1 μg/ml 
insulin and 100μM indomethacin. During differentiation (up to 28 days) media was 
changed every 3-4 days.      
2.3 Generation of Cog4KDs 
To generate Cog4 knock-down MSC lines, Y101 hTERT-MSCs were seeded into tissue 
culture wells and allowed to settle for 6 hours. Following this, cells were incubated 
overnight in media containing, 6μg/ml polybrene and MISSION® lentiviral particles, 
containing one of five shRNAs targeted to Cog4, which were designed and produced by 
Sigma-Aldrich. The five shRNAs were assigned a letter A-E (Table 3). The plasmid-
backbones used for the different shRNAs are shown in Figure 2.1. The difference between 
the two vectors is the presence of a Woodchuck Hepatitis Post-transcriptional regulatory 
element (WPRE), which has been shown to enhance transgene transcription. 
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Table 3. Details of shRNAs against Cog4. 
shRNAs were designed and produced by Sigma-Aldrich. 
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Name Description 
cppt Central polypurine tract 
hPGK Human phosphoglycerate kinase eukaryotic promoter 
puroR Puromycin resistance gene for mammalian selection 
WPRE Woodchuck Hepatitis Post-Transcriptional Regulatory Element 
SIN/LTR 3' self inactivating long terminal repeat 
f1 ori f1 origin of replication 
ampR Ampicillin resistance gene for bacterial selection 
pUC ori pUC origin of replication 
5' LTR 5' long terminal repeat 
Psi RNA packaging signal 
RRE Rev response element 
Figure 2.1 TRC1.5  and TRC2 Vector Maps (pLKO.1-puro). 
Taken directly from http://www.sigmaaldrich.com/life-science/functional-genomics-and-
rnai/shrna/library-information/vector-map.html (May 2015).  
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The multiplicity of infection (MOI) is the number of transducing lentiviral particles per 
cell. This was calculated as follows:   
i) (Total number of cells per well) x (Desired MOI) = Total transducing units needed (TU) 
ii) (Total TU needed) / (TU/ml reported on Certificate of Analysis) = Total ml of lentiviral 
particles to add to each well 
A range of MOI were used as recommended by the manufacturer, in order to determine 
criteria for highest transduction efficiency.  Following transduction, cells were cultured in 
normal media for 24 hours and then in media containing 2μg/ml puromycin, to select for 
positively transduced cells. Media was changed every 2 days and cells monitored until 
non-transduced control cells had died.  
2.3.1 Single-cell derived line formation 
To culture single-cell derived lines, transduced cells were trypsinized and 500 cells placed 
into a 10cm culture dish with 9ml clonal media. Clonal media was basal culture media 
supplemented with 10% Hyclone FBS; and was made with 50% conditioned media, which 
was collected from a T175 flask of non-transduced Y101 hTERT-MSCs and filtered before 
use; and contained 2μg/ml puromycin. Media was replaced every 3-4 days. Dishes were 
monitored regularly and single, adhered cells were circled using a lab pen. Once colonies 
contained at least 50 cells, plates were washed with 1xPBS and small metal clonal rings 
were adhered to the plate using sterile grease. Trypsin was added inside of the ring, and 
after 10 minutes incubation at 37oC, colonies were pipetted into separate wells of a 24 
well plate. Cog4KD hTERT-MSC colonies were named using the letter of the shRNA used 
during transduction, the MOI which was used, and finally a number given after initial 
transfer into a 24 well plate. For example, C1.6 was created using shRNA “C”, an MOI of 1 
and was the 6th clone transferred into a 24 well plate.    
 
2.4 Histochemistry  
2.4.1 Crystal violet 
Cells were washed twice in PBS before fixation in 95% ethanol at room temperature for 5 
minutes. Cells were then washed with PBS before being incubated at room temperature 
in 0.5% w/v crystal violet made in 95% ethanol, for 30 minutes. After removal of stain, 
cells were washed several times in tap water to remove non bound stain. Plates were 
53 
 
then left to air dry, at room temperature overnight, prior to imaging by bright-field 
microscopy.   
2.4.2 Alkaline Phosphatase (ALP) and phosphate (Von Kossa)  
Cells were washed twice with PBS before addition of ALP stain solution which contained: 
0.2mg/ml naphtol AS-MX in 1% N,N-dimethylformamide, 1mg/ml Fast Red TR diluted in 
0.1M Tris pH 9.2. After 5 minutes incubation with the ALP stain solution, the cells were 
washed twice with PBS before being fixed in 4% paraformaldehyde (PFA) for 5 minutes at 
room temperature. Cells were then washed with PBS, followed by water, before addition 
of 1% v/w silver nitrate solution. Plates were then placed on a light box for 30 minutes. 
Cells were then washed three times with distilled water (dH2O) and incubated for 5 
minutes with 2.5% w/v sodium thiosulphate to remove non-specific staining. Finally, cells 
were then washed twice with dH2O and stored in 20% glycerol in PBS before being 
imaged by bright-field microscopy.  
2.4.3 Oil red O  
Cells were washed 1x with PBS before being fixed with 4% PFA for 10 minutes. Following 
this, cells were washed 1x with dH2O. Cells were then incubated in 60% isopropanol for 5 
minutes, and then incubated for 10 minutes in 0.3% Oil red O solution. The 0.3% Oil red O 
solution was made by diluting a stock solution of 0.5% Oil red O (in isopropanol) with 
dH2O (3:2), this was left overnight for precipitate to settle as well as being filtered before 
use. Cells were then washed 1x with 60% isopropanol and 3x with dH2O. 100ul dH2O was 
then added before imaging. 
2.4.4 Alcian blue staining  
Cells were washed once with PBS before fixation for 10 minutes at room temperature 
with 4% PFA. Cells were then washed twice with dH2O, and then incubated overnight at 
room temperature in 0.5% w/v Alcian blue, 10% concentrated hydrochloric acid (HCL) v/v. 
Cells were then washed twice with dH2O and 100μl of PBS added to each well. Images of 
stained cells were then taken using a bright-field microscope. To quantify degree of 
staining, the stain was eluted by addition of 100μl 6M guanidine-HCL to each well. After 
48 hours, the guanidine solution was transferred into a new 96 well plate, and 
absorbance was read at 630nm.       
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2.5 Real time quantitative PCR methods 
During the following procedures filter tips as well as plasticware and regents that were 
set aside for ‘RNA work only’, were used in order to limit contamination of samples with 
RNAases.  
2.5.1 RNA extraction 
Cells were grown in 6 well tissue culture plates to allow for sufficient cell numbers to 
extract RNA from. To harvest RNA, cells were washed with PBS twice and then incubated 
with 500µl per well TRIzol reagent (ambion, life technologies) for 2.5 minutes at room 
temperature. Plates were then gently rocked before a further incubation of 2.5 minutes 
at room temperature. Cell lysate in TRIzol was then transferred into an eppendorf tube 
and frozen at -80oC. Samples were then defrosted at room temperature and 100µl of 
chloroform was added to each sample. Tubes were then shaken vigorously for 15 seconds 
and then incubated at room temperature for 15 minutes. Following this tubes were 
centrifuged at 12000g for 20 minutes at 4oC. The clear, upper phase was transferred into 
a new tube and 250µl isopropanol was added. The tubes were then inverted several times 
before being incubated at room temperature for 30 minutes, to allow RNA to precipitate. 
Samples were then centrifuged at 12000g for 15 minutes at 4oC, and the RNA pellet was 
then washed with 1ml 75% ethanol, before being centrifuged at 12000g for 5 minutes at 
4oC. Most of the supernatant was removed before allowing the pellet to air-dry for 10 
minutes. Finally the RNA pellet was resuspended in 12µl nuclease-free water (Hypure, 
Molecular biology grade water, ThermoScientific) and stored at -80oC. 
2.5.2 DNase treatment of RNA samples  
RNA samples were treated with RQ1 RNase-free DNase I (Promega) following the 
manufacture’s guidelines. In brief, RNA samples were defrosted on ice, before 1µl of RQ1 
RNase-Free DNase, 2µl of 10x reaction buffer and 5µl of nuclease-free water, were added 
to each sample. Samples were then incubated at 37oC for 30 minutes. 2µl of 50mM EDTA 
was then added to each sample before being incubated at 65 oC for 10 minutes in order to 
inactivate the DNase. 
2.5.3 cDNA synthesis 
Firstly, the RNA concentration of each sample was measured using a nanodrop. Reverse 
transcription was carried out on 1µg of RNA from each sample and on a water control 
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sample. The RNA sample was pipetted into a PCR tube with 1µl of Oligo(dT)12-18 Primer 
(Invitrogen); 1µl 10mM dNTPs; and water to make the total volume 12µl. After mixing, by 
gentle pipetting, samples were incubated at 65 oC for 5 minutes. Samples were then 
chilled on ice for 2 minutes and then spun briefly. A mixture containing 4µl 1st Strand 
buffer; 2 µl 0.1M DTT; and 1 µl of water; was then added to each sample and gently 
mixed by pipetting. Samples were then incubated for 2 minutes at 42 oC, before 1 µl of 
SuperScript II reverse transcriptase (Invitrogen) was added. After further mixing, samples 
were then incubated at 42 oC for 1 hour and at 70 oC for 15 minutes. Samples were then 
either left neat or diluted as required with water, before being used in real-time PCR 
quantitative reactions.      
2.5.4 Real time quantitative PCR reactions        
Real time quantitative PCR reactions were carried out using Fast SYBR Green master mix 
(Applied Biosciences) and run using a StepOnePlus Real time PCR system (Applied 
Biosciences) and analysed using StepOne v.2.3 software. 
To assay gene expression using real time quantitative PCR, a master mix containing 10µl 
of Fast SYBR Green reagent; 2µl of appropriate primer pair mix (each primer at 5mM); 
and 5µl of water was prepared, in triplicate, for each sample and pipetted into wells of a 
96 well plate (MicroAmp® Fast optical 96 well reaction plate with barcode, Life 
Technologies). Following this 3µl of diluted cDNA was added in triplicate. Plates were 
briefly centrifuged to bring contents to the bottom of each well, before being loaded into 
the StepOnePlus PCR machine. Settings on the StepOnePlus system were chosen for SYBR 
Green use, to generate comparative CT data and, when doing primer validation, 
(described in more detail below) to include a dissociation curve. Program settings were 
95oC for 20 seconds, before 40 cycles of 95oC for 3 seconds then 60oC for 30 seconds. 
When a dissociation curve was required, following each cycle, temperatures changed to 
95oC for 15 seconds, 60oC for 1 minute followed by 95oC for 15 seconds. 
2.5.5 Primers and validation       
Primers were designed using NCBI GenBank and NCBI Primer blast online tools. Primers 
were tested on cDNA from Y101 hTERT-MSCs, after 21 days in osteogenic media. cDNA 
was serially diluted and added in triplicate to the PCR master mix (as above). Water only 
controls were also added in triplicate to check for primer dimerization. Plates were then 
run as above including a dissociation curve stage. To test the efficiency of primers, the CT 
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values were plotted against the Log concentration and the slope of the line compared to 
that of the housekeeping gene RSP27a. If primers are efficient the CT values should 
increase by 3.33 cycles after a 10 fold dilution of cDNA. The dissociation curves were used 
to confirm primer specificity. The primer sequences and the efficiency graphs are shown 
in Figure 2.2. For analysis of samples from a time-course experiment, the 20μl of cDNA 
from the cDNA synthesis was used after dilution of 1/3 for BMP2 and BSP primers, 1/2 for 
Runx2 and 1/10 for RPS27a.  
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Figure 2.2 QPCR primer sequences and efficiencies 
A) Primer sequences for primers used in real time quantitative PCR with SYBRE green 
reagents. B) Primer efficiencies were measured using a serial dilution of a test sample 
with each primer. CT values were plotted against log cDNA concentration and slope of the 
line calculated. For efficient primers the slope of the line should be -3.33 +/- 0.2.    
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2.5.6 Real time quantitative PCR data analysis  
To analyse real time PCR data, the CT values from sample triplicates were averaged. This 
was done for gene of interest i.e. Runx2 and for the given housekeeping gene, which was 
RPS27a. Firstly the CT of RSP27a for that sample was taken away from the CT of the gene 
of interest to give “Delta CT”. To compare samples back to a Day 0 time point sample, all 
Delta CT values were divided by the Delta CT of the Day 0 time point sample, which 
calculates “Delta Delta CT” values. In order to display these results as fold change from 
the Day 0 time point, the formula: 2-Delta Delta CT , was used, setting the Day 0 time point to 
1. This was carried out for each gene of interest and when multiple cell types were used, 
the day 0 sample for untreated or wildtype was set to 1. Experiments were carried out 
twice, independently, to provide a biological replicate, resulting in n=6 for each sample.                
     
2.6 Flow cytometry 
Flow cytometry was used to assay the abundance of glycan structures on the cell surface. 
Samples were run using a flow cytometer (Beckman Coulter CyAn ADP analyser), and 
analysed using Summit 4.3 software.  
2.6.1 Flow cytometry of glycans 
Cells were first washed twice with PBS, and incubated with washing buffer (0.2% bovine 
serum albumin, 5mM EDTA in PBS) at 37oC for 10 minutes until cells detached from the 
flask. Cells were collected into a falcon tube and centrifuged for 5 minutes at 450g. The 
cell pellet was then resuspended in PBS and a cell count performed. Cells were then 
centrifuged again for 5 minutes at 450g and resuspended in ice-cold PBS so that the 
suspension contained 106 cells/ml. 100µl of the cell suspension was placed into an 
eppendorf tube for each sample. Tubes were then incubated on ice for 15 minutes in 
order to limit lectin internalisation by endocytosis. Following this, lectins, diluted in 100 µl 
of ice-cold washing buffer, were added to each sample. Concentrations of lectins used are 
detailed in Table 4. Samples were then incubated on ice in the dark for 15 minutes, 
flicked, and then incubated for a further 15 minutes. If lectins were directly conjugated, 
1ml of washing buffer was added and then the samples were centrifuged for 5 minutes at 
450g. The cell pellet was resuspended in 100µl of washing buffer containing 1µg/ml DAPI 
and incubated on ice in the dark for 5 minutes. Following this 1ml of washing buffer was 
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added and samples were then centrifuged for 5 minutes at 450g. Finally the cell pellet 
was resuspended in 400µl PBS and stored on ice in the dark prior to analysis by flow 
cytometry. If the lectins were conjugated to biotin rather than directly to fluorescein, 
samples were incubated with 100µl of streptavidin-fluorescein and then incubated on ice 
in the dark for 15 minutes, before being flicked to mix, and incubated for another 15 
minutes. 1ml of washing buffer was then added and samples centrifuged for 5 minutes at 
450g. This was repeated 3 times to remove non-specifically bound streptavidin. Cell 
pellets were then resuspended in 100µl of washing buffer containing 1µg/ml DAPI and 
treated as described for directly conjugated lectins.    
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Name of lectin Primary sugar specificity Dilution Conjugate 
Concanavalin A (ConA) Mannose 10µg/ml Fluorescein 
Wheat Germ agglutinin 
(WGA) 
N-Acetylglucosamine 1µg/ml Fluorescein 
Peanut agglutinin (PNA) galactosyl (β-1,3) N-
acetylgalactosamine  
(T-antigen) unsialylated only 
5µg/ml Fluorescein 
Vicia villosa (VVL) N-Acetylgalactosamine 
(Tn-antigen) and 
galactosyl (β-1,3) N-
acetylgalactosamine  
(T-antigen) 
10µg/ml Fluorescein 
Jacalin (Jac) N-Acetylgalactosamine 
(Tn-antigen) and 
galactosyl (β-1,3) N-
acetylgalactosamine  
(T-antigen) 
2µg/ml Fluorescein 
Sambucus Nigra (SNA) Sialic acid (α-2,6 linkage) 10µg/ml Biotin – use 
streptavidin 
secondary 
Maackia Amurensis II 
(MAL II) 
Sialic acid (α-2,3 linkage) 20µg/ml Biotin – use 
streptavidin 
secondary 
 
Secondary Specificity Dilution Conjugate 
Fluorescein- Streptavidin Biotin 5µg/ml Fluorescein 
Table 4. Lectin binding and concentrations for use in flow cytometry. 
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2.6.2 Flow cytometry data analysis  
Cells incubated with PBS only were run through the flow cytometry first, in order to 
adjust voltage of the lasers (405nm, 488nm and 633nm) so that the lower tail of the 
histogram was at 0, in all gates. Forward scattered light and side-scattered light were 
used to create a gate positively selecting cells, and negatively selecting cell debris, or cell 
clumps. Another gate selected negatively for violet fluorescence, thus selecting only live 
cells (unstained by DAPI). The count versus log green fluorescence of cells present in both 
gates was analysed and displayed as a histogram. The median fluorescence of the 
histogram was used in comparisons between samples. Also used was the coefficient of 
variation (half max) –CV(hm) –which is the width of a population at the point where the 
median value is half the maximum value of that population. The CV(hm) provided a 
numeric value of how wide or varied a population was. 
2.7 Cell assays 
2.7.1 p-Nitrophenyl Phosphate (pNPP) assay for ALP activity and picogreen 
assay for DNA content. 
Cells were cultured in 96 well tissue culture plates. At required time points cells were 
washed once with carbonate buffer (0.133M Na2CO3, 0.066M NaHCO3), then 150µl 0.1% 
Triton-X in carbonate buffer was added to each well. Plates were then frozen at -80oC 
until all samples were gathered. Cells were then freeze/thawed (using a 37oC incubator 
and -80oC freezer) three times. Triton-X was pipetted up and down to insure full cell lysis. 
50µl was transferred into a new clear 96 well tissue culture plate for pNPP assay and 50µl 
into a black opaque 96 well plate (Greiner 96 well microplate black, SLS) for the picogreen 
assay.  
For pNPP assay, 50µl of substrate solution (0.33mg/ml pNPP in carbonate buffer with 
3.3mM MgCl2) was added to each well. pNP standards (0.5-0.0125 µmol/ml) were added 
in triplicate to the plate which was then incubated at 370C for 10-30 minutes. Absorbance 
was then read at 405nm and a standard curve used to calculate ALP activity per minute.  
For the picogreen assay, salmon sperm DNA was diluted (8-0.25µg/ml) and pipetted in 
triplicate as standards. 50µl of the picogreen reagent (Quant-iT PicoGreen dsDNA 
Reagent, Invitrogen) diluted 1:50, in 100mM Tris, 1mM EDTA, pH7.5, was added to each 
well. Plates were covered with foil and left to rock for 5 minutes. Plates were read at 
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485nm excitation and 538nm emission, and a standard curve used to calculate amount of 
DNA per well, and used to make ALP activity relative to amount of DNA (μg PNP/min/μg 
DNA).    
2.7.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay  
For each cell line tested 1200 cells were seeded per well, into 6 wells of a 96 well culture 
plate. After 1, 2 and 4 days culture media was replaced with fresh media and 25µl MTT 
solution (5mg/ml in PBS). Plates were then incubated for 3 hours at 37oC in 5% CO2. MTT 
solution and media was removed from wells and 100µl of 0.04M HCL in isopropanol was 
added to each well. Plates were left to shake at room temperature for 10 minutes to 
allow for complete solubilisation. Absorbance was then read at 570nm, and average 
absorbance (with standard deviation) was used in comparisons.  
 
2.8 Glycan profiling 
2.8.1 Filter Aided N-glycan Separation (FANGS) 
The FANGS method was carried out as described by Rahman et al (2014) [123]. For all 
experiments here, 1x106 cells were seeded out into a 10cm tissue culture dish and 
allowed to settle for 24 hours (unless otherwise stated). Cells were then washed gently 
with 5ml of PBS (warmed to 370C), 6 times. 1ml of PBS was then added to the dish and a 
cell scrapper used to scrape cells into an eppendorf tube, which was placed on ice. The 
sample was then centrifuged at 16000g for 5 minutes, at 4oC. The supernatant was 
removed and the pellet re-suspended in a volume of lysis buffer (4% SDS, 100mM Tris 
pH7.6, 100mM DTT), approximately 10x volume of the cell pellet. The sample was then 
heated at 95oC for 5 minutes, followed by centrifugation at maximum speed (21000g) for 
5 minutes. The supernatant was then placed into a new tube and stored at -80oC if 
required. After defrosting, the supernatant was diluted 1:10 with 8M Urea and 100mM 
Tris pH 8.5. The sample was then concentrated through a concentrator filter system 
(millipore), by multiple centrifugation steps at 14000g for 5 minutes, by discarding the 
flow-through each time. The filter was then rinsed 2x with 8M Urea and 100mM Tris pH 
8.5, solution. Afterwards, 300µl of 50mM iodacetamide in Urea and Tris solution was 
added to filter unit, and incubated in the dark for 15 minutes, before it was spun through 
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at 14000g. The filter was washed again with Urea and Tris solution and then washed 4x 
with 20mM ammonium bicarbonate solution made using HPLC grade dH2O. 8-10 units of 
PNGaseF in total 100µl ammonium bicarbonate was added to each filter and mixed 
gently. Filter units were incubated for 16 hours at 37oC. A new collection tube was added 
to filter, prior to centrifugation at 14000g for 10 minutes. Retaining flow through in the 
tube, 200µl HPLC grade dH2O was added to the filter unit and mixed gently. Filter unit was 
then spun at 14000g for 10 minute and the last step repeated again. Flow through (500µl) 
was stored at -80oC.      
2.8.2 Permethylation 
15ml glass tubes (SLS) were washed in 3%v/v Decon and flamed clean just before use. 
Glycan filtrate (final flow through from FANGS) was placed into a glass tube. Glycan 
filtrate was dried down under vacuum, and then 300µl of HPLC grade dH2O was added to 
each tube. This was dried down under vacuum and repeated three times. Glycan samples 
were then stored at -20oC for at least 1 week. Glass tubes were allowed to reach room 
temperature before 20 drops of DMSO was added using a glass Pasteur pipette. Following 
this, 2 microspatulas of freshly ground sodium hydroxide was added to each sample. 0.5 
ml iodomethane was added to each sample and mixed once, by agitating the tube by 
hand. After 10 minutes this was repeated. After another 10 minutes, 1ml of iodomethane 
was added and mixed once by agitating the tube by hand. After 20 minutes 1ml of sodium 
thiosulphate (100mg/ml in H2O), was added and tube vortexed briefly. 1ml of 
dichlormethane was added and sample vortexed again. Samples were then centrifuged 
for 10 seconds and the upper aqueous layer was removed. 1ml of dH2O was added 
followed by a brief vortex and 10 second spin in centrifuge, and then removed as before. 
This was repeated 15x. The dichloromethane layer was then dried down under vacuum 
for 1 hour. Permethylated glycans were then stored at -20oC.        
2.8.3 Mass spectrometry 
Permethylated glycans were dissolved in 20µl methanol unless otherwise stated. 2µl of 
sample; 1µl of sodium nitrate (0.5M in 70% methanol, 30% H2O); and 2µl of 2,5-
dihydroxybenzoic acid (DHB) 20mg/ml in 70% methanol, 30% H2O; was mixed in a PCR 
tube. 2µl of this mix was placed onto a MALDI plate (Brucker) spot and allowed to air dry. 
Immediately after it dried 0.2 µl of ethanol was added to the spot in order for re-
crystallisation. Samples were analysed using MALDI-TOF/TOF mass spectrometry 
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(UltraFlex, Bruker). The spectra were acquired using positive-ion mode, with 4000 shots in 
steps of 800, which were summed to give one spectrum per spot. The Smartbeam laser 
power was set to 50-65%. Mass spectra were recorded over the m/z range of 800-
6000m/z.   
2.8.3.1 Spectra analysis 
Spectra were analysed using Flexi analysis 3.3 software (Bruker). Firstly, spectrum were all 
processed using Centroid peak detection algorithm, signal to noise limit of 3, and 
smoothed for 1 cycle at 0.1 mass/charge (m/z), using SavitzkyGolay alogrithm. Glycan 
peaks were identified from their mono-isotopic peak m/z value corresponding to a 
calculated m/z for known possible glycan structures. This was facilitated by the use of a 
simple algorithm that computes all possible combinations of the 4 main sugars (Mannose, 
GlcNAc, Fucose and Sialic acid), created by Dr. Peter Ashton (York). For a glycan to be 
included in analysis, at least 2 isotopic peaks had to be above noise, and the glycan had to 
have a comparable isotopic pattern to that which was predicted (Bruker Daltonics, 
Compass IsotopePattern software). The Peak intensity (height) of all isotope peaks for 
each glycan were summed (total peak intensity). In order to compare samples from 
different spectrum, the total peak intensity values were normalised using the formula: 
total peak intensity for a glycan X (100/total peak intensity identified in that spectrum). 
Normalised peak intensities could then be summed based on glycan structure 
characteristics and compared between samples.  
 
2.9 Western blotting 
2.9.1 Total cellular protein harvest 
Cells were cultured in a well of a 24 well plate until confluent. Media was then removed 
and cells washed once with PBS. 150μl of sample buffer (5% glycerol, 50mM Tris 50mM 
DTT, 1% SDS, 0.74mM bromphenol blue) was added to each well. Plates were incubated 
at room temperature for 10 minutes. Sample buffer was then pipetted up and down 
before being placed into an eppendorf tube and heated at 95oC for 5 minutes. Samples 
were then stored at -20oC until required.  
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2.9.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gels were prepared with a separating gel containing 10% acrylamide; 375mM 
Tris pH 8.8; 0.05% ammonium persulfate (APS); and 0.067% N,N,N′,N′-
Tetramethylethylenediamine (TEMED), and a stacking gel containing 4% acrylamide; 
125mM Tris pH 6.8; 0.1% APS; and 0.1% TEMED. Samples were loaded into wells 
alongside 5μl of a pre-stained protein ladder (Page Ruler Plus, Thermo-scientific). Running 
buffer containing 25mM Tris, 250mM glycine and 0.1% SDS was added to the gel-tank 
prior to gels being run at 120V for 10 minutes and then at 180V until either the dye 
reached the bottom of the plate or the ladder had separated as much as required.  
2.9.3 Semi-dry transfer 
Prior to use polyvinylidene fluoride (PVDF) membrane (Immun-Blot, Bio-Rad) was placed 
briefly into methanol before being placed into semi-dry transfer buffer containing: 48mM 
Tris, 39mM glycine, 20% methanol and 0.0375% SDS, and stored at 4oC until use. Two, 
3mm thick, pieces whatman paper were also soaked at 4oC, in transfer buffer. The SDS-
PAGE gel was placed onto the PVDF membrane in-between the two whatman pieces and 
semi-dry apparatus connected to power supply at 20V for 60 minutes.  
2.9.4 Immunoblotting and imaging 
After transfer membranes were blocked with 5% w/v milk powder in PBS with 0.05% 
Tween (PBST) for 1 hour at room temperature on a plate rocker. If required, membranes 
were then cut at appropriate molecular weight using the pre-stained ladder as a guide. 
Primary antibodies were added in 5% milk PBST and incubated either overnight at 4oC or 
for 1 hour at room temperature, on a shaker. Membranes were then washed 4 times with 
5% milk PBST for 10 minutes at room temperature on a shaker. Secondary antibodies 
were then added in 5% milk PBST and membranes incubated on a shaker for 1 hour at 
room temperature. Details of specific antibodies used and concentrations are shown in 
Table 5. Membranes were then washed twice with 5% milk PBST, and at least 4 times 
with PBST for 10 minutes on a shaker at room temperature. Membranes were then 
imaged using Immobilon western chemiluminescent HRP substrate (Millipore) and photos 
processed using Abobe Photoshop.  
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Antibody Concentration used  
Rabbit anti human Cog4 (as used in [124]) 1/500 
Mouse anti-human β tubulin (gift from G.Waters, Princeton 
University) 
1/2000 
Mouse anti-human ALP (Santa-Cruz, #sc-137213) 1/6000 
Mouse anti-human active β catenin (Millipore 050665)  1/2000 
Goat anti-mouse HRP (BioRad) 1/3000 
Goat anti-rabbit HRP (BioRad) 1/3000 
Table 5. Details of antibodies used for immunoblotting. 
 
2.10 Statistics 
Data was analysed using SigmaPlot 12.3 software. Before statistical tests were applied a 
normality test (Shapiro-Wilk) and a test of equal variance was performed. If data passed 
and only two groups were being compared, a Student’s T test was carried out. If more 
than one group was being compared, on a single factor, one-way ANOVA tests were 
carried out, followed by Holm Sidak post-hoc tests if required. If the data failed the 
normality or variance tests, equivalent non-parametric tests were applied instead. If two 
groups were being compared a Mann-Whitney test was carried out, and a Kruskal-Wallis 
One Way Analysis of Variance on Ranks, followed by Dunn’s post hoc tests was carried 
out if more than one group was being compared on one factor. Throughout *=P<0.05, 
**=P<0.01 and ***=P<0.001.     
     
    
 
Chapter 3 : Comparison of the N-glycan profile of hTERT-
MSCs and osteoblasts derived from them 
3.1 Rationale for the comparison of the N-glycan profile of hTERT-MSCs and 
osteoblasts derived from them 
Many studies have focused on discovering genomic and proteomic factors that influence 
MSC differentiation. Glycosylation is an abundant post-translational modification, which 
occurs to most cell surface proteins. Glycans have been shown to affect protein function 
and cellular behaviour. Previous studies have found differences in the glycan profile of 
MSCs compared to osteoblasts or adipocytes derived from them [118, 125]. The broad 
aim of this research was to investigate if glycans have a functional role in MSC 
differentiation. This was addressed utilizing immortalized human MSC cell lines (hTERT-
MSCs). These lines were previously generated by inducing the overexpression of human 
telomerase in primary human MSCs [122]. The advantages of using an immortalised cell 
line include having an unlimited supply of cells, compared to the primary human MSCs 
that senesce after several passages in culture. Furthermore, it is known that there is 
variability in response to treatments, between primary human MSCs from different 
donors, which impedes comparisons between different experiments. As the hTERT-MSCs 
were expanded from single-cell colonies, they provide an unlimited supply of a single 
subtype of MSC.  In agreement with the theory that primary human MSCs are a 
heterogeneous mixture of cells, three hTERT-MSC lines showed varying differentiation 
capacity ([122] and Figure 3.1). The Y101-hTERT-MSCs were capable of differentiating into 
osteoblasts, but showed limited adipogenic potential. The Y201 hTERT-MSCs were 
capable of differentiating into both osteoblasts and adipocytes, and the Y202 hTERT-
MSCs did not differentiate into either cell type (Figure 3.1).  
Although previous studies have compared the glycan profile of MSCs and osteoblasts, a 
heterogeneous mixture of primary MSCs were used [118]. Here, the Y101 hTERT-MSCs, 
which could be described as an osteoblast precursor or osteoblast progenitor line, were 
utilized. Differences that may have been missed due to the heterogeneity of the primary 
MSC population could be more pronounced in the Y101 hTERT-MSCs glycan profile. The 
Y101 hTERT-MSCs were differentiated into osteoblasts by culture in media supplemented 
with ascorbic acid, β-glycerophosphate and dexamethasome, which has been previously 
shown to induce osteogenesis [126]. Y101-hTERT-MSCs were cultured in osteogenic 
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media for 3 weeks prior to glycan analysis. There are many changes in gene expression 
and cellular physiology that occur during osteogenesis. During early stages and 
throughout osteogenesis ALP activity is known to increase. ALP is required for the 
initiation of mineralisation through increased localised phosphate production [127]. 
BMP2 is a bone morphogenetic protein that promotes osteogenesis by indirectly inducing 
Runx2 expression [128]. Runx2 is the major pro-osteogenic transcription factor that 
regulates the expression of several osteogenic genes [86]. BSP is one target of Runx2, and 
acts as a nucleator of hydroxyapatite crystal formation, required for matrix mineralisation 
[129], the process associated with later stages of osteogenesis. The functional readout of 
osteoblasts is mineralised ECM, which is visualised using Von kossa staining, which stains 
phosphates using the reduction of silver ions exposed to light [130]. In order to confirm 
osteogenic differentiation of the Y101 hTERT-MSCS, the expression of different markers 
of osteogenesis were monitored using histology, cell assays, and real time qPCR. As well 
as to confirm osteogenesis, these results provided an insight into the changes that occur 
at different cellular levels during osteogenesis, so that in later experiments the effect of 
altered glycosylation on differentiation can be monitored by comparing gene and protein 
expression, and functional activity back to control samples. This multi-parameter account 
of osteogenesis may provide mechanistic insight into the role of glycosylation in 
differentiation.     
Despite lectin staining being a convenient way to assess the glycans present on the cell 
surface, it has several caveats. Lectins have varied specificity in glycan binding and 
staining doesn’t provide detailed structural information of the glycans present, such as 
the degree of fucosylation. Mass spectrometry however can provide a more detailed 
profile with information on the relative abundance of specific glycan structures. 
Therefore, the N-glycans were profiled from the different cell types using mass 
spectrometry. Beforehand, the N-glycans were harvested using a medium through-put 
method called Filter Aided N-glycan Separation (FANGS) [123]. As this method required 
only 1x106 cells per sample, it facilitated the profiling of biological repeats, which enabled 
a statistical comparison to be made between the cell types. Prior to analysis by mass 
spectrometry, N-glycan samples were permethylated. This was to stabilize the terminal 
sialic acids and facilitate more uniform ionization of glycans. This permethylation step 
reduces variation, allowing for relative quantitation of individual glycans within a mixture 
[131].  
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Following the comparison of glycan profiles of Y101 hTERT-MSCs and osteoblasts derived 
from them, the N-glycan profiles of Y201 and Y202 hTERT-MSCs were analysed. These 
immortalized subpopulations of MSCs had altered differentiation capacity compared to 
Y101 hTERT-MSCs. The glycan profiling of these lines was to assess if there was a link 
between MSC glycan profile or abundance of a particular glycan, and differentiation 
capacity. Could glycan profiles be used to predict the differentiation capacity of subsets of 
MSC populations? Furthermore, comparisons of the hTERT-MSC glycans profiles with the 
osteoblast profile were also made, to establish if an osteoblast precursor glycoform 
existed.   
   
3.2  Chapter 3 Aims  
Specifically, the aims were to differentiate an immortalized human MSC line into 
osteoblasts in vitro. Subsequently, to then confirm osteogenesis using histology, cell 
assays, and qPCR. Following this, the aim was to harvest N-glycans from undifferentiated 
MSCs and osteoblasts using the FANGs method, and then to permethylate the samples. 
Glycans from each cell type were to be analysed by mass spectrometry.  
Furthermore, the aim was to obtain and compare the N-glycan profiles of 2 other 
immortalized MSC lines, each with varied differentiation capacities. Comparisons of the 
glycan profiles of different hTERT-MSCs lines and osteoblasts were then made, to 
determine if glycan profile could be used to predict differentiation capacity.      
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3.3 Chapter 3 Results 
3.3.1 Single cell derived colonies of hTERT-MSCs have varied differentiation 
capacity 
Prior to this research, primary human MSCs obtained from a single donor were 
immortalized by the over-expression of human telomerase [122]. Colonies derived from 
single cells were cultured into hTERT-MSC lines, named Y101, Y201, and Y202. Each line 
had a typical MSC phenotype, including plastic adherence and a fibroblast morphology, 
although the Y202 cells are more flattened (Figure 3.1  and [122]). To test their 
differentiation capacity each hTERT-MSC line was cultured for 21 days in osteogenic or 
adipogenic media. Cells cultured in osteogenic media were stained for phosphate (Von 
kossa). Cells cultured in adipogenic media were stained for fat using Oil-red O staining. 
The three hTERT-MSC lines showed varied differentiation capacity (Figure 3.1). The Y101 
and Y201 hTERT-MSCs differentiated into osteoblasts, as seen by positive Von kossa 
staining. The Y101 hTERT-MSCs showed limited adipogenic differentiation compared to 
the Y201 hTERT-MSCs, which had visible fat droplets in most of the cells after 21 days in 
adipogenic media. The Y202 hTERT-MSCs did not appear to differentiate into either 
osteoblasts or adipocytes, as there was little phosphate or fat staining. These results 
support the notion of a heterogeneous population of MSCs, with individual MSCs having 
varied differentiation capacities. The Y101 hTERT-MSCs may represent osteoblast 
progenitor cells, which selectively differentiate into osteoblasts. Since previous work 
studying the glycan profile of MSCs and osteoblasts used a mixed primary population, the 
Y101 hTERT-MSC line provided the opportunity to profile an unmixed MSC /osteoblast 
progenitor population. Prior to this, a more thorough analysis of the osteogenic 
differentiation of Y101 hTERT-MSCs was carried out. 
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Figure 3.1 Differentiation capacity of 3 hTERT-MSC lines. 
Brightfield microscopy images of 3 hTERT-MSCs lines named Y101, Y201 and Y202 
hTERT-MSCs. Top row shows cells cultured in basal media and then stained with crystal 
violet. Second row shows cells after culture in osteogenic media for 21 days and stained 
for phosphate (Von kossa). Third row shows cells after culture in adipogenic media for 21 
days and stained for fat (Oil red-O). 
 
3.3.2 Y101 hTERT-MSCs are positive for several osteogenic markers     
Increased ALP expression and activity is an early maker of osteogenesis. Y101 hTERT-
MSCs were cultured in basal or osteogenic media for 21 days. The ALP activity of samples 
collected at weekly time points were compared (Figure 3.2A). The activity of ALP was 
significantly increased in cells cultured in osteogenic media for 21 days, compared to 
basal media (Student’s T test, P<0.05, n=3).  
A key property of functional osteoblasts is the mineralisation of extracellular matrix. Y101 
hTERT-MSCs cultured in osteogenic media were stained for ALP and phosphate (Von 
kossa), at weekly timepoints (Figure 3.2). The amount of mineralisation steadily increased 
over 21 days in osteogenic media (Figure 3.2B). Y101 hTERT-MSCs were cultured in 
various sized tissue culture plates, for use in different assays. The degree of 
mineralisation was not affected by the size of the tissue culture plate or dish used, as 
seen by positive ALP and Von kossa staining after 21 days in osteogenic media (Figure 
3.2B).  
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Alongside histological staining, changes in gene expression during osteogenic 
differentiation were used as indicators of osteoblast formation. Using real-time qPCR the 
expression of Runx2, BMP and BSP were made relative to the control gene RSP27a. Basal 
and osteogenic media samples were then expressed as fold change from day 0 samples. 
Runx2 is the dominant pro-osteogenesis transcription factor, which controls the 
expression of many osteogenic genes [86]. Expression levels of Runx2 increased over 
time, up 6 fold by day 7 and up 28 fold after 21 days in osteogenic media, compared to 
day 0 samples (Figure 3.2part Ci). These levels of increase are comparable to those seen 
by Frank et al (2002), who measured a 5 fold increase in Runx2 expression, between MSCs 
cultured for 3 or 20 days in osteogenic media [132]. Bone morphogenetic protein-2 
(BMP2) is a pro-osteogenic cytokine. Through interactions with either, Dlx-5, Smad1 or 
Smad5, BMP2 increases the expression of Runx2 and Osterix, both pro-osteogenic 
transcription factors. The expression level of BMP2 increased over 21 days in osteogenic 
media, peaking at day 14 at 15 fold higher than day 0 samples (Figure 3.2Ci). Again this 
was similar to the 20 fold increase seen by Frank et al, between MSCs cultured for 3 or 20 
days in osteogenic media [132]. Bone sialoprotein (BSP) is an abundant non-collagenous 
protein present in mineralised bone and facilitates hydroxyapatite crystal formation 
[129]. Levels of BSP expression increased over time in cells cultured in osteogenic media. 
After 21 days, Y101 hTERT-MSCs expressed over 2000 fold more BSP compared to day 0 
samples (Figure 3.2C). Similar to results of Frank et al (2002), expression increased around 
10 fold between day 7 and day 21. This showed that although BSP is associated with later 
stages of osteogenesis, its’ expression increased 80 fold after 1 week in osteogenic media, 
when little phosphate staining was seen (Figure 3.2B). The Y101 hTERT-MSCs cultured in 
basal media for 21 days showed some increase in osteogenic gene expression, with levels 
above day 0 samples. However, expression levels were not as high as those for Y101-
hTERT-MSCs cultured in osteogenic media (Figure 3.2Ci). Together, these results suggest 
that Y101 hTERT-MSCs express osteoblast markers after 3 weeks culture in osteogenic 
media. Following this the glycan profile of Y101 hTERT-MSCs and osteoblasts derived 
from them were compared.  
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Figure 3.2 Osteogenic differentiation of Y101 hTERT-MSCs. 
Y101 hTERT-MSCs were cultured in basal or osteogenic media for 21 days and 
osteogenic differentiation assessed using several techniques and markers. A) Alkaline 
phosphatase activity was measured using pNP assay, after culture in basal or osteogenic 
media for 0, 7, 14, and 21 days. Activity was made relative to DNA content of each 
sample using a pico-green assay. Day 21 samples were compared using Student’s T test, 
**=P<0.01, n=3. B) Bright-field images of alkaline phosphatase staining - seen as pink - 
and phosphate (von Kossa) staining - seen as brown - at weekly time points during culture 
in osteogenic media. Staining was positive at day 21, independent of the size of the 
culture plate or dish used - see scale bars. Ci) cDNA produced from cells grown in 
osteogenic media for either 0,7,14,or 21 days, were analysed using primers for Runx2, 
BMP2, BSP and RSP27a. cDNA produced from cells grown in basal media for 21 days 
was also analysed as a control. CT values were made relative to RSP27a values and then 
expressed as fold change relative to day 0 values. Triplicate technical replicates from 2 
biological repeats are shown, error bars are standard deviation. Cii) Table shows mean 
CT values ± standard deviation of combined replicates. 
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3.3.3 Osteoblasts derived from Y101-hTERT-MSCs have an altered glycan 
profile 
To generate N-glycan samples for analysis by mass spectrometry, Y101 hTERT-MSCs were 
cultured either in basal media overnight or, in osteogenic or basal media for 21 days. The 
latter sample was to control for any changes to glycan profile induced by time cultured at 
full confluency, rather than by differentiation into osteoblasts. The N-glycans were 
harvested from the different cell samples using the FANGS method (see methods for 
details). Afterwards, N-glycans were permethylated and analysed by mass spectrometry 
(MALDI-TOF/TOF). Glycans were identified from spectra using the calculated mass of 
monosaccharide units and knowledge of possible glycan structures produced by the N-
glycan synthesis pathway. 65 different glycan structures were identified from the spectra 
of Y101 hTERT-MSCs (Figure 3.3). The spectra of osteoblasts derived from Y101 hTERT-
MSCs contained the same peaks seen in Y101 hTERT-MSC spectra (Figure 3.4), when the 
spectrum were compared, there were significant differences in the relative abundance of 
individual glycan structures (Figure 3.5 and Figure 3.6). When the normalised peak 
intensity from each glycan structure, were grouped by structure type, significant 
differences between Y101 hTERT-MSCs and osteoblasts were identified. Oligomannose 
type glycans were significantly less abundant in osteoblasts (change from 44 to 19%), with 
complex glycans being significantly more abundant (change from 46 to 70%) (Student’s T 
Test, **P<0.01, *P<0.05, n=3 and 5, (Figure 3.7)). There were also significantly more 
fucosylated glycans in osteoblast samples (63%) compared to Y101 hTERT-MSCs samples 
(42%) (Figure 3.7). The abundance of two specific oligomannose type glycan structures, 
Hex8HexNAc2 and Hex9HexNAc2, were significantly higher in Y101 hTERT-MSCs 
compared to osteoblasts (One way ANOVA, Holm Sidak post hoc test, ***P<0.001). The 
abundance of a singly sialylated, complex glycan structure: NeuAc1Fuc1Hex5HexNAc4, was 
significantly higher in osteoblast samples (One way ANOVA, Holm Sidak post hoc test, 
***P<0.001)(Figure 3.7).  
The N-glycan profile of Y101 hTERT-MSCs cultured in basal media for 21 days was overall 
more similar to Y101 hTERT-MSCs cultured overnight in basal media, than to osteoblast 
samples (Figure 3.5). When glycans were grouped by type there was no significant 
difference in abundance of oligomannose, hybrid or complex type glycans between Y101-
hTERT-MSCs cultured in basal media for 24 hours or for 21 days (Figure 3.8). There was 
also no significant difference in abundance of fucosylated glycans (Figure 3.8). However, 
75 
 
there were some small differences between the 2 basal samples. The abundance of 
Hex9HexNAc2, the structure that enters the Golgi, had an average peak intensity of 10au 
in Y101 hTERT-MSCs cultured overnight in basal media. The intensity was 5au, and 2au in 
Y101 hTERT-MSCs cultured in basal media or osteogenic media for 21 days respectively. In 
order to allow for easier comparison of the N-glycan profiles of the different cell samples, 
the data was arranged into a heat-map format similar to that used in genomic studies 
(Figure 3.8a). The heat map conveys several aspects of the data set. For one, that despite 
oligomannose glycans being as prominent as complex glycans, there were fewer different 
oligomannose structures identified (rows on the heat map), compared to the number of 
different complex glycan structures.  The similarity and differences in abundance of many 
glycans, between the cell samples is visible from the colour pattern. The partial similarity 
of the glycan profiles from cells cultured for 21 days might be due to some of the glycan 
structures being associated with time cultured at full confluency. However, another 
possibility is that the common structures could be associated with osteogenesis – as 
earlier qPCR data showed small increases in the expression of osteoblast associated 
genes, in samples cultured in basal media for 21 days.  
Importantly, the N-glycan profile of Y101 hTERT-MSCs was significantly different from 
that of osteoblasts derived from them, which was not an artefact of time in culture. The 
question remaining was whether the other hTERT-MSCs, which had varied differentiation 
capacities, had similar N-glycan profiles to the Y101 hTERT-MSCs or not.  
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Figure 3.3 MALDI-TOF/TOF spectrum of N-glycans from Y101 hTERT-MSCs. 
A representative spectrum (n=5) of N-glycans isolated from Y101 hTERT-MSCs. 1x106 cells were cultured in a 10cm dish, overnight before N-glycan 
harvest, and further processing. Glycan peaks were identified using calculated mass of monosaccharides and knowledge of the synthesis pathway. 
Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of mono-isotopic peak is labelled, with predicted structure pictured above. 
Spectrum shown is from 1000m/z to 5250m/z split into two sections.   
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Figure 3.4 N-glycan spectrum of osteoblasts derived from hTERT-MSCs. 
A representative spectrum (n=3) of N-glycans isolated from osteoblasts derived from WT hTERT-MSCs. 1x106 cells were cultured in a 10cm dish, for 21 
days in osteogenic media, before N-glycan harvest, and further processing. Glycan peaks were identified using calculated mass of monosaccharide units 
and knowledge of the synthesis pathway. Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of mono-isotopic peak is labelled, 
with predicted structure pictured above. Spectrum shown covers 1000m/z to 5250m/z. 
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Figure 3.5 Comparison of spectrum from MSCs in basal media 24 hours, in basal media 21 days, or in osteogenic media 21 days. 
A representative spectrum of N-glycans isolated from hTERT-MSCs cultured in basal media for 24 hours, n=5 (top), basal media 21 days, n=2 (middle) or 
MSCs in osteogenic media 21 days, n=3 (bottom). 1x106 cells were cultured in a 10cm dish for stated amount of time before N-glycan harvest, and further 
processing. Glycan peaks were identified using calculated mass of monosaccharide units and knowledge of the synthesis pathway. Glycans had to have 
two isotopic peaks, 3x above noise to be included. Major peaks between 1500m/z and 2400m/z are mostly oligomannose glycans, whilst those over 
2500m/z are typically complex type glycans. Spectrum shown covers 1000m/z to 5250m/z. 
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Figure 3.6 Comparison of mass spectrum of glycans isolated from MSCs or 
Osteoblasts. 
hTERT-MSCs were cultured in either basal media for 24 hours (black spectrum) or 
osteogenic media for 21 days (blue spectrum), prior to glycan harvesting, further 
processing and analysis by mass spectrometry. Glycan peaks were identified using 
calculated mass of monosaccharide units and knowledge of the synthesis pathway. 
Glycans had to have two isotopic peaks, 3x above noise to be included. Spectrum shown 
are from 1000m/z to 5250m/z split into two sections.     
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Figure 3.7 Glycan analysis of hTERT-MSCs and osteoblasts derived from 
them. 
 
hTERT-MSCs were cultured in either basal media for 24 hours or osteogenic media for 21 
days (osteoblast samples), prior to glycan harvesting, further processing and analysis by 
mass spectrometry. Glycans identified from spectrum were classed by type (A) and if they 
were fucosylated or not (B). Student’s T Test, *=P<0.05, **=P<0.01, ns =not significant. 
The normalised, average peak intensity of individual glycan structures were also 
compared. Those present above 3 au (out of 100) in either MSC or osteoblasts are shown 
in (C) and those above 1 au in (Ci). One way ANOVA, with Holm Sidak post-hoc tests, 
***=P<0.001, all other glycan pairs were not significantly different. Error bars show 
standard error of the mean.  
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Figure 3.8 Glycan analysis of hTERT-MSCs in basal media for 24 hours or 21 
days. 
hTERT-MSCs were cultured in basal media for either 24 hours or 21 days prior to glycan 
harvesting, further processing and analysis by mass spectrometry. Glycans identified from 
spectrum were classed by type (A) and if they were fucosylated or not (B). Student’s T 
Test, ns =not significant. Error bars show standard error of the mean.  
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Figure 3.8a Heat map 
comparing glycan profile of 
hTERT-MSCs after culture for 
24 hours in basal media, 21 
days in basal media, or 21 days 
in osteogenic media. 
Glycan peaks were identified from mass 
spectrometry spectra (basal media 24 
hours n=5, cells in basal media for 21 
days n=2, osteogenic media n=3). For 
each structure identified, the total peak 
intensities were summed, normalised 
and average (see materials and methods 
for details). Each row in the map shows 
average abundance of a single glycan 
structure in each of the cell types. 
Glycans have been grouped by type, 
O=Oligomannose, H= Hybrid and 
C=Complex type glycans. Colour 
denotes relative abundance, between all 
samples.    
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3.3.4 The Y101, Y201 and Y202 hTERT-MSCs have similar glycan profiles 
 In order to compare the hTERT-MSC lines each cell type was cultured at a density of 106 
cells/10cm dish, 24 hours in basal media, prior to harvest by FANGS. Spectrum from at 
least 4 biological repeats were averaged for each cell type (Y101 n=5, Y201 n=4, and Y202 
n=5). The mass spectrometry spectra from the different hTERT-MSC lines appeared 
similar (Figure 3.9). When the abundance of individual glycans were grouped by structure 
type, there was no significant difference between the hTERT-lines (Figure 3.10 
Comparison of glycans isolated from 3 hTERT-MSC lines.). However, there was a visible 
trend that the Y101 and Y202 hTERT-MSCs were more similar than the Y201 hTERT-MSCs, 
several oligomannose glycans, i.e. Hex6HexNAc2 and Hex9HexNAc2, were more abundant 
in Y201 cells compared to both Y101 and Y202 hTERT-MSCs (Figure 3.10). Analysis of 
individual glycan structures showed that NeuAc2Fuc1Hex5HexNAc2, was significantly less 
abundant in Y201s compared to Y101 and Y202 hTERT-MSCs (One way ANOVA, Holm 
Sidak post hoc, P<0.05, n=4 or 5) (Figure 3.10 C). The heat-map display of the glycan 
profiles of the hTERT-MSC lines and osteoblasts shows visually, that the 3 hTERT-MSC 
lines are all similar (Figure 3.10a). Furthermore, the Y101 hTERT-MSCs, despite potentially 
representing osteogenic progenitors, were as distinguishable from the osteoblasts, as the 
other hTERT-MSC lines (Figure 3.10a). 
Although these results showed that the N-glycan profile of the 3 hTERT-MSC lines was not 
as varied as their differentiation capacity, it did not rule out the contribution of glycans to 
differentiation. Differences in genome and proteome are likely responsible for the 
variation in the differentiation capacity of the hTERT-MSC lines. A genetic approach was 
used in the next chapter, to test the role of glycans in osteogenesis.    
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Figure 3.9 MALDI-TOF/TOF spectrum of N-glycans from 3 hTERT-MSC lines. 
One representative spectrum of N-glycans isolated from Y101 hTERT-MSCs (n=5), Y201 hTERT-MSCs (n=4) and Y202 hTERT-MSCs (n=5). 1x106 cells 
were cultured in a 10cm dish, overnight prior to glycan harvest and further processing. Full spectrum from 1000m/z to 5250m/z shown above for each cell 
line. 
 Figure 3.10 Comparison of glycans isolated from 3 hTERT-MSC lines. 
Glycans identified from spectrum were classed by type (A) and if they were fucosylated or 
not (B). The normalised, average peak intensity of individual glycan structures identified 
were also compared. Those present above 2 (out of 100) in either hTERT spectrum are 
shown in (C), with predicted structure above. Error bars show standard deviation. One 
way ANOVA, ns = not significant, n=5, 4 and 5, for Y101, Y201 and Y202 respectively. In 
C, * highlights a differential expressed glycan, NeuAc2Fuc1Hex6HexNAc5, P<0.05 between 
Y101 and Y201, and Y201 and Y202. Abundance in Y101 and Y202 was not significantly 
different. One way ANOVA, Holm Sidak post-hoc test.   
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Figure 3.10a Heat map comparing 
glycan profile of Y101, Y201 and 
Y202 hTERT-MSCs, and 
osteoblasts derived from Y101 
hTERT-MSCs. 
Glycan peaks were identified from mass 
spectrometry spectra (Y101 n=5, Y201 n=4, 
Y202 n=5, osteoblasts (Osteo) n=3).For 
each structure identified, the total peak 
intensities were summed, normalised and 
average (see materials and methods for 
details). Each line in the map shows 
average abundance of a single glycan 
structure in each of the cell types. Glycans 
have been grouped by type, 
O=Oligomannose, H= Hybrid and 
C=Complex type glycans. Colour denotes 
relative abundance, between all samples.    
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3.4  Chapter 3 Conclusion  
In order to investigate the role of glycans in MSC differentiation, the N-glycan profile of 
immortalised MSC lines and osteoblasts derived from them were compared. Three 
immortalised, primary human hTERT-MSC lines were shown to have varied differentiation 
capacity in vitro. These results supported the theory of a heterogeneous population of 
MSCs with mixed differentiation capacities. The ability of one line, Y101 hTERT-MSCs, to 
differentiate into osteoblasts was further characterised using several markers. During 
culture in osteogenic media the Y101 hTERT-MSCs had increased ALP activity and 
increased mineralised extracellular matrix compared to basal controls. Furthermore, Y101 
hTERT-MSCs expressed increased levels of osteoblast associated genes Runx2, BMP and 
BSP, during culture in osteogenic media, compared to basal controls. Mass spectrometry 
was used to profile the N-glycans of Y101 hTERT-MSCs and osteoblasts derived from 
them. Osteoblasts had significantly more complex glycans and less oligomannose type 
glycans. The abundance of fucosylated glycans was significantly increased in the 
osteoblast samples.   
To determine if a glycan profile could be used to predict differentiation capacity, the 
glycan profile of 2 other hTERT-MSC lines (Y201 and Y202) were compared to Y101 hTERT-
MSCs and osteoblasts derived from them. Despite having varied differentiation abilities, 
the glycan profile of the 3 hTERT-MSC lines appeared very similar. There were no 
significant differences in the abundance of glycans when grouped by structure type. One 
individual glycan structure, which was a sialylated, biantennary, fucosylated, complex 
glycan, was significantly less abundant in Y201 hTERT-MSCs compared to the other two. 
There was a trend for Y101 and Y202 glycan profiles to group away from that of Y201s.  
It is not possible to rule out the possibility that one of the hTERT-MSC lines has a single 
glycoprotein, which is alternatively glycosylated and functioning as consequence, 
differently, contributing to the lines differentiation capacity. Changes in glycosylation to 
single glycoproteins are likely beyond the detection limit of this total cellular, glycan 
profiling approach. Previous, studies have shown that small changes to single, 
glycoprotein can affect cell behaviour, such as changes to CD44’s glycoform, affecting 
ability of MSCs to migrate to bone marrow [120]. Considering the dissimilarity in 
differentiation potential, and the overall resemblance of the glycan profiles, it was 
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concluded that the glycan profile of hTERT-MSC subpopulations, using this method, could 
not be used to predict their osteogenic differentiation capacity. 
In the following chapter the glycan synthesis pathway was disrupted genetically, and the 
effect on osteogenic capacity assessed, using the same osteogenic assays introduced in 
this chapter.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 Genetic disruption of the glycosylation pathway 
4.1 Rationale for genetic disruption of glycosylation pathway 
The broad aim of this research was to investigate the role of glycans in MSC 
differentiation. In the previous chapter, mass spectrometry was used to profile the N-
glycans of immortalised MSC lines and of osteoblasts derived from them. In agreement 
with previously published results, the N-glycan profile was significantly altered in the 
osteoblasts, which had a higher abundance of complex glycans [118]. However, MSC lines 
with varied osteogenic potential were found to have similar N-glycan profiles, disproving 
the idea that glycan profiles could be used to predict the osteogenic capacity of sub-
populations of MSCs. Although N-glycans do not appear to be markers of differentiation 
potential, the question remains as to whether N-glycans have a functional role during the 
process of differentiation. In this chapter a genetic approach was used to determine the 
role of glycans in osteogenesis. Here, glycosylation synthesis was disrupted genetically 
and the ability of MSCs to then differentiate into osteoblasts was assessed. 
A simple method to look at the function of glycans would be to target enzymes 
responsible for their synthesis and then observe the effect on phenotype. However, the 
strategy to knock-down or knock-out a single Golgi resident enzyme was not chosen for 
several reasons. For one, there are different isoforms of enzymes at each stage of glycan 
processing that provide redundancy and would each need to be targeted. For example 
there are at least 3 different α1,2-mannosidase enzymes [133], and 19 different 
mammalian galactosyltransferases [134]. Disruption of enzymes responsible for the 
production of precursor monosaccharides, or of enzymes in the ER at the beginning of the 
synthesis pathway, would inhibit N-glycan formation. However, this would impede the 
exit of glycoproteins from the ER, leading to ER and cellular stress [135], which would 
hinder the interpretation of any changes to cellular behaviour.   
Instead, in the following chapter the Golgi organisation was perturbed by targeting COG 
with a shRNA. COG is responsible for the retrograde traffic of vesicles in the Golgi. This 
maintains the specific distribution of enzymes in different cisternae, which is required for 
glycan chain modulation. Although targeting COG should disrupt glycosylation, 
glycoproteins are likely to be trafficked to the cell surface. This allowed the role of the 
glycosylation to be tested, rather than the location of glycoproteins, or the effect of ER 
stress, unlike the strategies targeting specific enzymes in the E.R. This method, of 
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targeting COG is also advantageous, since several types of glycans are produced in the 
Golgi, disruption of COG may alter the processing or production of more than one type of 
glycan. Interestingly, COG related and other CDG patients display a wide variety of 
skeletal related symptoms such as: osteopenia, short limbs, and clinodactyly [121]. Added 
to this, Smits et al (2010) discovered that a form of lethal neonatal skeletal dysplasia is 
caused by mutations in Golgi microtubule-associated protein 210 (GMAP-210), which is 
responsible for maintaining Golgi architecture [136]. Altogether this indicates that the 
disruption of Golgi organisation, via COG-knock-down, should affect glycosylation and as 
a consequence may alter the differentiation of MSCs into osteoblasts.    
COG is an 8 subunit protein with subunits divided into lobe A and lobe B. Out of the 8 
subunits Cog4 was selected to be knocked-down by shRNA, in part because the crystal 
structure of a part of this subunit has been solved [124]. In the same study, HeLa cells 
with mutations to Cog4 had glycosylation defects [124]. Moreover, analysis of fibroblasts 
from a CDG patient, with a mutation in Cog4 showed reduced sialylation and 
galactosylation [65]. In addition, Cog4 is a subunit in lobe A and in yeast studies mutations 
to subunits in lobe A are lethal, whilst mutations in lobe B are less severe [12]. This may 
indicate that knocking-down Cog4 could have a greater effect than targeting a lobe B 
subunit. Together these studies suggest that Cog4 knock-down will cause glycosylation 
defects in MSCs. 
Primary human MSCs senesce in culture after several passages. In light of this, the 
immortalised human MSC line - Y101 hTERT-MSC - characterised in the previous chapter 
was used. This allowed the production of Cog4 knock-down lines, derived from a single 
cell. Furthermore, the unlimited supply of cells enabled the same cell population to be 
tested in assays for phenotype, glyco-type and osteogenic potential. This avoided the 
variation of cell behaviour seen with primary MSCs isolated from different donors [137] to 
affect the interpretation of results. Some of the experimental work involving Cog4KD 
hTERT-MSCs was performed by an undergraduate student working under my supervision. 
Their contributions are acknowledged on the relevant figures. 
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4.2  Chapter 4 Aims  
The aim of the work described in this chapter was to disrupt the glycosylation pathway 
genetically and to then assess the effect on osteogenesis.  
More specifically, the aim was to generate single-cell-derived lines of Y101 hTERT-MSCs in 
which Cog4 is knocked down, using two different shRNAs. The use of two different 
shRNAs was to control for non-specific targets of a shRNA, which could mask the effect of 
reduced Cog4 levels. Following this, the aim was to verify the predicted effect of Cog4 
knock-down on the glycosylation of MSCs, using lectins and flow cytometry, plus mass 
spectrometry. Finally, I assessed the effect of Cog4-knock down on MSC phenotype and 
osteogenic potential by comparing the change in gene and protein expression seen in 
wildtype Y101 hTERT-MSCs during osteogenesis to that of Cog4-knock down cells, as well 
as monitoring the functional capability of the cells, by testing for calcium phosphate 
deposition.   
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
4.3  Chapter 4 Results 
4.3.1 Generation of Cog4-knock-down (Cog4KD) hTERT-MSCs 
In order to genetically disrupt the glycosylation pathway hTERT-MSCs were transduced 
using lentivirus containing shRNA targeting Cog4. Five different shRNAs were used and 
assigned a letter A-E (see methods for details). Initially, shRNAs A, C and D were tested. 
During transduction a multiplicity of infection (MOI) of 1 and 10 was used. After 
transduction, colonies derived from single cells were cultured and protein harvested for 
analysis by western blot (Figure 4.1part i and ii). The efficiency of knock-down varied 
amongst the different colonies. Transduction using an MOI of 10 did not appear to 
increase the level of Cog4 knock-down achieved. Also hTERT-MSCs that were transduced 
using shRNA ‘C’ using an MOI of 10, were viable, but failed to form any colonies. In light 
of this, a MOI of 1 and 3 was used during transduction with lentivirus containing the 
shRNAs B and E. Again there was varied efficiency in the degree of Cog4 knock-down 
between the shRNAs and among the colonies (Figure 4.1part iii and iv). Of the colonies 
isolated and tested, those produced with shRNAs B, C or E expressed less Cog4 protein 
compared to WT than those produced using shRNA A or D. Two colonies with the greatest 
reduction in Cog4 protein, which were produced using shRNA C and B, were further 
expanded. These were named Cog4KDshRNA1 and Cog4KDshRNA2 respectively (Figure 
4.1 red boxes). In order to confirm that Cog4 knock-down had disrupted glycosylation, the 
glycan profile of the Cog4KD hTERT-MSCs was determined. 
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Figure 4.1 Western blots of single-cell derived colonies of Cog4KD hTERT-
MSCs. 
Whole cell lysates from wildtype (WT) hTERT-MSCs and colonies of Cog4KD hTERT-
MSCs were run on SDS-gels prior to transfer onto PVDF membrane and immunoblotting 
using antibodies against Cog4 and ß tubulin. Cog4KD colonies were created using 5 
different shRNAs named: A, B, C, D, and E. Different multiplicities of infection (MOI) were 
used, denoted by the first number in each colony name. The second number in each 
colony name was assigned during culture to distinguish between colonies with the same 
shRNA and same MOI. Samples were loaded in duplicate in blots i, ii, and iv. The red 
boxes highlight the colonies expanded in culture and used in further work. For simplicity 
C1.6 is referred to as Cog4KDshRNA1 and B1.7 is referred to Cog4KDshRNA2 in all 
further work. 
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4.3.2 Cog4KD hTERT-MSCs have an altered glycan profile 
4.3.2.1 Flow cytometry identified similarities and differences in the 
glycosylation of WT and Cog4KD hTERT-MSCs 
To find out if glycan synthesis was altered in Cog4KD hTERT-MSCs, cells were stained with 
several lectins and then analysed using flow cytometry. Prior to this experiment, WT 
hTERT-MSCs were used to test the affinity of each lectin. For all the lectins bar MAL II, the 
fluorescence histogram of the cells incubated with lectins alone shifted positively away 
from the histogram of cells incubated with lectins and an appropriate monosaccharide 
that competes with lectin binding. This demonstrated that the lectin staining was positive 
and specific (Figure 4.2). The lectin MAL II was conjugated to biotin and required 
incubation with streptavidin bound to fluorescein to analyse the cells by flow cytometry. 
The fluorescent histogram of cells stained with MAL II was not significantly different from 
that of cells incubated with streptavidin-fluorescein alone (Figure 4.2G)  
To detect small differences in staining, 3 to 4 experimental repeats were carried out, and 
the data was normalised to WT in each repeat. This was to account for the variation in 
absolute fluorescence intensity between experimental runs. The staining of WT and 
Cog4KD hTERT-MSCs was positive with: ConA, WGA, PNA, SNA, Jacalin and VVL lectins 
(Figure 4.3, Figure 4.4, Figure 4.5). ConA binds to the core mannose structure present in 
all N-glycans, and is not known to bind to O-glycans. WGA binds to GlcNAc either 
terminally or within multiple glycan structures. There was no significant difference in 
staining with ConA or WGA lectins, between WT and Cog4KDhTERT-MSCs (Figure 4.3I and 
ii). The coefficient of variation (half-max) - CV(hm) – is a statistic used to measure the 
width of a population. The Cog4KDshRNA2 hTERT-MSCs stained with WGA (Figure 4.3B) 
had a significantly higher CV(hm) than WT (One-way ANOVA, Holm-Sidak post hoc, n=4, 
P<0.001). This suggested a more varied amount of staining among the cells, despite the 
similarity in median fluorescence (Figure 4.3). SNA and MAL II are lectins that bind to 
sialic acid residues of glycans. MAL II binds to sialic acid in a (α 2, 3) linkage, whilst SNA 
prefers structures with sialic acid in a (α 2, 6) linkage. Staining with MAL II was not above 
controls for all cell types (Figure 4.4A).SNA staining was significantly lower (P<0.001) in 
both Cog4KD hTERT-MSC lines compared to WT (Figure 4.4B). The CV(hm) of 
Cog4KDshRNA1 hTERT-MSCs stained with SNA was significantly higher (P<0.05), 
suggesting a greater variation in staining compared to WT hTERT-MSCs (Figure 4.4Biii). 
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This indicated that Cog4 knock-down in hTERT-MSCs resulted in significantly reduced 
glycan sialylation.       
Some lectins, such as WGA described above, bind to glycan structures present in several 
types of glycans. PNA, Jacalin and VVL preferentially bind to structures present in O-
glycans. Jacalin binds to the T-antigen structure (galactosyl (β-1,3) N-
acetylgalactosamine), whether it is sialylated or not. Staining with Jacalin was positive for 
all cell types, with no significant difference between them (Figure 4.5A). Although PNA 
binds to the same structure as Jacalin, binding is inhibited if the structure is sialylated. 
Staining with PNA was increased in Cog4KD hTERT-MSCs (Figure 4.5B), indicating 
decreased O-glycan sialylation in Cog4KD hTERT-MSCs, which correlates with the reduced 
O-glycan sialylation seen in COG CDG patient ApoCII samples [63, 66, 70]. VVL binds to a 
single α-N-acetylgalactosamine linked to serine or threonine (Tn antigen). The Cog4KD 
hTERT-MSCs had a small, significant reduction in VVL staining compared to WT (Figure 
4.5C). The Tn-antigen structure is the beginning of all O-glycan structures. A reduction in 
VVL staining could mean fewer O-glycan chain initiation sites, or fewer truncated O-
glycans, with an increase in conversion of Tn-antigen into T-antigen structures instead. It 
is possible that disrupted Golgi-enzyme trafficking in Cog4KD hTERT-MSCs could lead to a 
combination of these changes occurring.  
Altogether these results show the presence of similar glycan structures in WT and Cog4KD 
hTERT-MSCs. Yet importantly, the Cog4KD hTERT-MSCs had a significant reduction in 
sialylated O- and/or N-glycans, as well as reduced abundance of Tn antigen structures.  
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Figure 4.2 Flow cytometry analysis of lectin affinity. 
To check the affinity of lectins for glycans, WT hTERT-MSCs were incubated with; PBS 
(black outline); lectin and appropriate monosaccharide at 0.5M (red stripe) ; or with lectin 
alone (blue stripe). All lectins apart from SNA and MAL II were directly conjugated to 
fluorescein. SNA and MAL II were biotin labelled and used streptavidin tagged with 
fluorescein. Staining with SNA and MAL II was compared to cells incubated with 
streptavidin-fluorescein alone (black stripe) instead of PBS. Histograms show log 
fluorescence of samples stained with A) ConA, B) WGA, C) PNA, D) Jacalin, E) VVL  F) 
SNA and G) MAL II. MAL II was not tested with a monosaccharide, as staining was not 
above negative control levels.   
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Figure 4.3 Flow cytometry analysis of WT, Cog4KDshRNA1 and 
Cog4KDshRNA2 hTERT-MSCs with ConA and WGA lectins. 
WT, Cog4KDshRNA1 and Cog4KDshRNA2 hTERT-MSCs were probed with A) ConA and 
B) WGA lectins. Histograms i) show log fluorescence of WT (black), Cog4KDshRNA1 
(pink) and Cog4KDshRNA2 (dark red) hTERT-MSCs after staining with lectin. The median 
fluorescence values were made relative to WT. The average relative fluorescence values 
of 4 independent experiments are shown in ii). The average Coefficient of variation (Half 
max) (CV (hm) are shown in iii). Error bars are standard deviation One way Anova, with 
Holm-Sidak post-hoc test, n=4, *** = P<0.001.        
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Figure 4.4 Flow cytometry analysis of WT, Cog4KDshRNA1 and 
Cog4KDshRNA2 hTERT-MSCs with MAL II and SNA lectins. 
WT, Cog4KDshRNA1 and Cog4KDshRNA2 hTERT-MSCs were probed with A) MAL II 
and B) SNA lectins. Histograms i) show log fluorescence of WT (black), Cog4KDshRNA1 
(pink) and Cog4KDshRNA2 (dark red) hTERT-MSCs after staining with lectin. The median 
fluorescence values were made relative to WT. The average relative fluorescence values 
of 3 independent experiments are shown in ii). The average Coefficient of variation (Half 
max) (CV (hm)) values, are shown in iii). Error bars show standard deviation. One way 
Anova with Holm-Sidak post-hoc test, n=3, * = P<0.05, ***= P<0.001. 
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Figure 4.5 Flow cytometry analysis of WT, Cog4KDshRNA1 and 
Cog4KDshRNA2 hTERT-MSCs with Jacalin, PNA and VVL lectins. 
WT, Cog4KDshRNA1 and Cog4KDshRNA2 hTERT-MSCs were probed with A) Jacalin, 
B) PNA and C) VVL lectins. Histograms i) show log fluorescence of WT (black), 
Cog4KDshRNA1 (pink) and Cog4KDshRNA2 (dark red) hTERT-MSCs after staining with 
lectin. The median fluorescence values were made relative to WT. The average relative 
fluorescence values of 4 independent experiments are shown in ii). The average 
Coefficient of variation (Half max) (CV (hm)) values, are shown in iii). Error bars show 
standard deviation. One way Anova on ranks, with Dunnett’s post-hoc test using WT as 
control sample, n=4, * = P<0.05.    
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4.3.2.2 Cog4KD hTERT-MSCs are missing larger complex N-glycans 
The largest difference in lectin staining between WT and Cog4KD hTERT-MSCs was in SNA 
staining. SNA can bind to sialic acid bound to terminal galactose, which is found in 
complex N-glycans, or, it can bind to sialic acid bound to GalNAc, found in O-glycans. In 
order to better determine the differences in N-glycan profile between WT and Cog4KD 
hTERT-MSCs, the more sensitive method of mass spectrometry was used. The N-glycans 
from Cog4KDshRNA1 were profiled, as this line showed the largest difference in SNA 
staining compared to WT.    
The N-glycan profile of Cog4KD hTERT-MSCs contained 52 different N-glycan structures, 
all of which were present in the WT hTERT-MSC profile (Figure 4.6 and Figure 4.7). 
Complex type glycans were the most common (50%), followed by oligomannose (43%) 
and then hybrid type glycans (5%). The differences in abundance of each glycan type were 
not significantly different from WT hTERT-MSCs (Figure 4.8A). Of potential importance, 17 
of the higher mass complex glycans, which were lowly abundant (<0.5 au) in WT hTERT-
MSC spectrum, were absent from the Cog4KD hTERT-MSC spectrum in each biological 
replicate. Although not statistically significant, two smaller, complex glycan structures, 
Fuc1Hex5HexNAc4 and NeuAc1Fuc1Hex5HexNAc4 were more abundant in Cog4KD than WT 
hTERT-MSCs (Figure 4.8C). When fucose containing glycan structures were grouped, there 
was no significant difference between cell types with 44% of the glycans from Cog4KD 
hTERT-MSCs containing at least one fucose sugar, compared to 41% of WT hTERT-MSCs 
glycans (Student’s T Test, n=5 and 3) (Figure 4.8B). These results describe a similar N-
glycan profile between WT and Cog4KD hTERT-MSCs. However, importantly the mass 
spectrometry data which showed Cog4KD hTERT-MSCs to have fewer high mass, complex 
N-glycans, indicates that reduced SNA staining was in part due to reduced N-glycan 
sialylation and not just reduced O-glycan sialylation.    
In order to test if these higher mass complex N-glycans are required for osteogenesis, the 
osteogenic capacity of Cog4KDhTERT-MSCs was assessed. Prior to osteogenic analysis of 
Cog4KD hTERT-MSCs, the basic phenotypic attributes of shape and proliferation were 
assessed, as these can affect differentiation.   
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Figure 4.6 N-glycan spectrum of Cog4KD hTERT-MSCs. 
A representative spectrum (n=3) of N-glycans isolated from Cog4KDshRNA1 hTERT-MSCs. 1x106 cells were cultured in a 10cm dish, overnight before N-
glycan harvest, and further processing. Glycan peaks were identified using calculated mass of monosaccharides and knowledge of the synthesis pathway. 
Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of mono-isotopic peak is labelled, with predicted structure pictured above. 
Spectrum shown is from 1000-5250m/z. 
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Figure 4.7 Comparison of N- glycan spectrum from WT and Cog4KDshRNA1 hTERT-MSCs. 
Comparison of spectrum of N-glycans isolated from WT and Cog4KDshRNA1 hTERT-MSCs.1x106 cells were cultured in a 10cm dish, overnight before N-
glycan harvest, and further processing. Spectrum shown is from 1000-5250m/z, with the inset focussed in from 3400m/z to 5250m/z showing decrease of 
high mass, complex glycans in Cog4KDshRNA1 hTERT-MSCs.  
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Figure 4.8 Comparison of glycans isolated from WT hTERT-MSCs and 
Cog4KDs. 
Glycans identified from spectrum were classed by type (A) and if they were fucosylated or 
not (B). The normalised average peak intensity of individual glycan structures identified 
were also compared. Those present above 2 au in either WT or Cog4KD spectrum are 
shown in (C). Error bars show standard deviation. One way ANOVA (A) and Student’s T 
test (B), ns = non significant, P>0.05, n=5 and 3.   
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4.3.3 Cog4KD hTERT-MSCs morphology and proliferation 
The morphology of the Cog4KD hTERT-MSCs was unchanged from WT-hTERT-MSCs 
(Figure 4.9). Cog4KD hTERT-MSCs remained adherent to tissue culture plastic and had a 
fibroblastic appearance. The proliferation rate of Cog4KD-hTERT-MSCs was measured 
indirectly using an MTT assay. Cells were seeded into wells of a 96 well plate at sub-
confluency and then assayed after 1, 2, 4, and 7 days. The metabolically active cells 
convert MTT into an insoluble purple product, which is dissolved in isopropanol and 
measured on a spectrophotometer at 570nm. Thus the measured absorbance in this case 
is directly proportional to the number of cells. The MTT assay results showed that the 
Cog4KDshRNA1 line had a higher proliferation rate than WT hTERT-MSCs. The 
Cog4KDshRNA2 line showed similar levels of proliferation to WT hTERT-MSCs (Figure 4.9). 
Although there was a difference in the proliferation rate between Cog4KDshRNA1 and WT 
hTERT-MSCs, the increase in proliferation should not negatively affect osteogenesis since 
all osteogenic assays begin at full confluency. With consideration of the proliferation data, 
several assays to test the osteogenic capacity of Cog4KD hTERT-MSCs were carried out.  
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Figure 4.9 Phenotype of Cog4KD hTERT-MSCs. 
A) Bright-field image of wildtype (WT) hTERT-MSCs, Cog4KDshRNA1 and 
Cog4KDshRNA2 cells after staining with crystal violet. B) Western blot of Cog4 protein 
levels in WT hTERT-MSCs and Cog4KDshRNA1 and Cog4KDshRNA 2 cells. ß-tubulin 
was used as a loading control. C) Proliferation of WT, Cog4KDshRNA1 and 
Cog4KDshRNA2 hTERT-MSCs was tested using a MTT assay, after 1,2,4 and 7 days in 
culture. Data was made relative to day 1 vaules. ** = P<0.01, ns = non significant, one 
way ANOVA, Holm-Sidak post hoc test, n=6. 
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4.3.4 Cog4KD hTERT-MSCs are less osteogenic 
4.3.4.1 Cog4KD hTERT-MSCs have reduced phosphate staining after 
osteogenesis  
WT and Cog4KD hTERT-MSCs were seeded at full confluency into wells of a 24 well plate 
and cultured in osteogenic media for 3 weeks. Every 7 days plates were stained for 
alkaline phosphatase (ALP - pink) and calcium phosphate mineral deposition (Von Kossa -
brown). Increased ALP expression is associated with early osteogenesis whilst mineral 
deposition is carried out by functional active mature osteoblasts. Conveniently both of 
these stains can be carried out in parallel, on the same sample. WT and Cog4KD hTERT-
MSCs stained positive for ALP, however, Cog4KD hTERT-MSCs had reduced levels of 
mineral deposition compared to WT (Figure 4.10).   
4.3.4.2 Cog4KD hTERT-MSCs have lower ALP activity and reduced ALP 
protein levels compared to WT 
In order to  more closely examine ALP activity and ALP protein levels in WT and Cog4KD 
hTERT-MSCs, an assay measuring activity and western blots were carried out. The levels 
of ALP activity were measured every 7 days, during culture in osteogenic media. The ALP 
activity levels of WT hTERT-MSCs increased over time in osteogenic media. Although both 
Cog4KDshRNA1 and Cog4KDshRNA2 hTERT-MSCs showed an increase in ALP activity over 
time, the levels were significantly lower than WT hTERT-MSCs after 21 days in osteogenic 
media (Student’s T test, P<0.05, n=6) (Figure 4.11). Western blot analysis of ALP protein 
showed that levels of ALP continued to increase in WT hTERT-MSCs cultured in osteogenic 
media, even after 4 weeks (Figure 4.12). The levels of ALP protein were reduced in both 
Cog4KD hTERT-MSC lines at all time-points compared to WT (Figure 4.12). The lower 
amounts of mineral deposition and ALP protein levels and activities in the Cog4KD hTERT-
MSCs indicated reduced osteogenic capacity. To investigate this further, the expression 
levels of genes known to increase in osteoblasts derived from WT hTERT-MSCs were 
measured.   
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Figure 4.10 Osteogenic capacity of Cog4KDs. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of WT and Cog4KD hTERT-MSCs at weekly time points 
during culture in osteogenic media. X = cell layer peeled off. 
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Figure 4.11 Alkaline phosphatase activity of WT and Cog4KD hTERT-MSCs. 
Alkaline phosphatase activity was measured using pNP assay, after culture in osteogenic 
media for 0, 7, 14, and 21 days. Activity was made relative to DNA content of each 
sample using a pico-green assay. A) Comparison of WT and Cog4KDshRNA1 hTERT-
MSCs. B) Comparison of WT and Cog4KDshRNA2 hTERT-MSCs. ALP activity of cells 
after 21 days in osteogenic media was compared using Student’s T test, **=P<0.01, 
***=P<0.001, n=6, error bars show standard deviation. 
Data and image in A) printed with permission of A. Jagger who completed the 
experimental work for A). 
 
 
 Figure 4.12 Western blot analysis of ALP levels in WT and Cog4KD hTERT-
MSCs. 
Protein samples were harvested after cells were cultured in osteogenic media for 0, 7, 14, 
21 and 28 days. WT hTERT-MSC samples were run alongside (A) Cog4KDshRNA1 and 
(B) Cog4KDshRNA2. Western-blots were probed for ALP and ß tubulin as a loading 
control. ‘X’ indicates when the cell layer peeled off preventing sample harvest. 
 
4.3.4.3 Expression of osteogenic markers is altered in Cog4KD-MSCs 
In the previous chapter, the expression level of Runx2, which is a major pro-osteogenic 
transcription factor, was found to increase in WT hTERT-MSCs during incubation in 
osteogenic media. When testing the Cog4KD hTERT-MSC lines, however, I found 
differences in Runx2 expression patterns during osteogenic stimulation. The 
Cog4KDshRNA1 line showed the same expression pattern as WT hTERT-MSCs. In contrast, 
while the expression of Runx2 in the Cog4KDshRNA2 line did increase several fold in 
osteogenic media, at day 14 levels were notably lower than in WT or Cog4KDshRNA1 
hTERT-MSCs (Figure 4.13A). 
The expression level of BMP2, an osteogenic cytokine which can stimulate osteogenesis, 
was also different in the two Cog4KD hTERT-MSC lines. The Cog4KDshRNA1 hTERT-MSCs 
had expression levels as high as or higher than WT, which continued to increase overtime 
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(Figure 4.13B). The expression levels in Cog4KDshRNA2 hTERT-MSCs, were similar to WT 
at day 7, but failed to increase at day 14 unlike WT and Cog4KDshRNA1 hTERT-MSCs.  
Although there was reduced phosphate staining in the Cog4KD hTERT-MSCs, the 
expression of BSP did increase to levels comparable with WT hTERT-MSCs after 7 and 14 
days in osteogenic media (Figure 4.13C). BSP is a protein associated with the later, 
mineralisation stage of osteogenesis and in accordance with this, the expression in WT 
hTERT-MSCs was highest (2500 fold higher than day 0), after 21 days in osteogenic media. 
The level of BSP expressed by Cog4KDshRNA1 at day 21 was considerably lower than WT 
hTERT-MSCs, with levels unchanged from day 14. This supports the histology data (Figure 
4.10), suggesting that Cog4KD hTERT-MSCs do differentiate but fail to mineralise. A 
sample from Cog4KDshRNA2 hTERT-MSCs after 21 days in osteogenic media was not 
obtained as the cell layer peeled off, in both biological repeats. This hinders the 
interpretation of the qPCR data for Cog4KDshRNA2, however the levels of BSP are lower 
than WT at day 14, which also suggests a reduced mineralization capacity.   
The ability of the Cog4KD hTERT-MSCs to show any degree of positive osteogenesis, such 
as the small increase in ALP activity and the small increase in osteogenic gene expression 
during osteogenic stimulation, could be the result of Cog4 expression returning to WT 
levels whilst the cells are incubated in osteogenic media. Although Cog4KD hTERT-MSCs 
were maintained in culture media in the presence of the selective antibiotic, this was not 
included in media used for longer term assays. To test this theory, protein samples from 
WT and Cog4KD hTERT-MSCs cultured in osteogenic or basal media for 21 days were 
analysed for levels of Cog4 protein. 
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Figure 4.13 Real-time quantitative PCR analysis of Runx2, BMP2, and BSP 
expression in WT and Cog4KD hTERT-MSCs. 
cDNA produced from WT, Cog4KDshRNA1 and Cog4KDshRNA2 hTERT-MSCs grown in 
osteogenic media for either 0,7,14,or 21 days, were analysed using primers for Runx2 (A), 
BMP2 (B), BSP (C) and RSP27a. cDNA produced from WT, Cog4KDshRNA1 and 
Cog4KDshRNA2 hTERT-MSCs grown in basal media for 21 days was also analysed as a 
control (21 basal). CT values were made relative to RSP27a values and then expressed 
as fold change relative to day 0, WT values. Triplicate technical replicates from 2 
biological repeats are shown, error bars are standard deviation. Samples which peeled off 
and were not used are represented as X. Tables show mean CT values ± standard 
deviation of combined replicates.    
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4.3.5 Protein levels of Cog4 remain knocked down throughout differentiation  
Puromycin was used as the selective antibiotic after hTERT-MSC transduction, in order to 
identify successfully transduced cells. Cog4KD hTERT-MSCs were cultured in media 
containing puromycin to ensure the cells maintained the shRNA for Cog4. As the effect of 
puromycin on differentiation was unknown, it was not included in the media used for 
osteogenic assays. To check that the levels of Cog4 remained knocked-down, protein 
samples were harvested from cells cultured for 21 days in either basal or osteogenic 
media (both without puromycin) (Figure 4.14). The western blot showed that Cog4 
protein levels remained lower in both Cog4KD hTERT-MSC lines compared to WT after 
culture in either basal or osteogenic media. This confirms that the change to 
mineralization capacity - without affecting osteogenic differentiation altogether- is not 
due to Cog4 protein levels reverting to WT levels during osteogenic assays. The degree of 
Cog4 knock-down did not differ between the two Cog4KDshRNA lines. This suggests the 
difference in osteogenic gene expression between the Cog4KD lines, is not due to varying 
amounts of Cog4 protein. Interestingly, the protein level of Cog4 increased in WT cells 
after 21 days of culture in either media (Figure 4.14).  
 
 
Figure 4.14 Western blot analysis of Cog4 levels after 21 days in media 
without puromycin. 
WT and Cog4KD hTERT-MSCs were cultured in basal (B) or osteogenic (O) media for 21 
days without puromycin. Protein harvested from day 0 and day 21 samples, were loaded 
to determine the effect of removing puromycin from Cog4KD hTERT-MSCs, on levels of 
Cog4 protein. ß tubulin was used as loading control. Samples were loaded on the same 
blot and exposed for the same amount of time, the images have been edited to exclude 
irrelevant samples. 
 
113 
 
4.4  Chapter 4 Conclusion 
The glycosylation of hTERT-MSCs was successfully disrupted, using shRNA targeted to 
Cog4. Lectin staining with SNA and VVL was significantly lower in Cog4KD hTERT-MSCs, 
indicating decreased N- and/or O-glycan sialylation, which supports glycan analysis of 
COG CDG patient derived samples. Analysis of N-glycans using mass spectrometry 
confirmed that Cog4KD hTERT-MSCs had reduced levels of sialylated N-glycans, with 
large, complex glycans missing from the Cog4KDshRNA hTERT-MSC spectrum. Due to the 
Cog4KDshRNA2 hTERT-MSCs being produced late into the project, the N-glycan spectrum 
from this line was not obtained. Future experiments could investigate if this line also had 
reduced high mass, complex, glycans. Histology, western blots and qPCR data indicated 
that Cog4KD hTERT-MSCs were capable of osteogenic differentiation, however were 
unable to mineralise extracellular matrix. This change in differentiation capacity was 
rendered in the continued presence of reduced Cog4 protein levels, during osteogenic 
induction.    
In the next chapter, to investigate if disrupted N-glycan sialylation caused the reduced 
ability of Cog4KD hTERT-MSCs to mineralise, the synthesis of different types of glycans 
were disrupted using chemical inhibitors.  
 
 
 
 
 
 
 
 
 
 
Chapter 5 Chemical inhibition of glycosylation  
5.1 Rationale 
In chapter 3 the glycan profiles of hTERT-MSCs and osteoblasts derived from them, were 
identified by mass spectrometry. Osteoblasts had more complex type glycans than hTERT-
MSCs. After genetic disruption of the glycan pathway, via Cog4 knock-down, the 
mineralisation capacity was reduced. Lectin staining and mass spectrometry were used to 
identify changes in the glycan profile. Cog4KD-hTERT-MSCs had reduced SNA staining and 
lacked several high mass, complex N-glycan structures, which was in agreement with the 
reported reduction in sialylation of O-and N-glycans from COG CDG patient samples. Due 
to the binding specificity of SNA, the reduction in staining with this lectin could have been 
caused by a reduced O or N-glycan sialylation. The disruption of the glycan synthesis 
pathway via COG knockdown, could have affected N-glycan, O-glycan, glycolipid or 
proteoglycan syntheses, as they all share some of the synthesis pathways in the Golgi. In 
order to elucidate which glycan structure disruptions in the Cog4KD hTERT-MSCs were 
functionally relevant, leading to reduced mineralization capacity, the effects of chemical 
inhibitors disrupting the different glycan synthesis pathways on osteogenesis were 
assessed.     
Starting with the N-glycan synthesis pathway, the effects of two N-glycan synthesis 
inhibitors were tested. Swainsonine is an indolizidine alkaloid, originally derived from an 
Australian plant Swainsona canescens, which is toxic to cattle and horses [138]. It was 
initially identified as a lysosomal mannosidase inhibitor, as the cattle that ate it had 
symptoms similar to patients with lysosomal mannosidase deficiency. Later studies 
showed that swainsonine is a more potent inhibitor of Golgi mannosidase II [139, 140]. 
Mannosidase II resides in the cis Golgi and removes two mannose residues from the 
precursor oligosaccharide structure containing a single GlcNAc (Figure 5.1). This allows 
the addition of a further N-acetlyglucosamine, which is the beginning of a complex glycan 
branch. Inhibition of mannosidase II prevents complex glycan formation, allowing only 
oligomannose or hybrid type glycans to be formed (Figure 5.1). Several in vitro studies 
have confirmed that swainsonine decreases complex glycan formation and importantly, 
showed that swainsonine was non-toxic and had no effect on cell proliferation [141, 142]. 
However in cancer studies, swainsonine has been shown to have functional effects on 
cells in several ways. The proliferation of several cancer lines was reduced by swainsonine 
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treatment in vitro [143, 144]. Swainsonine treatment in vivo reduced tumour growth and 
metastasis [143-145]. Further studies showed that swainsonine modulated immune cell 
efficiency and promoted HSC proliferation in vivo [146-148]. Following these initial 
studies, swainsonine was tested in a clinical trial. Disappointingly, no clinical improvement 
was seen in the 17 kidney cancer patients treated with swainsonine [149]. Overall these 
studies suggest that swainsonine treatment of MSCs would be non-toxic and could have a 
functional effect.  
 
Figure 5.1 Chemical inhibition of N-glycan synthesis. 
Schematic of N-glycan synthesis in the endoplasmic reticulum and Golgi. Kifunensine 
inhibits Golgi α mannosidase I in the cis Golgi. Swainsonine inhibits mannosidase II in 
medial Golgi. For simplicity only one possible complex N-glycan structure shown in the 
trans Golgi. 
 
Although treatment with swainsonine inhibits complex glycan formation, hybrid glycans 
can also contain sialylated branches. Several types of lectins bind to sialic acid and are 
involved in a variety of cellular processes, including immunity and cell adhesion [150]. A 
study using MSCs showed that homing to bone marrow was improved by manipulating 
the glyco-form of CD44 in order to bind to E-selectin, a sialic acid and fucose binding 
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lectin [120]. Since sialic acid has cellular functions and the Cog4KDs showed reduced SNA 
lectin staining, an enzyme earlier in the glycosylation pathway was also targeted. 
Inhibition of Golgi mannosidase I prevents the removal of mannose from the precursor 
oligosaccharide which in turn prevents the formation of Hex5HexNAc2 (Figure 5.1). 
Subsequently only oligomannose type glycans can be produced. Kifunensine is small 
molecule that predominantly inhibits Golgi mannosidase I [151]. Unlike swainsonine, 
there have been few studies looking at the functional effect of kifunensine treatment. 
One study with epithelial cells used kifunensine to examine the role of glycans in the 
polarized secretion of Wnt3a and Wnt11 [152]. As this study found kifunensine to be 
effective at inhibiting Golgi mannosidase I in vitro, with no toxicity, kifunensine was used 
to test the effect of complete loss of sialylated N-glycans on MSC differentiation.   
Another glycan synthesis pathway potentially disrupted in Cog4KD hTERT-MSCs is O-
glycan synthesis. Evidence for this was the altered staining of Cog4KD-hTERT-MSCs, using 
VVL and PNA which are O-glycan binding lectins. SNA can bind to NeuAc-Gal, which is 
found in N- and O-glycans, or NeuAc-GalNAc which is found in O-glycans [153]. As such, 
the reduced SNA staining seen in Cog4KD-hTERT-MSCs may have been due to lower levels 
of sialylated O-glycans. To test if disrupted O-glycan synthesis was responsible for the loss 
of mineralisation in Cog4KD hTERT-MSCs, hTERT-MSCs were treated with an O-glycan 
inhibitor. Benzyl 2-acetamido-2-deoxy-α-D-Galactopyranoside (BadGal) is a competitive 
substrate of the glycosyltransferase which normally adds galactose (Gal) to N-
acetylgalactosamine (GalNAc), forming a core 1 or T-antigen O-glycan structure (Figure 
5.2). BadGal treatment of colon carcinoma cells was shown to increase the amount of 
truncated O-glycan structures, comprising of just GalNAc attached to serine or threonine 
(Tn-antigen structure) [154]. The treated cells accumulated free intracellular BadGal-Gal 
disaccharides, which acted as a competitive substrate of sialyltransferases. This resulted 
in increased T-antigen abundance, along with decreased sialylated O-glycans compared to 
untreated controls [154]. To test if disrupted O-glycan synthesis affected osteogenesis, 
hTERT-MSCs were treated with BadGal.     
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Figure 5.2 Competitive inhibition of O-glycan formation by BadGal. 
Schematic showing competitive inhibition of T antigen formation and sialylated O-glycans 
by BadGal. C1GalT-1 = Core 1 β1-3  galactosyltransferase. ST3Gal1 = Core 1 α2-3 
sialyltransferase.   
 
Inhibitors of glycolipid and proteoglycan synthesis were also used to see if their disrupted 
syntheses were responsible for the altered mineralisation in Cog4KD hTERT-MSCs. 
Gaucher’s disease is a lysosomal storage disease, caused by disrupted glycolipid 
degradation. Due to disrupted degradation, the cellular supply of glycolipid precursors 
may be altered resulting in disrupted glycolipid synthesis. Patients with Gaucher’s disease 
can suffer from a variety of skeletal symptoms such as osteopenia, osteoporosis, 
osteolytic lesions, and osteonecrosis. Using Gaucher’s disease mice models, in vitro 
analysis of osteoblasts found that osteoblasts had reduced proliferation and reduced 
osteogenic differentiation capacity compared to osteoblasts isolated from healthy control 
mice [155]. In view of this, disrupted glycolipid synthesis in the Cog4KD hTERT-MSCs could 
have contributed towards the reduction in mineralization capacity. In order to test this, 
hTERT-MSCs were treated with a glycolipid inhibitor called N-butyldeoxynojirimycin (NB-
DNJ) [156] and the effect on osteogenesis was measured using ALP and Von kossa 
staining. As mentioned in the introduction (section 1.2.3), proteoglycans are a major 
component of bone tissue, forming the ECM that is then mineralized. Ex vivo and in vitro 
studies have shown that GAG synthesis and sulfation are required for osteogenesis [157, 
158]. It is possible then, that the reduced mineralization capacity of Cog4KD hTERT-MSCs 
could also be due to improper GAG synthesis or sulfation, as both processes requires 
Golgi resident enzymes. Therefore, the influence of sodium chlorate, a GAG sulfation 
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inhibitor, on the osteogenesis of hTERT-MSCs was analysed using ALP and Von kossa 
staining. Some of the experimental work involving glycosylation inhibitors was performed 
by undergraduate students working under my supervision. Their contributions are 
acknowledged on the relevant figures.   
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5.2 Results for Chemical inhibition of glycosylation 
5.2.1 Swainsonine treatment significantly alters the glycan profile of hTERT-
MSCs 
After 48 hours treatment with 10μg/ml swainsonine glycans were harvested from hTERT-
MSCs and then analysed by mass spectrometry (MALDI-TOF-TOF). The change in N-glycan 
profile was consistent with mannosidase II inhibition. Spectra from swainsonine treated 
cells had several hybrid structures, which were not present in the untreated hTERT-MSC 
profile (Figure 5.3 and Figure 5.4). The abundance of oligomannose and complex glycans 
was significantly lower in swainsonine treated hTERT-MSCs (One way ANOVA, Holm-Sidak 
post hoc, P<0.001, n=3) Figure 5.5A). Hybrid type glycans were the most common, with 
the structure NeuAc1Fuc1Hex6HexNAc3 being the most abundant (Figure 5.4 and Figure 
5.5C). The high intensity of this fucosylated structure contributed to the significant 
increase in fucosylation seen in swainsonine treated cells (Student’s T test, P<0.01, n=3) 
(Figure 5.5B). As treatment with swainsonine successfully altered the N-glycan profile of 
hTERT-MSCs, tests were then carried out to see if this caused a change in phenotype.     
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Figure 5.3 MALDI-TOF/TOF spectrum of N-glycans from hTERT-MSCs treated with swainsonine. 
A representative spectrum (n=3) of N-glycans isolated from hTERT-MSCs treated with swainsonine.1x106 cells were cultured in a 10cm dish, in media with 
swainsonine (10µg/ml) for 48 hours, before N-glycan harvest, and further processing. Glycan peaks were identified using calculated mass of 
monosaccharide units and knowledge of the synthesis pathway. Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of mono-
isotopic peak is labelled, with predicted structure pictured above. Spectrum shown is from 1000-5250m/z. 
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Figure 5.4 Comparison of spectrum from untreated and swainsonine treated hTERT-MSCs. 
A representative spectrum (n=5 untreated, and n=3 treated with swainsonine) of N-glycans isolated from hTERT-MSCs.1x106 cells were cultured in a 10cm 
dish, in media with swainsonine (10µg/ml) for 48 hours, before N-glycan harvest, and further processing. Glycan peaks were identified using calculated 
mass of monosaccharide units and knowledge of the synthesis pathway. Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of 
mono-isotopic peak is labelled, with predicted structure pictured above. Spectrum shown is from 1000-5250m/z. 
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Figure 5.5 Comparison of glycans isolated from untreated hTERT-MSCs and 
swainsonine treated hTERT-MSCs. 
Glycans identified from spectrum were classed by type (A) and if they were fucosylated or 
not (B). One way ANOVA, Holm Sidak post hoc test (A) Student’s T test (B)**=P<0.01, 
***=P<0.001, n=5 and 3. The normalised average peak intensity of individual glycan 
structures were also compared. Those present above 5au, in either spectrum are shown 
in (C). Error bars show standard deviation. 
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5.2.2 Swainsonine treatment does not affect morphology or proliferation of 
hTERT-MSCs 
In order to check if swainsonine treatment affected cell morphology, hTERT-MSCs that 
had been treated with swainsonine for 48 hours were stained with crystal violet and 
imaged. No difference between untreated and swainsonine treated hTERT-MSCs was 
observed (Figure 5.6B). Results from a MTT assay indicated no significant difference in 
proliferation between untreated and swainsonine treated hTERT-MSCs (Figure 5.6B).  
5.2.3 Swainsonine does not prevent osteogenesis 
To determine if osteogenesis would still occur in the presence of swainsonine hTERT-
MSCs were cultured in osteogenic media supplemented with 10μg/ml swainsonine for 21 
days. Every 7 days cells were either stained for ALP and phosphate (Von kossa), or 
harvested for use in an ALP activity assay. Swainsonine treatment did not inhibit 
osteogenesis, as seen by positive ALP and phosphate staining (Figure 5.7). There was also 
no significant change in ALP activity of swainsonine treated cells (Figure 5.8).  
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Figure 5.6 Effect of swainsonine, kifunensine or BadGal on phenotype. 
A-D left-handside) Bright-field images of untreated hTERT-MSCs, cells treated with 
10µg/ml swainsonine, 2µg/ml kifunensine or 10mM BadGal after staining with crystal 
violet. Right-handside B-D) Effect of treatments on proliferation was tested using MTT 
assays. 
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Figure 5.7 Effect of swainsonine on osteogenesis. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of hTERT-MSCs at weekly time points during culture in 
either normal osteogenic media or osteogenic media supplemented with 10µg/ml 
swainsonine. 
 
 
 
Figure 5.8 Effect of swainsonine on ALP activity. 
ALP activity was measured using pNP assay, after culture in osteogenic media for 0, 7, 
14, and 21 days. Activity was made relative to DNA content of each sample using a pico-
green assay. White bars represent untreated hTERT-MSC, orange bars represent 
hTERT-MSCs treated continuously with 10µg/ml swainsonine. One way ANOVA on ranks, 
Dunn’s post hoc test, ns=non-significant, n=6, error bars show standard deviation. 
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5.2.4 Kifunensine further decreased the abundance of complex glycans 
As swainsonine treatment had no effect on osteogenesis, an enzyme earlier in the N-
glycan synthesis pathway was targeted. Inhibition of mannosidase I should inhibit the 
production of any hybrid or complex glycans, resulting in only oligomannose type glycans. 
Indeed, hTERT-MSCs treated with kifunensine, a mannosidase I inhibitor, had an N-glycan 
profile dominated by oligomannose type glycans (Figure 5.9 and Figure 5.10). Of the 17 
glycan structures identified in kifunensine treated profiles, Hex9HexNAc2 was the most 
abundant structure (Figure 5.10 and Figure 5.11C). Compared to the swainsonine treated 
cells there were 3x fewer complex glycans, indicating that kifunensine treatment was 
more potent than swainsonine. Phenotypic tests were then carried out to test the effect 
of this more extreme glycan profile alteration, on cell morphology and proliferation.  
5.2.5 Kifunensine does not affect morphology or proliferation of hTERT-MSCs  
As with swainsonine treatment, kifunensine did not affect the morphology of hTERT-
MSCs. Crystal violet staining of kifunensine treated cells revealed similar cell morphology 
between treated and untreated cells (Figure 5.6C). Again using an MTT assay as an 
indicator of proliferation, there was no significant difference between untreated and 
kifunensine treated cells (Figure 5.6C). Following this, the effect of kifunensine on 
osteogenesis was tested by including kifunensine in the osteogenic media. 
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Figure 5.9 MALDI-TOF/TOF spectrum of N-glycans from hTERT-MSCs treated with kifunensine. 
A representative spectrum (n=3) of N-glycans isolated from hTERT-MSCs treated with kifunensine.1x106 cells were cultured in a 10cm dish, in media with 
kifunensine (2µg/ml) for 48 hours, before N-glycan harvest, and further processing. Glycan peaks were identified using calculated mass of monosaccharide 
units and knowledge of the synthesis pathway. Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of mono-isotopic peak is 
labelled, with predicted structure pictured above. Spectrum shown is from 1000-5250m/z. 
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Figure 5.10 Comparison of spectrum from untreated and kifunensine treated hTERT-MSCs. 
A representative spectrum of N-glycans isolated from hTERT-MSCs untreated or treated with kifunensine.1x106 cells were cultured in a 10cm dish, in basal 
media or media with kifunensine (2µg/ml) for 48 hours, before N-glycan harvest, and further processing. Glycan peaks were identified using calculated 
mass of monosaccharide units and knowledge of the synthesis pathway. Glycans had to have two isotopic peaks, 3x above noise to be included. Mass of 
mono-isotopic peak is labelled, with predicted structure pictured above. Spectrum shown is from 1000-5250m/z. 
 
 Figure 5.11 Comparison of glycans isolated from untreated hTERT-MSCs 
and hTERT-MSCs treated with kifunensine. 
Glycans identified from spectrum were classed by type (A) and if they were fucosylated or 
not (B). One way ANOVA, Holm Sidak post hoc test (A) Student’s T test (B)**=P<0.01, 
***=P<0.001, NT =not tested, n=5 and 3. The normalised average peak intensity of 
individual glycan structures were also compared. Those present above 2au, in either 
spectrum are shown in (C). Error bars show standard deviation. 
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5.2.6 Altered osteogenesis with kifunensine treatment 
5.2.6.1 Phosphate staining is increased after kifunensine treatment 
To test the effect of kifunensine on osteogenesis cells were cultured in osteogenic media 
containing kifunensine (2μg/ml). Phosphate staining was notably increased in treated 
cells (Figure 5.12). The difference between untreated and kifunensine treated cells was 
visible in samples stained at day 14 and day 21. To help determine if kifunensine affected 
the differentiation of MSCs into osteoblasts, or, the mineralisation activity of osteoblasts, 
a pre-treatment with kifunensine, followed by culture in normal osteogenic media was 
tested. This pre-treatment also increased phosphate staining (Figure 5.12), suggesting 
that the differentiation of hTERT-MSCs had altered. Other osteogenic assays were then 
performed using pre-treatment and continuous kifunensine treatment, to further 
characterise and determine the mechanism by which kifunensine alters osteogenesis.  
 
Figure 5.12 Effect of kifunensine on osteogenesis. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of hTERT-MSCs at weekly time points. Cells were 
cultured in either normal osteogenic media or osteogenic media supplemented with 
2µg/ml kifunensine. The third row shows hTERT-MSCs treated for 48 hours with 2µg/ml 
kifunensine in basal media, prior to 21 days culture in osteogenic media. 
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5.2.6.2 ALP activity is unaffected by kifunensine 
Following the results from the kifunensine pre-treatment tests, ALP activity and protein 
levels were measured, as ALP is used as an early marker of osteogenesis. There was no 
significant difference in ALP activity between untreated and hTERT-MSCs continuously 
treated with kifunensine (Figure 5.13A). Interestingly, western blots showed reduced 
levels of ALP protein after 14-28 days in osteogenic media with either kifunensine 
treatment (Figure 5.13B,C). As ALP is described as an early marker of osteogenesis, 
another time-course was carried out harvesting cells after 0, 2, 4, 6, 8 and 10 days. 
Samples were grouped by time so that the membranes could be cut and exposed for 
different lengths of time, to try and detect ALP at earlier time-points (Figure 5.14). 
Kifunensine pre-treatment reduced the amount of ALP in all of the samples, despite 
reaching close to untreated levels by day 28 (Figure 5.13 and Figure 5.14). Continuous 
treatment with kifunensine did not have the same effect with levels matching untreated 
samples until day 8, when ALP levels were lower in kifunensine treated cells.  The ALP 
protein from continuously treated cells ran at a lower molecular weight, showing that ALP 
is N-glycosylated. The shift in molecular weight occurred in samples from day 4 onwards, 
the ALP from the kifunensine pre-treated samples ran at the same molecular weight as 
untreated, likely due to ALP turnover after the pre-treatment. To investigate what effect 
lower ALP protein levels and kifunensine treatment had on the expression of osteogenic 
associated genes, real time qPCR experiments were carried out.   
 
132 
 
 
Figure 5.13 Effect of kifunensine on ALP activity and protein levels. 
A) ALP activity was measured using pNP assay, after culture in osteogenic media for 0, 7, 
14, and 21 days. Activity was made relative to DNA content of each sample using a pico-
green assay. One way ANOVA, n=6, ns= non significant, error bars show standard 
deviation. Data and graph in A) is printed with permission of A.Jagger who carried out the 
experimental work for A). Protein samples were harvested after cells were cultured in 
osteogenic media for 0, 7, 14, 21 and 28 days. Untreated hTERT-MSC samples were run 
alongside hTERT-MSCs treated with kifunensine continuously (B) or for 48 hours prior to 
addition of osteogenic media (C). Western-blots were probed for ALP and ß tubulin as a 
loading control. L = protein ladder. 
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Figure 5.14 Effect of kifunensine treatments on ALP levels during early 
osteogenesis. 
Protein samples were harvested after hTERT-MSCs were cultured in osteogenic media 
for 0, 2,4,6,8, and10 days. Cells received either normal osteogenic media (Unt), 
osteogenic media with kifunensine added continuously (+Kif), or a 48 hour pre-treatment 
with kifunensine in basal media then normal osteogenic media (+Kif P.T). Samples were 
run in time-point order and the membranes were cut into sections to enable varying 
exposure times, and avoid burning the membrane. Western blots were probed for ALP 
and ß tubulin as a loading control.     
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5.2.6.3 Kifunensine treatment reduces expression of BMP, BSP, and 
Runx2 
In order to further characterise the effect of kifunensine treatment on osteogenesis, real 
time qPCR was used to analyse the expression level of 3 osteogenic markers used in 
previous chapters. BMP is a cytokine that stimulates osteogenesis via Smad-5 and Runx2. 
BMP expression levels in untreated hTERT-MSCs, peaked after 14 days in osteogenic 
media (Figure 5.15i). The BMP levels in the kifunensine treated samples did not peak at 
day 14, instead levels gradually increased matching untreated expression levels at day 7 
and day 21. The expression of Runx2, which is activated downstream of BMP, increased 
over time in both kifunensine treated samples. However, levels were lower than 
untreated hTERT-MSCs at day 14 and day 21 (Figure 5.15ii). BSP is a major non-
collagenous protein found in bone. As it plays a role in bone mineralisation, the 
expression levels were expected to be higher in kifunensine treated cells. In fact, the 
expression levels were notably lower in both kifunensine treated samples (Figure 5.15iii). 
Overall the qPCR results did not provide a mechanism of action of kifunensine treatment 
on osteogenesis. The reduced expression of Runx2 and BSP, together with reduced ALP 
protein levels, would be expected to result in reduced osteogenic differentiation in 
kifunensine treated cells. This contradicts the increased phosphate staining seen, which is 
indicative of functional osteoblasts. Further experiments are required to determine if the 
mineralisation observed via kifunensine treatment is the result of increased osteogenesis, 
or aberrant mineralisation by MSCs. 
The purpose of testing glycosylation inhibitors was to identify the cause of reduced 
mineralisation by Cog4KD hTERT-MSCs. As kifunensine increased mineralisation a rescue 
experiment of Cog4KD hTERT-MSCs was then carried out.   
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Figure 5.15 Real-time quantitative PCR analysis of BMP2, Runx2 and BSP 
expression in hTERT-MSCs after kifunensine treatments. 
cDNA was produced from hTERT-MSCs which were cultured for 48 hours in basal media 
containing 2µg/ml kifunensine prior to culture in osteogenic-inductive media, as well as 
from hTERT-MSCs cultured continuously in osteogenic media containing 2µg/ml 
kifunensine or standard osteogenic media. Samples were harvested at 0,7,14,or 21 days. 
Primers for BMP2 (i) Runx2 (ii), BSP (iii) and RSP27a were used in real-time qPCR 
experiments. cDNA produced from hTERT-MSCs grown in basal media for 21 days were 
also analysed as a control (21 basal). CT values were made relative to RSP27a values 
and then expressed as fold change relative to day 0 untreated values. Triplicate technical 
replicates from 2 biological repeats are shown, error bars are standard deviation. Tables 
show mean CT values ± standard deviation of combined replicates.   
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5.2.7 Kifunensine does not rescue Cog4KD hTERT-MSCs’ mineralisation  
Cog4KDshRNA1 hTERT-MSCs were treated continuously with kifunensine and osteogenic 
media. Phosphate staining remained reduced in the kifunensine treated Cog4KDshRNA1 
hTERT-MSCs (Figure 5.16). This result as well as the increased phosphate staining seen in 
kifunensine treated cells, which have significantly reduced complex glycan abundance, 
indicates that disrupted N-glycosylation is not the cause of reduced mineralisation in the 
Cog4KD hTERT-MSCs. 
Disrupted O-glycan synthesis is another potential cause of the Cog4KD hTERT-MSC 
phenotype. So the effect of an O-glycan inhibitor was tested next.  
 
 
 
Figure 5.16 Effect of kifunensine on Cog4KD hTERT-MSCs. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of hTERT-MSCs at weekly time points. WT hTERT-
MSCs were cultured in normal osteogenic media. Cog4KD hTERT-MSCs were cultured in 
normal osteogenic media or osteogenic media supplemented continuously with 2µg/ml 
kifunensine (bottom row). Kifunensine treatment started 48 hours prior to addition of 
osteogenic media. 
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5.2.8 BadGal treatment alters O-glycan synthesis  
In order to test if disrupted O-glycan synthesis was the cause of reduced mineralisation in 
Cog4KD hTERT-MSCs, benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside (BadGal) was 
used. BadGal is a competitive inhibitor of the glycosyltransferase that normally adds 
galactose to N-acetylgalactosamine, forming a core 1 or T-antigen O-glycan structure. 
Flow cytometry with lectins was carried out on BadGal treated hTERT-MSCs. Jacalin and 
VVL lectins can both bind to N-acetylgalactosamine or the Tn antigen structure. In line 
with glycosyltransferase inhibition BadGal treated hTERT-MSCs had significantly higher 
Jacalin and VVL staining (P<0.05 and P<0.001 respectively) (Figure 5.17A and Figure 
5.17B). Staining with PNA, which binds to the T-antigen structure if unsialylated, was 
significantly increased in BadGal treated hTERT-MSCs (P<0.001) (Figure 5.17C). This could 
have been caused by binding of PNA to BadGal-galactose disaccharides, which have been 
shown to form in other cell types, however the staining should be preferential for surface 
glycans rather than intracellular structures. Alternatively, as PNA binding is inhibited by 
sialic acid, the BadGal-galactose disaccharide may have acted as a competitive inhibitor of 
sialyltransferases, resulting in fewer sialylated O-glycans. The binding of SNA increased 
significantly (P<0.05) (Figure 5.18A), but as binding can occur to sialylated N-glycans as 
well as sialylated O-glycans, it could be another consequence of altered sialyltransferase 
substrate competition. The binding of MAL II was not significantly different in BadGal 
treated hTERT-MSCs compared to untreated cells (Figure 5.18B). Overall the lectin 
staining indicated that BadGal treatment reduced O-glycan elongation. Phenotypic tests 
were then carried out to test the effect of reduced O-glycan synthesis. 
5.2.9 BadGal treatment does not alter morphology or proliferation  
BadGal treatment did not affect the morphology of hTERT-MSCs. Crystal violet staining of 
BadGal treated cells revealed similar cell morphology, between treated and untreated 
cells (Figure 5.6D). The proliferation of hTERT-MSCs were also unaffected by BadGal 
treatment, shown using an MTT assay (Figure 5.6D). Following this, the effect of altered 
O-glycan synthesis on osteogenesis was tested by adding BadGal (2mM) to osteogenic 
media.  
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Figure 5.17 Flow cytometry analysis of BadGal treated hTERT-MSCs with 
lectins. 
Untreated hTERT-MSCs and hTERT-MSCs treated with 2mM BadGal were probed with 
A) Jacalin B) VVL and C) PNA lectins. Histograms i) show log fluorescence of untreated 
hTERT-MSCs (black) and hTERT-MSCs treated with 2mM BadGal (yellow) after staining 
with lectin. Median fluorescence values were made relative to WT set at 100. Average 
relative values of 3 independent experiments are shown in ii). Coefficient of variation (Half 
max) (CV (hm)) values, average of 3 independent experiments are shown in iii). Student’s 
T test, n=3, * = P<0.05, ***= P<0.001. Error bars are standard deviation.       
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Figure 5.18 Flow cytometry analysis of BadGal treated hTERT-MSCs with 
lectins (continued). 
Untreated hTERT-MSCs and hTERT-MSCs treated with 2mM BadGal were probed with 
A) SNA, and B) MAL II lectins. Histograms i) show log fluorescence of untreated hTERT-
MSCs (black) and hTERT-MSCs treated with 2mM BadGal (yellow) after staining with 
lectin. Median fluorescence values were made relative to WT set at 100. Average relative 
values of 3 independent experiments are shown in ii). Coefficient of variation (Half max) 
(CV (hm)) values, average of 3 independent experiments are shown in iii). Student’s T 
test, n=3, * = P<0.05. Error bars are standard deviation. 
 
 
 
140 
 
5.2.10 BadGal treatment mimics Cog4 knock down effect on osteogenesis 
5.2.10.1 Phosphate staining is reduced in BadGal treated hTERT-MSCs 
hTERT-MSCs were cultured in basal media containing BadGal (2mM) for 48 hours prior to 
the addition of osteogenic media, containing BadGal (2mM). Weekly ALP and phosphate 
(Von kossa) staining indicated reduced mineralisation in BadGal treated hTERT-MSCs 
(Figure 5.19). ALP staining (seen as pink) was unchanged between samples. As with the 
kifunensine treatments, to test if the change in mineralization capacity with BadGal 
treatment was due to impaired differentiation or impaired mineralisation, the effect of a 
pre-treatment of BadGal, prior to normal osteogenic media was assessed. This 
experiment showed that a reduction in mineralization occurred after a 72 hour pre-
treatment with BadGal, seen by reduced phosphate staining, compared to untreated 
samples (Figure 5.20).    
This reduction in phosphate staining was similar to the Cog4KD hTERT-MSCs. Following 
this, the effect of BadGal was tested using other osteogenic markers.  
 
Figure 5.19 Effect of BadGal on osteogenesis. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of hTERT-MSCs at weekly time points during culture in 
either normal osteogenic media, osteogenic media supplemented with 2mM BadGal, or 
osteogenic media supplemented with 2mM BadGal and 2µg/ml kifunensine. Treatments 
started 48 hours prior to addition of osteogenic media.    
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Figure 5.20 Effect of BadGal pre-treatment on osteogenesis. 
Bright-field images of alkaline phosphatase staining - seen as pink - and phosphate (von 
Kossa) staining - seen as brown - of hTERT-MSCs at weekly time points during culture in 
osteogenic media. Untreated cells were grown in basal media for 72 hours prior to 
osteogenic media, whilst treated cells recieved 2mM BadGal for 72 hours prior to addition 
of normal osteogenic media. The images here are printed with the permission of 
I.G.Cantanhede who carried out the experimental work for this figure. 
 
 
 
5.2.10.2 BadGal treatment does not affect ALP levels or, BMP, BSP, and 
Runx2 expression 
To further test the effect of BadGal on osteogenesis, the activity and protein levels of ALP 
were measured in BadGal treated hTERT-MSCs. The activity of ALP was significantly lower 
in the BadGal treated hTERT-MSCs at day 21 (Figure 5.21A). Despite this, Western blots of 
ALP protein showed similar amounts of ALP between samples, although it ran at a lower 
molecular weight (Figure 5.21B). This suggests ALP is also O-glycosylated. This western 
differs from that of the Cog4KD hTERT-MSCs, which had reduced levels of ALP protein. 
During culture with osteogenic media containing BadGal the expression levels of 
osteogenic genes BMP2, BSP, and Runx2 were similar to untreated samples (Figure 5.22). 
Despite the lack of visible mineralisation seen by Von kossa staining of BadGal treated 
hTERT-MSCs, the levels of BSP were as high as untreated cells.  
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Figure 5.21 Effect of BadGal on ALP activity and protein levels. 
A) ALP activity was measured using pNP assay, after culture in osteogenic media for 0, 7, 
14, and 21 days. Activity was made relative to DNA content of each sample using a pico-
green assay. White bars represent untreated hTERT-MSC, yellow bars represent hTERT-
MSCs treated continuously with 2mM BadGal. Mann Whitney U test on day 21 data only, 
** = P<0.01, n=6, error bars show standard deviation. B) Protein samples were harvested 
after cells were cultured in osteogenic media for 0, 7, 14, 21 and 28 days. Untreated 
hTERT-MSC samples were run alongside hTERT-MSCs treated with 2mM BadGal 
continuously. Western-blots were probed for ALP and ß tubulin as a loading control. L = 
protein ladder.    
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Figure 5.22 Real-time quantitative PCR analysis of BMP2, Runx2 and BSP 
expression after BadGal treatment. 
cDNA was produced from hTERT-MSCs which were cultured in osteogenic media 
containing 2mM BadGal or normal osteogenic media. Samples were harvested at 
0,7,14,or 21 days. Primers for BMP2 (i) Runx2 (ii), BSP (iii) and RSP27a were used in 
real-time qPCR experiments. cDNA produced from hTERT-MSCs grown in basal media 
for 21 days were also analysed as a control (21 basal). CT values were made relative to 
RSP27a values and then expressed as fold change relative to day 0 untreated values. 
Triplicate technical replicates from 2 biological repeats are shown, error bars are standard 
deviation. Tables show mean CT values ± standard deviation of combined replicates.   
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5.2.10.3 Kifunensine but not BadGal treatment significantly affects β 
catenin levels 
Both kifunensine and BadGal treatments were able to affect mineralization capacity of 
hTERT-MSCs after a short treatment, prior to the addition of osteogenic media, which 
indicates a change in MSCs that affects the differentiation of the cells, rather than their 
mineralization machinery. Multiple signalling pathways initiate osteogenic differentiation, 
by inducing the expression of osteogenic transcription factors and genes. Active Wnt 
signalling involves unphosphorylated β-catenin translocating to the nucleus and affecting 
gene transcription. Since studies have shown active Wnt signalling to promote 
osteogenesis [98, 99], the levels of unphosphorylated β-catenin were assessed after 
kifunensine or BadGal treatments by western blot. The amount of unphosphorylated β-
catenin was significantly increased after 48 hour kifunensine treatment (Figure 5.23). The 
level of unphosphorylated β-catenin after BadGal treatment, did also increase, but was 
not significantly different to levels in untreated hTERT-MSCs. This suggests that the 
mechanism of action of kifunensine could be via β-catenin, which is downstream of Wnt 
signalling. Further experiments are required to identify which signalling pathway BadGal 
acts on to affect osteogenesis. To further test the role of O-glycans in osteogenesis, a 
combined treatment of BadGal and kifunensine was carried out.  
5.2.11 Reduced mineralisation with BadGal treatment is not rescued by 
kifunensine  
WT hTERT-MSCs were treated with BadGal and kifunensine continuously during 
osteogenesis. The level of phosphate staining was the same as that of cells treated with 
BadGal alone (Figure 5.19). This supports the notion that O-glycosylation is disrupted in 
the Cog4KD hTERT-MSCs, as their mineralisation was also not restored by kifunensine 
treatment (Figure 5.16).  
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Figure 5.23 Effect of kifunensine or BadGal on ß catenin expression. 
A) Protein samples were harvested from cells cultured in either basal media alone for 48 
hours (untreated), or basal media supplemented with 2µg/ml kifunensine for 48 hours, or 
basal media supplemented with 2mM BadGal for 48 hours. Samples were run in triplicate 
on a SDS-page gel. After western blot, the membrane was cut, and blotted with antibodies 
against ß catenin or ß tubulin as loading control. Densitrometry was carried out on images 
of the blots in A) using ImageJ software. ß catenin density was made relative to ß tubulin 
density. The density of the first untreated lane was set to 1. Average relative ß catenin 
density is plotted in B). Error bars show standard deviation, ns = non-significant, * = 
P<0.05, One way ANOVA, with Holm Sidak post hoc test, n=3.    
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5.2.12 ALP is both O-and N-glycosylated and glycosylation levels correlate with 
protein levels 
The protein harvested from cells treated with kifunensine, BadGal, or both was run 
alongside protein from untreated cells, and blotted for ALP (Figure 5.24). The ALP from 
untreated cells migrated at 95KDa whilst the ALP from BadGal treated cells migrated at 
80KDa. This suggests ALP is O-glycosylated. The ALP from kifunensine treated cells 
migrated at 70KDa, showing ALP to be N-glycosylated as well. The amount of ALP protein 
varied depending on the glycan inhibitor treatment. The amount of ALP protein was 
reduced in cells treated with kifunensine. It was further reduced in cells receiving double 
treatment. One explanation for this is that N-and O-glycosylation contributes to the 
turnover rate of ALP. On the other hand, as glycan inhibitors were shown to affect 
osteogenesis, the altered levels could be a consequence of altered cell differentiation 
triggered by the change in cellular glycome.  
 
 
 
Figure 5.24 Effect of kifunensine and BadGal on ALP protein levels. 
Protein samples of hTERT-MSCs cultured for 21 days in osteogenic media containing 
either no supplement, kifunensine, BadGal, or both kifunensine and BadGal supplements, 
were loaded (indicated by -/+). Western-blots were probed for ALP and ß tubulin as a 
loading control.   
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Despite the evidence implying that disrupted O-glycan sialylation in the Cog4KD hTERT-
MSCs, could be causing the reduced mineralization capacity, other types of glycans that 
are also synthesised in the Golgi could be also affected by the Cog4 knock-down and 
contribute to their altered osteogenesis. In order to test this I.G.Cantanhede carried out 
experiments with a glycolipid inhibitor – deoxynojirimycin (NB DNJ) – and with sodium 
chlorate, an inhibitor of GAG sulfation.   
5.2.13 Glycolipid inhibition by NB DNJ does not phenocopy Cog4KD hTERT-MSCs 
NB DNJ is an imino sugar that has been shown to inhibit the synthesis of glycolipids that 
contain a glucose attached to ceramide at the start of the glycolipid chain [156]. Previous 
studies showed that treatment with 50μM NB DNJ could reduce cholera toxin (a protein 
that binds glycolipids) binding by 90% [156]. To ensure full inhibition hTERT-MSCs were 
treated with 150μM NB DNJ. This treatment did not affect proliferation of the cells, as 
shown by no change in absorbance in a MTT assay (Figure 5.25A). NB DNJ has been 
proposed to inhibit α-glucosidase I and II, which are responsible for cleaving the glucose 
units from the precursor oligosaccharide structure in the N-glycan synthesis pathway 
[156]. To test if NB DNJ was affecting N-glycan synthesis treated cells were stained with 
the lectin ConA and staining was compared to untreated hTERT-MSCs using flow 
cytometry. The ConA staining was unaffected by NB DNJ treatment, as seen by the 
overlapping fluorescence histograms from the flow cytometry (Figure 5.25B). This 
indicated that NB DNJ, at these concentrations, did not inhibit N-glycan synthesis, and 
could be used to test the role of glycolipid synthesis in MSC differentiation. The effect of 
glycolipid inhibition on osteogenesis was assessed by inclusion of NB DNJ in osteogenic 
media continuously, and by pre-treating cells with NB DNJ prior to normal osteogenic 
media. Staining of ALP and phosphate (von kossa) at weekly time-points indicated that 
pre-treatment or continuous treatment with NB DNJ had no effect on osteogenesis 
(Figure 5.25C). This indicated that disrupted synthesis of the most abundant type of 
glycolipid – glucosyl-ceramide based – was not responsible for the loss of mineralization 
capacity seen in the Cog4KD hTERT-MSCs.  
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Figure 5.25 Effect of NB DNJ treatment on hTERT-MSCs. 
A) Effect of continuous treatment with 150µM NB DNJ on the proliferation of hTERT-
MSCs was estimated using an MTT assay, at days 1,2, and 7. ns= non-significant, One 
way ANOVA on Ranks, Dunn’s post hoc test, n=6, error bars show standard deviation. B) 
Black histogram shows log fluorescence of untreated hTERT-MSCs after staining with 
ConA lectin. Red histogram shows log fluorescence of hTERT-MSCs treated with 150µM 
NB DNJ for 48 hours, after staining with ConA. C) Brightfield images of hTERT-MSCs 
after culture in osteogenic media with either no supplement, pre-treatment with NB DNJ, 
or continuous treatment with NB DNJ. Cells were stained for ALP and phosphate (Von 
kossa) at weekly timepoints.      
These images and data are printed with the permission of I.G.Cantanhede who carried out 
the experimental work for this figure. 
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5.2.14 Continuous inhibition of GAG sulfation reduces mineralization capacity 
As proteoglycans and GAG chains are synthesised in the Golgi alongside O-glycans, it is 
possible that proteoglycan synthesis was disrupted in the Cog4KD hTERT-MSCs. To test 
this, hTERT-MSCs were treated with sodium chlorate, which is a competitive inhibitor of 
ATP-sulfurylase an enzyme required for the synthesis of the sulfation substrate 3'-
phosphoadenosine 5'-phosphosulfate (PAPS) [159]. Treatment of hTERT-MSCs with a 
range of sodium chlorate concentrations showed that 125mM sodium chlorate had a 
negative effect on proliferation, whilst 25mM or lower did not (Figure 5.26A). Following 
this, Alcian blue staining was carried out to test if 1, 5, and 25mM sodium chlorate 
treatment for 3 days, visibly reduced hTERT-MSC GAG sulfation. Only treatment with 
25mM sodium chlorate significantly reduced GAG sulfation of hTERT-MSCs, shown by 
reduced absorbance at 630nm of the eluted Alcian blue stain (Figure 5.26B). 
Subsequently, hTERT-MSCs were either pre-treated with 25mM sodium chlorate for 48 
hours, prior to culture in osteogenic media, or cultured continuously in osteogenic media 
supplemented with 25mM sodium chlorate. As osteoblasts produce a proteoglycan rich 
ECM, which is later mineralized, the ability of sodium chlorate to continue to inhibit GAG 
sulfation was assessed by Alcian blue staining at weekly time-points during incubation in 
osteogenic media. The Alcian blue staining (Figure 5.26C) and corresponding eluate 
(Figure 5.26D) showed that as expected levels of sulphated GAGs increased during 
osteogenesis. The levels of sulphated GAGs recovered to untreated levels, in cells which 
were pre-treated with sodium chlorate. Cells which were continuously treated with 
osteogenic media supplemented with sodium chlorate, did show some increase in Alcian 
blue staining over the time-course. However, levels of sulphated GAGs were significantly 
lower after 21 days compared to untreated controls (Figure 5.26C, D) (One way ANOVA 
on ranks, Dunn’s post hoc test, P=<0.05, n=6). The effect of disrupted GAG sulfation on 
osteogenesis was assessed by ALP and phosphate staining at weekly time-points during 
osteogenic treatments. The pre-treatment with sodium chlorate had no effect on ALP or 
phosphate staining after 21 days osteogenic differentiation (Figure 5.26C). However, the 
continuous inclusion of sodium chlorate in osteogenic media, did not affect ALP staining, 
but did clearly reduce the level of phosphate staining (Figure 5.26C). This suggested that 
GAG sulfation is required for ECM mineralization by osteoblasts. To determine if Cog4KD 
hTERT-MSCs have altered proteoglycans further experiments are required, such as the 
staining of cells with Alcian blue, or a more sensitive dye such as 1,9-dimethylmethylene 
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blue or  alternatively, immunohistochemistry staining with antibodies directed against 
sulphated heparan sulphate.   
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Figure 5.26 Effect of sodium chlorate (NaCIO3) on osteogenesis. 
A) The effect of different concentrations of NaCIO3 on proliferation of hTERT-MSCs, was 
estimated using an MTT assay, after 1, 2, 5, and 7 days of treatment. B) hTERT-MSCs 
were stained with Alcian blue after treatments with NaCIO3 for 3 days. The stain was then 
eluted and absorbance at 630nm measured. One way ANOVA, Holm Sidak post hoc 
test,***=P<0.001, n=6. C) The long term effect of NaCIO3 pre-treatment (48 hours) or 
continuous treatment was assessed. Bright field images of Alcian blue or ALP von kossa 
staining of hTERT-MSCs in osteogenic media for 0, 7 and 21 days. The Alcian blue stain 
was quantified in D) after elution and absorbance read at 630nm. One way ANOVA on 
Ranks, (day 21 data), Dunn’s post hoc test, *=P<0.05, n=6.  
The data and images here are printed with the permission of I.G.Cantanhede who carried 
out the experimental work for this figure. 
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5.3  Chapter 5 Conclusion 
Disruption of the glycosylation synthesis pathway genetically, via Cog4 knock-down, 
altered the ability of hTERT-MSCs to differentiate, with cells showing some positive 
osteogenic markers, but unable to mineralize ECM. Many types of glycan are synthesised 
in the Golgi and could be affected in the Cog4KD hTERT-MSCs. To determine which 
altered glycan structures were functionally responsible for the change in phenotype, 
inhibitors of different glycan syntheses were used, and the effect on osteogenesis 
monitored.   
Due to the altered lectin staining and N-glycan profile of Cog4KD hTERT-MSCs, N-glycan 
synthesis was disrupted first. Swainsonine treatment changed the N-glycan profile of 
hTERT-MSCs to one dominated by hybrid type glycans. This shift was consistent with 
mannosidase II inhibition. The large change in N-glycan profile did not affect cell viability, 
morphology or proliferation. Swainsonine treated hTERT-MSCs underwent normal 
osteogenesis, as seen by positive ALP staining and ALP activity assays. There was a small 
reduction in phosphate staining, after 21 days in osteogenic media compared to 
untreated hTERT-MSCs, but this did not compare to the absence of phosphate staining 
seen with Cog4KD hTERT-MSCs.  
Rather than dismiss N-glycans as potential mediators of the reduced mineralization 
capacity, an enzyme earlier in the N-glycan synthesis pathway was targeted. This was to 
reduce the presence sialic acid at the cell surface even further, as hybrid N-glycans can 
contain some sialic acid. Evidence to suggest that the sialic acid may be involved in 
altering the osteogenic potential in the Cog4KD hTERT-MSCs includes the mass 
spectrometry profiles that identified the absence of several complex glycans in the 
Cog4KD hTERT-MSCs. Furthermore, osteoblast N-glycan profiles contained significantly 
more sialic acid containing complex glycan structures, than MSCs. Siglecs are a group of 
sialic acid binding lectins that are known to have diverse, functional roles in the immune 
system, modifying cell-cell interactions and cell signalling [160].Besides regulating 
immune cell behaviour, siglecs (Siglec-15) has been shown to affect osteoclast 
differentiation [161]. Their role in osteoblast function is currently not known, it is possible 
that siglecs mediate cell-signalling required for mineralization. 
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In order to further reduce the presence of sialic acid containing N-glycans on hTERT-
MSCs, cells were treated with a mannosidase I inhibitor called kifunensine. The N-glycan 
profile of hTERT-MSCs treated with kifunensine contained mostly oligomannose type 
glycans. The amount of complex glycans in kifunensine treated cells was 3x lower than in 
swainsonine treated cells. The phenotype of hTERT-MSCs was unaffected by kifunensine 
treatment, with no change in morphology or proliferation observed. Unexpectedly, 
kifunensine treatment altered the osteogenic capacity, with notably increased phosphate 
staining. This suggested that loss of complex N-glycans was not responsible for loss of 
mineralisation in Cog4KD hTERT-MSCs. An increase in mineralization was also seen with a 
pre-treatment of kifunensine prior to addition of normal osteogenic media.  This result 
suggested a change in differentiation capacity rather than mineralisation ability. The 
mechanism by which kifunensine affected osteogenesis did not involve BMP2 or Runx2 
signalling pathways, as their expression was not up-regulated in kifunensine treated cells. 
Despite the increase in phosphate staining, kifunensine treated cells showed decreased 
expression of BSP and decreased levels of ALP protein suggesting a defective 
differentiation capacity with aberrant ECM mineralisation. This phenotype may be caused 
by altered Wnt signalling indicated by an increase in β catenin levels in kifunensine 
treated cells.     
Since the phosphate staining in the Cog4KD hTERT-MSCs was lower than WT, a rescue 
experiment with kifunensine was carried out. Cog4KDshRNA1 hTERT-MSCs that were 
cultured with osteogenic media supplemented with kifunensine, remained negative for 
phosphate after 21 days. This showed that the defect in Cog4KD hTERT-MSCs is dominant 
over the alteration caused by kifunensine. To identify which glycan structures were 
responsible for the Cog4KD hTERT-MSCs altered differentiation, the synthesis of another 
type of glycan structure was disrupted.  
The effect of Cog4 knock-down on O-glycan synthesis was assessed in the previous 
chapter using lectin staining and flow cytometry. Cog4KD hTERT-MSCs had reduced VVL 
staining that binds to Tn and T antigen O-glycan structures. The reduced SNA staining of 
Cog4KD hTERT-MSCs could also indicated reduced O-glycan elongation, as SNA can stain 
sialic acid present in both N- and O-glycan structures. To test if these changes in O-glycan 
synthesis were responsible for the Cog4KDhTERT-MSCs mineralisation defect, cells were 
treated with an O-glycan synthesis inhibitor. Lectin staining and flow cytometry confirmed 
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that BadGal treatment altered O-glycan synthesis with reduced O-glycan elongation. 
Treatment with BadGal did not alter morphology or proliferation of hTERT-MSCs. Similar 
to the Cog4KD hTERT-MSCs, pre-treatment or continuous treatment with BadGal resulted 
in reduced phosphate staining after 21 days in osteogenic media. This suggested altered 
O-glycan synthesis may be responsible for the reduced mineralisation capacity of the 
Cog4KD hTERT-MSCs.  The ability to influence differentiation capacity with a pre-
treatment of BadGal suggested the effect was via a cell signalling pathway. Unlike 
kifunensine treatment, β catenin levels were not altered by BadGal treatment, indicating 
a different signalling pathway was responsible. Western blots showed that levels of ALP 
protein were unchanged after BadGal treatment, and that ALP is normally O-glycosylated.  
The expression of BMP, BSP and Runx2 were also unchanged by BadGal treatment. 
Further experiments are required to identify the osteogenic signalling pathway sensitive 
to changes in O-glycan synthesis. In further support of O-glycans mediating the change in 
differentiation capacity of Cog4KD hTERT-MSCs, hTERT-MSCs co-treated with BadGal and 
kifunensine did not stain for phosphate after 21 days in osteogenic media, just as 
kifunensine treatment of Cog4KD hTERT-MSCs did not restore phosphate staining. This 
suggests a hierarchy of functional importance of glycans in osteoblast mineralisation, with 
O-glycans being above N-glycans.   
Finally, since glycolipids and proteoglycans are also synthesised in the Golgi, the effect of 
inhibitors of these synthesis pathways on osteogenesis, were also tested. Inhibition of the 
synthesis of glycolipids (starting with glucose attached to ceramide) did not affect 
osteogenesis. The continued inhibition of proteoglycan sulfation with sodium chlorate 
during osteogenesis did reduce mineralisation, whilst pre-treatment alone did not. This 
result is not surprising as bone ECM is rich in proteoglycans, and is required as a scaffold 
for mineralisation. The selectivity of BadGal on O-glycan inhibition requires further 
testing, as it is possible that BadGal can act as an alternative substrate to GalNAc, and 
inhibit the elongation of GAG chains, CS and DS both of which contain GalNAc. This would 
mimic EXT1/2 mutations, which results in reduced HS chain elongation and causes 
Hereditary multiple exostoses, in which skeletogenesis defects are the prominent 
symptom [39]. 
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Further experiments identifying if proteoglycans are affected by the Cog4 knock-down are 
required to ascertain if a combination of O-glycan and proteoglycan changes mediate the 
loss of mineralisation in Cog4KD hTERT-MSCs.            
This chapter has shown using chemical inhibitors that disruption of either O or N-glycan 
synthesis or proteoglycan sulfation can affect osteogenesis. Treatment with kifunensine 
shifted the glycan profile towards only oligomannose type N-glycans and increased ECM 
mineralisation. Treated cells had increased β catenin levels, implicating the Wnt signalling 
pathway in this N-glycan mediated effect. On the other hand, O-glycan inhibition or 
proteoglycan disruption ablated mineralization seen by reduced phosphate staining. This 
showed a novel functional role of O-glycans in MSC osteogenesis. Furthermore, co-
treatment experiments with kifunensine and BadGal, suggested a hierarchy of importance 
of glycans in mineralisation, with O-glycans above N-glycans. Since chemical inhibition of 
either O-glycan or proteoglycan synthesis mimicked the loss of mineralisation seen in 
Cog4KD hTERT-MSCs, changes to both glycan structures may be responsible for the loss of 
mineralization. Further experiments identifying if proteoglycans are also affected by the 
Cog4 knock-down are required. The positive effect of kifunensine on osteoblast 
mineralisation is an interesting finding, and experiments in additional models are 
required to confirm the effect and further characterise the mechanism of action.         
 
 
 
 
 
 
 
 
Chapter 6 : Discussion  
The use of MSCs in regenerative medicine is an exciting area of science. Their multi-
lineage potential and relatively easy extraction from patients make them potential tools 
for the treatment of multiple diseases. Being able to understand and manipulate stem cell 
fate decisions would improve the efficiency of MSC differentiation in vitro and could 
identify targets for manipulation in situ. Genomic and proteomic studies have identified a 
web of interconnecting signalling pathways and transcription factors that contribute to 
the regulation of cellular differentiation. Nearly every cell surface and secreted protein is 
glycosylated. These post-translational modifications have already been shown to effect 
protein function and a number of cellular processes. Despite evidence for altered glycan 
profiles of cells at different stages of development, the functional role of glycans in MSC 
differentiation had not been studied. Here, utilizing immortalised human primary MSCs, 
the role of glycans in osteogenic differentiation was investigated. 
6.1 Osteogenic differentiation of hTERT-MSCs 
In chapter 3, hTERT-MSCs were cultured in osteogenic media and their differentiation was 
confirmed using a variety of cellular methods. Positive osteogenesis was indicated by 
increased phosphate and ALP staining, increased protein and activity levels of ALP, as well 
as by increased expression of Runx2, BMP2, and BSP, all of which confirmed the 
differentiation of hTERT-MSCs into functional osteoblasts. hTERT-MSCs grown in basal 
media showed a small increase in ALP activity and no visible matrix mineralisation (data 
not shown). There was also an increase in expression of Runx2, BMP2 and BSP in the 
hTERT-MSCs cultured for 21 days in basal media compared to day 0 samples, but these 
levels were lower than cells cultured in osteogenic media. The absence of β-
glycerophosphate in the basal media prevented any spontaneous mineralisation as the 
cells require a phosphate donor in order to produce calcium phosphate. The change in 
gene expression after 21 days in basal media could be attributed to the confluent culture 
conditions resulting in pro-osteogenic signalling leading to a change in gene expression. 
Overall the changes in gene and protein expression, and the mineralised ECM, pointed 
towards successful osteogenic differentiation of hTERT-MSCs after 3 weeks in osteogenic 
media.  
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6.2 Quantitative N-glycan analysis of hTERT-MSCs and osteoblasts   
A previous study using lectin staining identified differences in the N-glycan profiles of 
mouse MSCs and osteoblasts or adipocytes derived from them. The mouse MSCs and 
adipocytes were both found to have fewer complex N-glycans than the osteoblasts [119]. 
Heiskanen et al (2009) used the more sensitive method of mass spectrometry to profile 
N-glycans on human primary MSCs and osteoblasts derived from them [118]. Their 
findings agreed with the lectin staining that osteoblasts had more complex type N-glycans 
than MSCs, with an estimate of 34% and 45% abundance in MSCs and osteoblasts 
respectively. However, importantly, derivitisation of the N-glycans prior to mass 
spectrometry was not included [118]. This step is essential if quantitative results are to be 
obtained [131]. Permethylation neutralizes the negative charge of sialic acid, which 
reduces the chemical variation between different N-glycan structures leading to more 
uniform ionization. The inclusion of a permethylation step in my work thus makes the 
analysis more quantitative, and shows a higher abundance of complex N-glycans found in 
both hTERT-MSCs (46%) and osteoblasts (70%) derived from them (section 3.3.3). 
Hamouda et al (2013) compared the N-glycans isolated from the membranes of human 
primary MSCs and adipocytes derived from them [125]. A permethylation step was 
included in their method and the N-glycans were removed from the membrane proteins 
by incubation with first EndoH that removed oligomannose type N-glycans, followed by 
incubation with PNGaseF that removed remaining hybrid and complex type N-glycans 
[125]. As analysis was carried out on the N-glycans retrieved from each enzyme 
incubation step separately, conclusions about the relative abundance of different 
structures in MSCs could not be made. Therefore, the N-glycan profiles of hTERT-MSCs 
and osteoblasts obtained in chapter 3 provides novel data, allowing for the first time the 
relative abundance of different N-glycan structures to be reliably quantified and 
compared between the cell types. The N-glycan profile of hTERT-MSCs and osteoblasts in 
section 3.1.3, contained the same variety of N-glycan structures, only in differing 
abundance. This was also found to be the case by Heiskanen et al (2009) and Hamouda et 
al (2013), but in my work the permethylation step allowed reliable quantification of 
glycan abundance between spectra enabling the identification of profile characteristics 
typical to the different cell types. Compared to the vast number of possible glycan 
structures, the degree of similarity in N-glycan profiles between hTERT-MSCs and 
osteoblasts could be explained by the relative similarity in cell type. Both cell types are of 
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mesoderm origin, found in vivo in the bone marrow. The most abundant N-glycans 
identified by Hamouda et al (2013) were also the most abundant in hTERT-MSC profiles. 
Interestingly, Hamouda et al (2013) noted that the structure Hex10HexNAc2 was present in 
MSCs but absent in adipocytes [125]. The same pattern was observed for hTERT-MSCs 
and osteoblasts. The structure Hex10HexNAc2 is the oligomannose structure Hex9HexNAc2 
which enters the Golgi, with a branch terminating, glucose still attached. This would 
normally signal incomplete folding of a protein, resulting in recycling to the ER. It is 
unclear why MSCs would have more incompletely folded proteins than differentiated 
cells. In terms of studying the role of glycans in cellular interactions, the analysis of N-
glycans from just plasma membrane proteins would be beneficial. A potential method to 
do this is biotinylation of cell-surface proteins and a streptavidin pull-down assay. 
Hamouda et al (2013) centrifuged cell lysates to isolate cell-membrane proteins [125]. 
Their samples would be enriched for membrane proteins; however this method required 
up to 13.3x106 cells per sample whilst the FANGS method used in this research required 
only 1x106 cells per sample. The use of fewer cells per sample allows for the testing of 
biological repeats or profiling of samples with limited cell numbers.  
6.3 Use of N-glycans as markers of osteogenic potential 
In the study mentioned earlier where adipocytes had fewer complex N-glycans, they were 
also found to be less supportive for haematopoiesis [119]. Investigators then treated 
MSCs with deoxymannojirimycin (DMJ), a Golgi mannosidase I inhibitor, to block complex 
N-glycan formation. DMJ treatment reduced the myelopoietic supportive capacity of 
MSCs, showing one role of N-glycans in MSC function. The effect of DMJ on MSC 
differentiation capacity was not tested [119]. Although differences in the N-glycan profile 
of MSCs and osteoblasts had been identified, to date no-one had determined the role (if 
any) of N-glycans in the differentiation of MSCs. To initially investigate this, in chapter 3, 
the N-glycan profiles of different hTERT-MSC lines, with varied differentiation capabilities, 
were compared. Section 3.1.1, confirmed the varied ability of three hTERT-MSC lines to 
differentiate into osteoblasts or adipocytes. This finding agrees with the hypothesis that 
MSCs are a heterogeneous population of cells, with varied differentiation capacity and 
function in the bone marrow [76]. The ability to identify different MSC subpopulations 
could improve the effectiveness of cellular therapies in regenerative medicine. The results 
presented in section 3.1.4, showed that despite the differences in multi-potency, the 
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three hTERT-MSC lines had similar N-glycan profiles. This finding does not rule out a role 
of glycans during differentiation, but does suggest that N-glycan profiles, obtained using 
these methods, are not a good candidate for identifying multi-potency or immuno-
regulatory capacity in subpopulations of MSCs. This is in contrast to the gene and protein 
expression profiles of the different hTERT-MSC lines that had already been shown to 
facilitate the isolation of CD317+ subpopulations of the primary human MSCs with 
specific differentiation and immune-regulatory capacities [122]. Instead of being markers 
of differentiation potential, glycans could mediate the differentiation process. In order to 
investigate this, the glycosylation pathway was disrupted genetically and then chemically.     
6.4 Genetic disruption of glycosylation  
In chapter 4, a genetic approach was taken to disrupt the glycan synthesis pathway and 
the effect on osteogenesis was monitored. The hTERT-MSCs were utilized again, as their 
unlimited growth enabled the creation of colonies derived from single cells after genetic 
manipulation. A subunit of COG was targeted by shRNA, which would hinder the 
retrograde traffic of vesicles at the Golgi. Following this, Golgi enzyme localization would 
be disrupted, resulting in aberrant glycan synthesis. Importantly, proteins would still be 
glycosylated to a degree and correctly trafficked to the cell membrane, allowing the effect 
of glycosylation to be tested rather than protein localization. Using lenti-virus Y101 
hTERT-MSCs were transduced with a plasmid containing a shRNA for Cog4. The 
transduction efficiency was high, which was fortunate in light of findings that a sequential 
transduction with retrovirus had an efficacy 3 to 4 fold lower than the initial transduction 
[162]. There was also no evidence of the Cog4 shRNA plasmid disrupting the expression of 
hTERT, as cells continued to proliferate during culture.   
The effectiveness of the shRNAs was low with many of the colonies expressing similar to 
WT levels of Cog4 protein. For shRNAs to knock-down target gene expression they need 
to be processed in the nucleus by Drosha; then transported into the cytosol and 
processed further by Dicer; and then loaded into the RNA-induced silencing complex 
(RISC). Of the colonies tested those produced using shRNA B, C or E were more effective 
than those produced using shRNA A or D. What alters the ability of a shRNA to be 
processed at each step is currently unknown. Nevertheless, in section 4.3.1 two colonies 
were identified with <50% WT levels of Cog4, which were produced using shRNAs B and 
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C. These colonies were further expanded into Cog4KD hTERT-MSC lines and further 
characterised. 
As predicted the disrupted recycling of Golgi resident enzymes, via Cog4 knock-down 
leads to incomplete glycan chain modulation. This was shown by reduced staining of 
Cog4KD hTERT-MSCs with the lectin SNA, which binds to sialic acid. Furthermore, staining 
with PNA, that recognises non-sialylated terminal galactose, was increased in the Cog4KD 
hTERT-MSCS. These changes are in agreement with the altered glycan profiles of Cog4-
CDG patient fibroblasts, which also showed reduced sialylation [65]. In section 4.3.2, the 
N-glycans of Cog4KD hTERT-MSCs were profiled using mass spectrometry. The N-glycan 
profile of Cog4KD hTERT-MSCs was similar to WT, however, the Cog4KD hTERT-MSC 
profile lacked several complex N-glycans. As they were lowly abundant in WT profiles, 
their loss did not significantly lower the overall abundance of complex N-glycans in 
Cog4KD hTERT-MSCs. The intensity of N-glycan peaks did not always decrease linearly 
with increase in mass, suggesting that the lower abundance of some high mass, complex 
N-glycans was real, rather than a consequence of lower detection by mass spectrometry. 
In support of this, the lectin staining of WT hTERT-MSCs with SNA (sialic acid binding) was 
lower than the staining with lectins that bind oligomannose or non-sialylated glycans. The 
N-glycan profiles of serum from CDG patients with mutations in Cog subunits 1, 4, 7, or 8 
was on aggregate similar to control serum, but importantly the abundance of sialylated 
glycans was lower [65]. This supports the lower abundance of sialylated complex N-
glycans seen in the Cog4KD hTERT-MSCs.   
The lectin VVL binds to the Tn antigen structure which is a terminal α-N-
acetylgalactosamine linked to serine or threonine. This is the first monosaccharide in an 
O-glycan structure. The binding of VVL was reduced in Cog4KD hTERT-MSCs. Currently 
over 24 different polypeptide-N-acetyl-galactosaminyltransferases (ppGalNAcTs) have 
been identified, which are expressed through-out the Golgi cisternae [32]. Due to the 
ppGalNAcTs varied substrate specificities, the disruption of enzyme localization in Cog4KD 
hTERT-MSCs may lead to reduced Tn antigen abundance [32]. As the Tn antigen is the 
start of an O-glycan chain, fewer extended O-glycan structures would also be a 
consequence. SNA binds to sialic acid with a α2-6 linkage to galactose or GalNAc, both of 
which may be present in extended O-glycans [153]. The reduced SNA staining of Cog4KD 
hTERT-MSCs could therefore be caused by lower abundance of sialylated O-glycans. In 
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support of this, mass spectrometry or isoelectric focussing of ApoC-III, has shown that 
CDG-patients with mutations in different COG subunits to have defects in O-glycan 
sialylation [66, 68, 69, 163]. Overall the change in N- and O glycan profile of Cog4KD 
hTERT-MSCs is consistent with changes seen in samples from COG related CDG patients. 
In order to determine if sialylated glycans have a functional role in stem cell 
differentiation, the osteogenic capacity Cog4KD hTERT-MSCs were assessed.   
When Cog4KD hTERT-MSCs were cultured in osteogenic media for 21 days, ALP staining 
was visible but the cells did not form any mineralised extracellular matrix. This change 
was not caused by reduced proliferation, as data from a MTT assay suggested that the 
Cog4KD hTERT-MSCs had equal or higher rates of proliferation compared to WT. Results 
described in section 4.3.4 showed that the Cog4KD hTERT-MSCs had lower levels of ALP 
activity and ALP protein expression compared to WT. This suggested reduced levels 
osteogenesis in the Cog4KD hTERT-MSCs. In contrast, real time qPCR data did not support 
this, showing increases in expression of BMP2 and Runx2 in the Cog4KD hTERT-MSCs 
during culture in osteogenic media. The expression of BSP, which supports crystal 
nucleation during bone mineralization, was reduced at day 21 for one Cog4KD line, which 
supports the notion that Cog4KD hTERT-MSCs were capable of differentiating but had a 
mineralization defect.  
 The expression level of Cog4 remained low in the Cog4KD hTERT-MSCs after culture in 
either basal or osteogenic media for 21 days. This showed that the mild change in 
phenotype was not due to Cog4 levels returning to normal, due to absence of selective 
antibiotic in osteogenic media. Complete knock-out of Cog4 may result in a more severe 
phenotype, however, it’s also possible that there is some functional redundancy between 
the 8 COG subunits, in which case knock-out would not cause a greater change. The 
reduction in mineralization capacity in Cog4KD hTERT-MSCs is a phenotype shared by 
Mgat5 -/- MSCs [164]. Mgat5 is an enzyme responsible for the transfer of GlcNAc onto 
complex N-glycans, which initiates the formation of a tetra antennary complex N-glycan 
structure. Mgat5 -/- mice have reduced bone mass density and MSCs isolated from them 
were unable to mineralise extracellular matrix [164]. 
In order to confirm the effect of Cog4 knock-down on osteogenesis, ideally rescue 
experiments with a shRNA resistant form of Cog4 would be carried out. However, the 
interpretation of the results would be difficult. A lack of rescue could be due to cellular 
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stress resulting from the third round of genetic manipulation. Also, a previous study 
found the overexpression of Cog4 in fibroblasts had a dominant negative effect, with 
defective retrograde vesicle traffic compared to controls [65]. For these reasons, 
alternative experiments using chemical inhibitors of several Golgi localised, glycan 
synthesis pathways were carried out to confirm that changes in N-or O-glycan synthesis 
were responsible for the aberrant osteogenic potential of the Cog4KD hTERT-MSCs.  
 
6.5 Chemical disruption of glycosylation  
In chapter 5, the N-and O-glycan, glycolipid and proteoglycan synthesis pathways were 
disrupted using chemical inhibitors. Despite significant effects on glycosylation, none of 
the inhibitors caused changes proliferation at working concentrations. Proliferation was 
monitored because MSCs need to be viable and able to proliferate, prior to arrest and 
differentiation into osteoblasts. Also, there have been reports studying cancer cells 
showing that glycosylation can regulate proliferation. One study suggests that growth 
receptors that have highly branched glycan structures bind to galectins at the cell surface, 
forming a lattice. This results in slower turnover of the glycoprotein from the cell 
membrane and increased signalling. The degree of glycan branching is influenced by 
metabolic conditions, thus linking growth to glycosylation [165]. Again in cancer cell lines, 
the removal of all cell surface glycans enzymatically has been shown to induce apoptosis 
[166]. In contrast, treatment of mice with swainsonine has been shown to cause an 
increase in HSC proliferation [167]. In agreement with findings in chapter 5, treatment of 
mammalian cell lines with swainsonine, kifunensine or BadGal has been shown previously 
to have no effect on cell proliferation [141, 152, 168].  
In section 5.2.1, inhibition of mannosidase II with swainsonine, caused a significant 
change in the N-glycan profile of hTERT-MSCs. The profile of treated cells was dominated 
by hybrid type glycans, with fewer oligomannose and complex N-glycans. The addition of 
swainsonine to osteogenic media did not appear to influence differentiation. The staining 
of treated cells for ALP and mineralised extracellular matrix was positive, and ALP activity 
was not significantly different from untreated controls. Since hybrid type glycans can be 
sialylated, the availability of sialic acid to lectins, would not have altered significantly on 
swainsonine treated cells. In order to further reduce the abundance of sialylated glycans, 
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hTERT-MSCs were treated with kifunensine, a mannosidase I inhibitor. This enzyme 
normally removes mannose oligosaccharides to allow the addition of GlcNAc, which 
initiates complex or hybrid N-glycan assembly. As predicted, the profile of kifunensine 
treated cells was dominated by oligomannose type N-glycans. Also the abundance of 
fucosylated N-glycans was significantly reduced by kifunensine treatment. If the absence 
of high mass complex N-glycans in Cog4KD hTERT-MSCs was responsible for the reduced 
mineralisation capacity, kifunensine treatment should have reduced the osteogenic 
potential even further. However, this was not the case. In section 5.2.6, osteogenic assays 
showed that phosphate staining was increased in kifunensine treated cells. This effect 
was also seen when a pre-treatment of kifunensine was administered for 48 hours prior 
to addition of osteogenic media. This indicates that kifunensine was altering the 
behaviour of a glycoprotein that acts early during osteogenesis, most likely a signalling 
protein. Western blot analysis of hTERT-MSCs treated with kifunensine for 48 hours 
showed an increase in active β catenin levels compared to untreated controls. β catenin 
acts downstream of the Wnt signalling pathway and modulates LEF/TCF transcription 
factor expression. At odds with this finding is that Wnt pathway stimulation has been 
shown to suppress MSC differentiation, but enhance osteoblast mineralisation [101]. Due 
to their poor adipogenic differentiation, the Y101 hTERT-MSCs used in the kifunensine 
experiments could be described as osteoblast progenitor cells, and the effect of Wnt 
stimulation of this subpopulation of MSCs could be positive. Further osteogenic analysis 
of kifunensine continuously and pre-treated hTERT-MSCs was carried out to try and 
further characterise the mechanism by which kifunensine increased mineralisation 
activity.      
Analysis of ALP protein levels showed that ALP was N-glycosylated and levels were 
reduced in kifunensine treated cells. Both kifunensine treatments caused little change to 
BMP2 expression levels, but interestingly caused a small decrease in Runx2 expression. If 
kifunensine was modulating the Wnt signalling pathway the expression of Runx2, the 
major osteogenic transcription factor, would be expected to increase. Also, despite the 
increase in mineralised extracellular matrix, BSP expression was lower in kifunensine 
treated cells compared to untreated. BSP is a major non-collagenous glycoprotein found 
in bone, and thought to act as a protein nucleator of hydroxyapatite crystal. Transcription 
of BSP is regulated by Runx2, so the lower levels of BSP may be a consequence of lower 
Runx2 expression. The real-time qPCR data didn’t provide a clearer mechanism of action 
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of kifunensine treatment on osteogenesis. As with all qPCR data, the levels and activity of 
a protein may not be reflected by expression levels of mRNA. A speculative explanation 
for the mechanism of kifunensine, is that a receptor protein sensitive to changes in N-
glycosylation, triggers a change in response to osteogenic stimuli, resulting in increased 
levels of β catenin and causing changes to gene and protein expression of osteogenic 
effectors not looked at in this study, which ultimately enhance ECM mineralisation. 
Further experiments are required to determine if the mineralisation observed via 
kifunensine treatment is the result of increased osteogenesis, or aberrant mineralisation 
by MSCs. Transmission electron microscopy could be used to confirm if the phosphate 
produced by kifunensine treated hTERT-MSCs is hydroxyapatite, and if the crystals 
formed have the same structure as those found in vivo. Furthermore, the pro-osteogenic 
effect of kifunensine should be tested in an alternative model to tissue culture.  
The loss of nearly all complex N-glycans did not phenocopy the Cog4KD hTERT-MSCs. This 
indicated that the loss of complex N-glycans was not the cause of reduced mineralisation. 
Furthermore kifunensine treatment did not rescue the phenotype of the Cog4KD hTERT-
MSCs, showing that the defect was dominant over the positive effector of the kifunensine 
treatment.   
O-glycans are another subset of glycans that are synthesised in the Golgi. In section 5.2.8, 
flow cytometry with lectins confirmed that BadGal is a competitive inhibitor of O-glycan 
synthesis. I propose BadGal has two targets, firstly as a competitive inhibitor of the 
galactose-transferase responsible of forming the T antigen structure. Secondly, the 
BadGal-Gal disaccharides then act as competitive inhibitors of sialyltransferases. Evidence 
of both types of inhibition were seen in the BadGal treated hTERT-MSCs, by the increased 
Jacalin and VVL (Tn antigen binding lectins) staining, and increased PNA (terminal 
galactose binding lectin) staining. However, the staining with SNA (sialic acid binding) was 
increased after BadGal treatment. This contradicts the increased PNA staining, which 
suggested reduced sialylation. The altered availability of substrates for sialyltransferases 
may have resulted in increased N-glycan sialylation, a theory which could be tested by 
profiling the N-glycans of BadGal treated hTERT-MSCs.    
O-glycan synthesis inhibition in hTERT-MSCs phenocopied the Cog4 knock-down, with 
reduced phosphate staining after culture in osteogenic media. Both continuous and pre-
treatment with BadGal resulted in reduced phosphate staining, suggesting a change in 
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differentiation via a signalling pathway. This pathway appears to be different to that 
affected by kifunensine, as the levels of β catenin were not affected by BadGal treatment.  
The activity and protein levels of ALP were also not altered by continuous BadGal 
treatment, although the western blot showed that ALP is O-glycosylated. The expression 
of Runx2, BMP and BSP were also not changed by continuous BadGal treatment leading 
to the conclusion that O-glycan inhibition did not affect all of osteogenesis, rather caused 
a defect specifically in mineralisation, as was the case in the Cog4KDhTERT-MSCs. Just as 
kifunensine treatment did not rescue the mineralisation of Cog4KD hTERT-MSCs, cells 
treated with both BadGal and kifunensine also failed to mineralise. This suggests a 
hierarchy of glycan importance in mineralisation with O-glycans being above N-glycans. In 
this study the O-glycan profile of osteoblasts was not analysed. A previous study found 
that osteoblasts had more sialylated O-glycans than MSCs [118], and results described 
here suggest for the first time, that extended O-glycans have a functional role in 
osteogenic differentiation.  
Sharing the Golgi during synthesis with N- and O-glycans, are glycolipids and 
proteoglycans. When hTERT-MSCs were cultured with osteogenic media supplemented 
with a glycolipid synthesis inhibitor (NB DNJ), ALP and phosphate staining were 
unaffected showing glycolipid synthesis to be dispensable for the osteogenesis of hTERT-
MSCs. It is possible that the concentration of NB DNJ used was ineffective at altering 
glycolipid synthesis, analysis of NB DNJ treated hTERT-MSCs using thin layer liquid 
chromatography could be used to disprove this. Proteoglycans are a major component of 
ECM and osteoblasts deposit ECM during osteogenesis that is then mineralized at later 
stages. As expected the staining of sulphated GAGs, using alcian blue, increased during 
hTERT-MSC incubation with osteogenic media for 3 weeks. The addition of sodium 
chlorate to culture media disrupted GAG sulphation, as seen by the reduced alcian blue 
staining. This effect was maintained during 3 weeks culture in osteogenic media. 
Accompanying the decrease in sulphated GAG synthesis, phosphate staining was also 
reduced in cells cultured with osteogenic media and sodium chlorate. The Cog4knock-
down may have affected O-glycan and proteoglycan synthesis leading to reduced 
mineralisation capacity. The effect of the different chemical inhibitors on glycan profile 
was assessed here by mass spectrometry, which is a sensitive method, but only semi-
quantitative. Lectin staining of cells treated with kifunensine and/or BadGal would 
validate that the change in phenotype was caused by the intended change in type of 
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glycan structures produced – rather than change in overall abundance of glycans – which 
may also have an effect on cellular differentiation. Analysis of the proteoglycans of WT 
and Cog4KD hTERT-MSCs, by alcian blue staining, or by a more sensitive method such as 
immuno-histochemistry, would help discern this. 
 
6.6 Future work 
Further experiments are required to confirm that glycans have a functional role in 
mineralisation. The effect of kifunensine and BadGal on primary human MSC 
differentiation would naturally follow this work, as primary human MSCs are the gold 
standard cellular model. However, there are reports of variability in responsiveness to 
treatments between donors, and suggestions that in vitro osteogenic assays do not 
always predict in vivo bone forming capacities [137, 169]. An intermediate between the 
two systems is an ex vivo set-up using neonatal rodent calvariae. When the explants are 
cultured in osteogenic media the calvariae bone continues to develop, and the effect of 
inhibitors added to the media can be assessed by measuring the thickness of new bone 
growth. Alongside this, experiments addressing the effect of kifunensine and BadGal on 
adipogenesis and chondrogenesis are still to be carried out. Considering how important 
the balance between adipogenic and osteogenic signalling is to stem cell fate, the effect 
of glycan inhibition on adipogenesis could help identify the mechanism of action of 
kifunensine and BadGal. Returning to chapter 3, it would be interesting to compare the 
abundance of sialylated O-glycans between the 3 hTERT-lines. Rather than using flow 
cytometry, this could be carried out using alkaline β elimination and mass spectrometry. 
If sialylated O-glycans were identified as a marker of subpopulations of MSCs, this could 
be used to improve expansion of MSCs for use in regenerative medicine. The experiments 
with sodium chlorate identified proteoglycans as a possible candidate for causing the 
reduced mineralization capacity of Cog4KDhTERT-MSCs. The analysis of the proteoglycans 
present on the Cog4KD hTERT-MSCs is another experiment that would follow this 
research, as well as analysis of the effect of sodium chlorate on the expression of other 
osteogenic markers.    
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6.7 Conclusion 
The aim of this research was to determine the role of glycans in the differentiation of 
MSCs. Mass spectrometry was used to produce quantifiable N-glycan profiles of MSCs 
and osteoblasts derived from them. In agreement with previous research, osteoblasts 
were found to have more complex type N-glycans than MSCs. Disruption of the N-glycan 
synthesis pathway genetically and chemically lead to reduced abundance of sialylated 
glycans. Kifunensine, which promoted oligomannose type N-glycans, appears to be a 
novel osteogenic stimulator, albeit through an unknown (potentially Wnt-mediated) 
signalling mechanism. In contrast, inhibition of O-glycan sialylation prevented 
mineralisation, despite expression of other osteogenic markers, and appears to act via an 
alternative signalling pathway to kifunensine. Glycolipid synthesis inhibition had no effect 
on osteogenesis, whilst continued proteoglycan disruption inhibited mineralization. 
Further experiments in primary human MSCs and in vivo/ex vivo are required to confirm 
these results. Importantly, the data described here shows for the first time a functional 
role of both N- and O-glycans in the osteogenic differentiation of MSCs.      
  
 
Abbreviations 
ALP = Alkaline phosphatase 
ApoCII = Apolipoprotein C II  
BMP2 = Bone morphogenetic protein 2 
BSP = Bone sialoprotein  
CDGs = Congenital disorders of glycosylation 
CHO = Chinese ovary hamster cell line 
COG = Conserved Oligomeric Golgi Complex 
ConA = Concanavalin A 
COPI = Coatomer protein complex-I 
CS = Chondroitin sulphate 
CV(hm) = The coefficient of variation (half-max)  
DMJ = deoxymannojirimycin  
DS = Dermatan sulphate 
ECM = Extracellular matrix  
EGFR = Epidermal growth factor receptor 
EndoH = Endoglycosidase H 
ER = Endoplasmic reticulum 
FGF = Fibroblast growth factor 
FTC = Familial tumoral calcinosis  
GAGs = Glycoaminoglycans 
GalNAc = N-acetylgalactosamine  
GlcNAc = N-acetylglucosamine 
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GMAP-210 = Golgi microtubule-associated protein 210 
GPI = Glycosylphosphatidylinositol 
GSL = Glycosphingolipids 
HA = Hyaluronan 
hESCs = Human embryonic stem cells  
Hh = Hedgehog (signalling pathway) 
HMRS = Hyperphosphatasia with Mental Retardation Syndrome 
HS = Heparan sulphate 
HSCs = Hematopoietic stem cells 
IHh = Indian Hedgehog  
KS = Keratan sulphate 
LDL = Low-density lipoprotein  
MALDI-TOF/TOF = Matrix-assisted laser desorption/ionization 
MALII = Maackia Amurensis Lectin II  
Man = Mannose 
MOI = Multiplicity of infection 
MSCs = Mesenchymal stem cells 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NPCs = Neural progenitors cells  
OST = oligosaccharyl transferase 
PBS = phosphate buffered saline 
PBST = phosphate buffered saline with 0.05% v/v Tween 
PIGA = phosphatidylinositol glycan class A  
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PNA = Peanut agglutinin 
PNGaseF = Peptide N Glycosidase F 
PNH = Paroxysmal nocturnal hemoglobinuria 
pNPP = p-Nitrophenyl Phosphate  
ppGalNAcTs = polypeptide-N-acetyl-galactosaminyltransferases  
qPCR = Quantitative real-time polymerase chain reaction  
shRNA = short-hairpin RNA 
SNA = Sambucus nigra lectin 
TGFβ = Transforming growth factor beta 
VSG = Variant surface glycoprotein 
VSVG = Vesicular stomatitis virus G protein 
VVL = Vicia villosa Lectin 
WGA = Wheat germ agglutinin 
WT = Wild-type 
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